[S02DA03, antipyrine, The risk or severity of hyperkalemia can be increased when Antipyrine is combined with Canagliflozin.]
[A14AA02, stanozolol, Stanozolol may increase the hypoglycemic activities of Canagliflozin.]
[B01AD01, streptokinase, The risk or severity of adverse effects can be increased when Streptokinase is combined with Canagliflozin.]
[J01GA01, streptomycin, Canagliflozin may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[M03AB01, succinylcholine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Canagliflozin.]
[A02BX02, sucralfate, Canagliflozin may increase the excretion rate of Sucralfate which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CG01, sulbactam, Canagliflozin may increase the excretion rate of Sulbactam which could result in a lower serum level and potentially a reduction in efficacy.]
[J01EC02, sulfadiazine, Canagliflozin may increase the hypoglycemic activities of Sulfadiazine.]
[J01ED01, sulfadimethoxine, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Sulfadimethoxine.]
[A07AB03, sulfaguanidine, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Sulfaguanidine.]
[J01ED02, sulfalene, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Sulfametopyrazine.]
[J01ED07, sulfamerazine, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Sulfamerazine.]
[J01EB03, sulfamethazine, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Sulfamethazine.]
[S01AB01, sulfamethizole, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Sulfamethizole.]
[J01EC01, sulfamethoxazole, Canagliflozin may increase the hypoglycemic activities of Sulfamethoxazole.]
[J01ED05, sulfamethoxypyridazine, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Sulfamethoxypyridazine.]
[J01EC03, sulfamoxole, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Sulfamoxole.]
[J01EB04, sulfapyridine, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Sulfapyridine.]
[J01EB01, sulfisomidine, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Sulfaisodimidine.]
[S01AB02, sulfisoxazole, Canagliflozin may increase the hypoglycemic activities of Sulfisoxazole.]
[M01AB02, sulindac, The risk or severity of hyperkalemia can be increased when Sulindac is combined with Canagliflozin.]
[A10BB04, glibornuride, Canagliflozin may increase the hypoglycemic activities of Glibornuride.]
[A10BC01, glymidine, Canagliflozin may increase the hypoglycemic activities of Glymidine.]
[M01AX04, apazone, The risk or severity of hyperkalemia can be increased when Azapropazone is combined with Canagliflozin.]
[L02BA01, tamoxifen, The serum concentration of Canagliflozin can be increased when it is combined with Tamoxifen.]
[N05CD07, temazepam, Canagliflozin may increase the excretion rate of Temazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CC03, terbutaline, Canagliflozin may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AE07, dabigatran etexilate, The serum concentration of Dabigatran etexilate can be increased when it is combined with Canagliflozin.]
[G03BA03, testosterone, Canagliflozin may increase the excretion rate of Testosterone which could result in a lower serum level and potentially a reduction in efficacy.]
[S03AA02, tetracycline, Canagliflozin may increase the excretion rate of Tetracycline which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[N05AE05, lurasidone, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lurasidone.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Canagliflozin.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Thalidomide is combined with Canagliflozin.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CA02, thiabendazole, Canagliflozin may increase the excretion rate of Thiabendazole which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AD03, thiethylperazine, Canagliflozin may increase the excretion rate of Thiethylperazine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CA19, thiopental, The serum concentration of Canagliflozin can be decreased when it is combined with Thiopental.]
[N05AC02, thioridazine, The risk or severity of adverse effects can be increased when Thioridazine is combined with Canagliflozin.]
[G04BE06, moxisylyte, Canagliflozin may increase the excretion rate of Moxisylyte which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AL03, tiapride, Canagliflozin may increase the excretion rate of Tiapride which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC05, ticlopidine, Canagliflozin may increase the excretion rate of Ticlopidine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AX01, tilidine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Tilidine.]
[S01ED01, timolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Timolol.]
[P01AB02, tinidazole, Canagliflozin may increase the excretion rate of Tinidazole which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA12, tobramycin, Canagliflozin may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, Canagliflozin may increase the hypoglycemic activities of Tolazamide.]
[M02AX02, tolazoline, The risk or severity of adverse effects can be increased when Tolazoline is combined with Canagliflozin.]
[V04CA01, tolbutamide, Canagliflozin may increase the hypoglycemic activities of Tolbutamide.]
[M02AA21, tolmetin, The risk or severity of hyperkalemia can be increased when Tolmetin is combined with Canagliflozin.]
[N02AX02, tramadol, Canagliflozin may increase the excretion rate of Tramadol which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the orthostatic hypotensive activities of Canagliflozin.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Canagliflozin.]
[S01BA05, triamcinolone, The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Canagliflozin.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, Canagliflozin may increase the excretion rate of Triazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA06, trichlormethiazide, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Trichlormethiazide.]
[A16AX12, trientine, Canagliflozin may increase the excretion rate of Triethylenetetramine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AD02, trifluridine, Canagliflozin may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BA09, clobetasone, The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Canagliflozin.]
[S01BA10, alclometasone, The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Canagliflozin.]
[D07AC02, fluclorolone, The risk or severity of hyperglycemia can be increased when Fluclorolone is combined with Canagliflozin.]
[R03BA07, mometasone, The risk or severity of hyperglycemia can be increased when Mometasone is combined with Canagliflozin.]
[A03AA05, trimebutine, Canagliflozin may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AC02, trimethadione, The risk or severity of hypoglycemia can be increased when Trimethadione is combined with Canagliflozin.]
[C02BA01, trimethaphan, Canagliflozin may increase the hypotensive activities of Trimethaphan.]
[J01EA01, trimethoprim, Canagliflozin may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA06, trimipramine, The serum concentration of Trimipramine can be increased when it is combined with Canagliflozin.]
[J01FA08, troleandomycin, The metabolism of Canagliflozin can be decreased when combined with Troleandomycin.]
[C09CA09, azilsartan medoxomil, The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Azilsartan medoxomil.]
[R03DX07, roflumilast, Canagliflozin may increase the excretion rate of Roflumilast which could result in a lower serum level and potentially a reduction in efficacy.]
[L01FX04, ipilimumab, Canagliflozin may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX04, vandetanib, The serum concentration of Canagliflozin can be increased when it is combined with Vandetanib.]
[R02AA14, oxyquinoline, Canagliflozin may increase the excretion rate of Oxyquinoline which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BH05, linagliptin, Canagliflozin may increase the hypoglycemic activities of Linagliptin.]
[J05AP03, boceprevir, The metabolism of Canagliflozin can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Canagliflozin can be decreased when combined with Telaprevir.]
[S01AA28, vancomycin, Canagliflozin may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, Canagliflozin may increase the excretion rate of Ezogabine which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AF01, rivaroxaban, The serum concentration of Rivaroxaban can be increased when it is combined with Canagliflozin.]
[R03AC18, indacaterol, The serum concentration of Indacaterol can be increased when it is combined with Canagliflozin.]
[B01AC24, ticagrelor, The serum concentration of Canagliflozin can be increased when it is combined with Ticagrelor.]
[C08DA01, verapamil, The metabolism of Canagliflozin can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Canagliflozin can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The serum concentration of Vinblastine can be increased when it is combined with Canagliflozin.]
[C04AX07, vincamine, Canagliflozin may increase the hypotensive activities of Vincamine.]
[L01CA02, vincristine, The excretion of Vincristine can be decreased when combined with Canagliflozin.]
[B03BA01, vitamin B12, Canagliflozin may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AA03, warfarin, Canagliflozin may decrease the excretion rate of Warfarin which could result in a higher serum level.]
[C03BA10, xipamide, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Xipamide.]
[J05AE02, indinavir, The metabolism of Canagliflozin can be decreased when combined with Indinavir.]
[L01EC01, vemurafenib, The serum concentration of Canagliflozin can be increased when it is combined with Vemurafenib.]
[L01FX05, brentuximab vedotin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Canagliflozin.]
[M05BA05, tiludronic acid, Canagliflozin may increase the excretion rate of Tiludronic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[B06AC02, icatibant, Canagliflozin may increase the excretion rate of Icatibant which could result in a lower serum level and potentially a reduction in efficacy.]
[L01ED01, crizotinib, The serum concentration of Crizotinib can be increased when it is combined with Canagliflozin.]
[A02BC04, rabeprazole, Canagliflozin may increase the excretion rate of Rabeprazole which could result in a lower serum level and potentially a reduction in efficacy.]
[J01MA13, trovafloxacin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Trovafloxacin.]
[N05AE04, ziprasidone, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Ziprasidone.]
[G03AC10, drospirenone, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Drospirenone.]
[V03AC02, deferiprone, Canagliflozin may increase the excretion rate of Deferiprone which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA01, aspirin, The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Canagliflozin.]
[L01EJ01, ruxolitinib, Canagliflozin may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD07, tolterodine, Canagliflozin may increase the excretion rate of Tolterodine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DH04, doripenem, Canagliflozin may increase the excretion rate of Doripenem which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB03, atenolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Atenolol.]
[J02AC03, voriconazole, The metabolism of Canagliflozin can be decreased when combined with Voriconazole.]
[M01CB03, auranofin, Canagliflozin may increase the excretion rate of Auranofin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EK01, axitinib, The serum concentration of Axitinib can be increased when it is combined with Canagliflozin.]
[R07AX02, ivacaftor, The serum concentration of Canagliflozin can be increased when it is combined with Ivacaftor.]
[H02AB11, prednylidene, The risk or severity of hyperglycemia can be increased when Prednylidene is combined with Canagliflozin.]
[B03XA04, peginesatide, Canagliflozin may increase the excretion rate of Peginesatide which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC07, azacitidine, Canagliflozin may increase the excretion rate of Azacitidine which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX01, azathioprine, Canagliflozin may increase the excretion rate of Azathioprine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC05, gemcitabine, The serum concentration of Gemcitabine can be increased when it is combined with Canagliflozin.]
[J01DF01, aztreonam, Canagliflozin may increase the excretion rate of Aztreonam which could result in a lower serum level and potentially a reduction in efficacy.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Canagliflozin.]
[M03BX01, baclofen, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Baclofen.]
[A08AA11, lorcaserin, Canagliflozin may increase the excretion rate of Lorcaserin which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD12, mirabegron, The serum concentration of Canagliflozin can be increased when it is combined with Mirabegron.]
[L01XG02, carfilzomib, The serum concentration of Carfilzomib can be increased when it is combined with Canagliflozin.]
[V03AX03, cobicistat, The metabolism of Canagliflozin can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Canagliflozin can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Canagliflozin can be decreased when it is combined with Enzalutamide.]
[A06AX04, linaclotide, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Linaclotide.]
[L01EA04, bosutinib, The serum concentration of Bosutinib can be increased when it is combined with Canagliflozin.]
[H02AA01, aldosterone, The risk or severity of hyperglycemia can be increased when Aldosterone is combined with Canagliflozin.]
[L01EX05, regorafenib, The serum concentration of Regorafenib can be increased when it is combined with Canagliflozin.]
[N05CA04, barbital, The serum concentration of Canagliflozin can be decreased when it is combined with Barbital.]
[D02BA02, octinoxate, Canagliflozin may increase the excretion rate of Octinoxate which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE04, nelfinavir, The metabolism of Canagliflozin can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, The serum concentration of Bendamustine can be increased when it is combined with Canagliflozin.]
[N04BD02, rasagiline, Rasagiline may increase the orthostatic hypotensive activities of Canagliflozin.]
[C08CA13, lercanidipine, The risk or severity of hypoglycemia can be increased when Lercanidipine is combined with Canagliflozin.]
[V09IX04, fluorodeoxyglucose F18, Canagliflozin may increase the excretion rate of Fludeoxyglucose (18F) which could result in a lower serum level and potentially a reduction in efficacy.]
[H01CB05, pasireotide, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Pasireotide.]
[G04BE03, sildenafil, The serum concentration of Canagliflozin can be increased when it is combined with Sildenafil.]
[V08CA11, gadofosveset, Canagliflozin may increase the excretion rate of Gadofosveset trisodium which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EA05, ponatinib, The serum concentration of Canagliflozin can be increased when it is combined with Ponatinib.]
[B01AF02, apixaban, The serum concentration of Apixaban can be increased when it is combined with Canagliflozin.]
[A16AX08, teduglutide, Canagliflozin may increase the excretion rate of Teduglutide which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AX12, lomitapide, The serum concentration of Canagliflozin can be increased when it is combined with Lomitapide.]
[C04AX11, bencyclane, The risk or severity of hypoglycemia can be increased when Bencyclane is combined with Canagliflozin.]
[A10BH04, alogliptin, Canagliflozin may increase the hypoglycemic activities of Alogliptin.]
[A16AX09, glycerol phenylbutyrate, Canagliflozin may increase the excretion rate of Glycerol phenylbutyrate which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA01, bendroflumethiazide, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Bendroflumethiazide.]
[L04AX06, pomalidomide, The serum concentration of Pomalidomide can be increased when it is combined with Canagliflozin.]
[N02BA10, benorilate, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Benorilate.]
[S01AA13, fusidic acid, The metabolism of Canagliflozin can be decreased when combined with Fusidic acid.]
[J01MB04, pipemidic acid, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Pipemidic acid.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J01MA15, gemifloxacin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Gemifloxacin.]
[S01AE07, moxifloxacin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Moxifloxacin.]
[A06AX06, tegaserod, The serum concentration of Tegaserod can be increased when it is combined with Canagliflozin.]
[H03AA04, tiratricol, Tiratricol may decrease the hypoglycemic activities of Canagliflozin.]
[A10AE05, insulin detemir, The risk or severity of hypoglycemia can be increased when Canagliflozin is combined with Insulin detemir.]
[A10BX05, pramlintide, Canagliflozin may increase the hypoglycemic activities of Pramlintide.]
[L03AA12, ancestim, Canagliflozin may increase the excretion rate of Ancestim which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH01, celecoxib, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Celecoxib.]
[L04AA18, everolimus, The serum concentration of Everolimus can be increased when it is combined with Canagliflozin.]
[N04AC01, benztropine, Canagliflozin may increase the excretion rate of Benzatropine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EC02, dabrafenib, The serum concentration of Canagliflozin can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, Canagliflozin may increase the excretion rate of Benzydamine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EE01, trametinib, Canagliflozin may increase the excretion rate of Trametinib which could result in a lower serum level and potentially a reduction in efficacy.]
[V09AX05, florbetapir F-18, Canagliflozin may increase the excretion rate of Florbetapir (18F) which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EB03, afatinib, The serum concentration of Afatinib can be increased when it is combined with Canagliflozin.]
[N06AX28, levomilnacipran, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Canagliflozin.]
[J05AJ03, dolutegravir, The serum concentration of Dolutegravir can be increased when it is combined with Canagliflozin.]
[C08EA02, bepridil, The risk or severity of hypoglycemia can be increased when Bepridil is combined with Canagliflozin.]
[C02KX05, riociguat, The serum concentration of Riociguat can be increased when it is combined with Canagliflozin.]
[A10BJ03, lixisenatide, Canagliflozin may increase the hypoglycemic activities of Lixisenatide.]
[C02KX04, macitentan, Canagliflozin may increase the excretion rate of Macitentan which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX26, vortioxetine, Canagliflozin may increase the excretion rate of Vortioxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[G03AC08, etonogestrel, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Etonogestrel.]
[J05AP05, simeprevir, The metabolism of Canagliflozin can be decreased when combined with Simeprevir.]
[J05AP08, sofosbuvir, The serum concentration of Sofosbuvir can be increased when it is combined with Canagliflozin.]
[A10BK01, dapagliflozin, Dapagliflozin may increase the hypoglycemic activities of Canagliflozin.]
[C01CA27, droxidopa, Canagliflozin may increase the excretion rate of Droxidopa which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB04, acebutolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Acebutolol.]
[N05CH03, tasimelteon, Canagliflozin may increase the excretion rate of Tasimelteon which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AA07, metreleptin, The metabolism of Canagliflozin can be increased when combined with Metreleptin.]
[L04AA32, apremilast, Canagliflozin may increase the excretion rate of Apremilast which could result in a lower serum level and potentially a reduction in efficacy.]
[L02BG02, formestane, Canagliflozin may increase the excretion rate of Formestane which could result in a lower serum level and potentially a reduction in efficacy.]
[S03BA03, betamethasone, The risk or severity of hyperglycemia can be increased when Betamethasone is combined with Canagliflozin.]
[S01ED02, betaxolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Betaxolol.]
[V03AB34, fomepizole, Canagliflozin may increase the excretion rate of Fomepizole which could result in a lower serum level and potentially a reduction in efficacy.]
[C02CC01, bethanidine, Canagliflozin may increase the hypotensive activities of Bethanidine.]
[A10BJ04, albiglutide, Canagliflozin may increase the hypoglycemic activities of Albiglutide.]
[L01ED02, ceritinib, The serum concentration of Ceritinib can be increased when it is combined with Canagliflozin.]
[B01AC26, vorapaxar, The serum concentration of Canagliflozin can be increased when it is combined with Vorapaxar.]
[L01XH04, belinostat, The serum concentration of Belinostat can be increased when it is combined with Canagliflozin.]
[L01EM01, idelalisib, The serum concentration of Idelalisib can be increased when it is combined with Canagliflozin.]
[A10BK03, empagliflozin, Empagliflozin may increase the diuretic activities of Canagliflozin.]
[V08AA01, diatrizoic acid, Canagliflozin may increase the excretion rate of Diatrizoate which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AA04, iothalamic acid, Canagliflozin may increase the excretion rate of Diatrizoate which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CM19, suvorexant, The serum concentration of Canagliflozin can be increased when it is combined with Suvorexant.]
[A16AX10, eliglustat, The serum concentration of Canagliflozin can be increased when it is combined with Eliglustat.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[A06AB04, phenolphthalein, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Phenolphthalein.]
[A10BJ05, dulaglutide, Canagliflozin may increase the hypoglycemic activities of Dulaglutide.]
[A06AH03, naloxegol, The serum concentration of Naloxegol can be increased when it is combined with Canagliflozin.]
[L01EX09, nintedanib, The serum concentration of Nintedanib can be increased when it is combined with Canagliflozin.]
[A06AG02, bisacodyl, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Bisacodyl.]
[S03AA06, gentamicin, Canagliflozin may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[J05AP09, dasabuvir, The serum concentration of Dasabuvir can be increased when it is combined with Canagliflozin.]
[B01AF03, edoxaban, The serum concentration of Edoxaban can be increased when it is combined with Canagliflozin.]
[L01EF01, palbociclib, The serum concentration of Canagliflozin can be increased when it is combined with Palbociclib.]
[L01EX08, lenvatinib, The serum concentration of Lenvatinib can be increased when it is combined with Canagliflozin.]
[L01XH03, panobinostat, The serum concentration of Panobinostat can be increased when it is combined with Canagliflozin.]
[J05AP07, daclatasvir, The serum concentration of Canagliflozin can be increased when it is combined with Daclatasvir.]
[N02BE01, acetaminophen, Canagliflozin may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy.]
[L01DC01, bleomycin, Canagliflozin may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J05AP06, asunaprevir, The serum concentration of Canagliflozin can be increased when it is combined with Asunaprevir.]
[A07DA06, eluxadoline, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Eluxadoline.]
[N05AX16, brexpiprazole, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Brexpiprazole.]
[A04AD14, rolapitant, The serum concentration of Canagliflozin can be increased when it is combined with Rolapitant.]
[G02CX02, flibanserin, The serum concentration of Canagliflozin can be increased when it is combined with Flibanserin.]
[A06AD03, magnesium peroxide, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Magnesium peroxide.]
[A10BF01, acarbose, Canagliflozin may increase the hypoglycemic activities of Acarbose.]
[M02AA25, aceclofenac, Canagliflozin may increase the excretion rate of Aceclofenac which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AB11, acemetacin, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Acemetacin.]
[S01EC01, acetazolamide, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Acetazolamide.]
[A10AE06, insulin degludec, The risk or severity of hypoglycemia can be increased when Canagliflozin is combined with Insulin degludec.]
[V03AB37, idarucizumab, Canagliflozin may increase the excretion rate of Idarucizumab which could result in a lower serum level and potentially a reduction in efficacy.]
[J02AC05, isavuconazole, The serum concentration of Canagliflozin can be increased when it is combined with Isavuconazole.]
[L01EB04, osimertinib, The serum concentration of Osimertinib can be increased when it is combined with Canagliflozin.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Canagliflozin.]
[L01EE02, cobimetinib, The serum concentration of Cobimetinib can be increased when it is combined with Canagliflozin.]
[L01XG03, ixazomib, Canagliflozin may increase the excretion rate of Ixazomib which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC27, selexipag, The serum concentration of Selexipag can be increased when it is combined with Canagliflozin.]
[A10BB31, acetohexamide, Canagliflozin may increase the hypoglycemic activities of Acetohexamide.]
[M04AB05, lesinurad, Canagliflozin may increase the excretion rate of Lesinurad which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AP10, elbasvir, The serum concentration of Elbasvir can be increased when it is combined with Canagliflozin.]
[J05AP11, grazoprevir, The serum concentration of Grazoprevir can be increased when it is combined with Canagliflozin.]
[M01AE16, alminoprofen, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Alminoprofen.]
[N02BA02, aloxiprin, Aloxiprin may increase the hypoglycemic activities of Canagliflozin.]
[N03AX23, brivaracetam, Canagliflozin may increase the excretion rate of Brivaracetam which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XX52, venetoclax, The serum concentration of Venetoclax can be increased when it is combined with Canagliflozin.]
[N05BA08, bromazepam, Canagliflozin may increase the excretion rate of Bromazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BC01, bromocriptine, Canagliflozin may increase the hypoglycemic activities of Bromocriptine.]
[A02AD05, aluminum magnesium silicate, Canagliflozin may increase the excretion rate of Almasilate which could result in a lower serum level and potentially a reduction in efficacy.]
[D07AC11, amcinonide, The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Canagliflozin.]
[N06AA19, amineptin, Amineptine may decrease the hypoglycemic activities of Canagliflozin.]
[C08CA01, amlodipine, The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Canagliflozin.]
[C03CA02, bumetanide, The risk or severity of hypotension can be increased when Canagliflozin is combined with Bumetanide.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Canagliflozin.]
[C07AA19, bupranolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Bupranolol.]
[N07BC01, buprenorphine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Buprenorphine.]
[L02AE01, buserelin, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Buserelin.]
[N05BE01, buspirone, Canagliflozin may increase the excretion rate of Buspirone which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XX27, arsenic trioxide, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Arsenic trioxide.]
[M02AA03, clofezone, Canagliflozin may increase the excretion rate of Rabeprazole which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AF01, butorphanol, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Butorphanol.]
[J01MA09, sparfloxacin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Sparfloxacin.]
[A06AX07, plecanatide, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Plecanatide.]
[L01EF02, ribociclib, The metabolism of Canagliflozin can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, Balsalazide may increase the hypoglycemic activities of Canagliflozin.]
[A06AH05, naldemedine, Canagliflozin may increase the excretion rate of Naldemedine which could result in a lower serum level and potentially a reduction in efficacy.]
[N07XX16, deutetrabenazine, Canagliflozin may increase the excretion rate of Deutetrabenazine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BF02, pregabalin, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Canagliflozin.]
[C09AA07, benazepril, The risk or severity of hypoglycemia can be increased when Benazepril is combined with Canagliflozin.]
[A10BX06, benfluorex, Canagliflozin may increase the hypoglycemic activities of Benfluorex.]
[P01CA02, benznidazole, Canagliflozin may increase the excretion rate of Benznidazole which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XX08, linezolid, Linezolid may increase the orthostatic hypotensive activities of Canagliflozin.]
[J05AF06, abacavir, Canagliflozin may increase the excretion rate of Abacavir which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE09, tipranavir, The metabolism of Canagliflozin can be decreased when combined with Tipranavir.]
[N07XX13, valbenazine, Canagliflozin may increase the excretion rate of Valbenazine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX10, midostaurin, The metabolism of Canagliflozin can be decreased when combined with Midostaurin.]
[N04BD03, safinamide, Safinamide may increase the orthostatic hypotensive activities of Canagliflozin.]
[J01MA23, delafloxacin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Delafloxacin.]
[B01AF04, betrixaban, The serum concentration of Betrixaban can be increased when it is combined with Canagliflozin.]
[L01BC06, capecitabine, Canagliflozin may increase the excretion rate of Capecitabine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XX59, enasidenib, The serum concentration of Canagliflozin can be increased when it is combined with Enasidenib.]
[L01EH02, neratinib, The serum concentration of Canagliflozin can be increased when it is combined with Neratinib.]
[L01FB01, inotuzumab ozogamicin, The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Canagliflozin.]
[L01XH01, vorinostat, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Vorinostat.]
[L01EM02, copanlisib, The serum concentration of Copanlisib can be increased when it is combined with Canagliflozin.]
[L01EF03, abemaciclib, The serum concentration of Abemaciclib can be increased when it is combined with Canagliflozin.]
[C07AB07, bisoprolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Bisoprolol.]
[J05AG03, efavirenz, The serum concentration of Canagliflozin can be decreased when it is combined with Efavirenz.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[C07AA17, bopindolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Bopindolol.]
[C01DX19, nesiritide, The risk or severity of adverse effects can be increased when Nesiritide is combined with Canagliflozin.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, The risk or severity of hyperglycemia can be increased when Budesonide is combined with Canagliflozin.]
[M01AB07, bumadizone, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Bumadizone.]
[N06AA15, butriptyline, Butriptyline may decrease the hypoglycemic activities of Canagliflozin.]
[C01AA02, acetyldigoxins, Canagliflozin may decrease the excretion rate of Acetyldigoxin which could result in a higher serum level.]
[A10BJ06, semaglutide, Canagliflozin may increase the hypoglycemic activities of Semaglutide.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Ertugliflozin.]
[R06AX18, acrivastine, Canagliflozin may increase the excretion rate of Acrivastine which could result in a lower serum level and potentially a reduction in efficacy.]
[C09AA01, captopril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Captopril.]
[L02BB05, apalutamide, The serum concentration of Canagliflozin can be decreased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Canagliflozin can be increased when combined with Carbamazepine.]
[A06AC08, calcium polycarbophil, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Calcium polycarbophil.]
[C07AG02, carvedilol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Carvedilol.]
[B02BX09, fostamatinib, The risk or severity of hypotension can be increased when Fostamatinib is combined with Canagliflozin.]
[N03AX24, cannabidiol, The metabolism of Canagliflozin can be decreased when combined with Cannabidiol.]
[B02BX08, avatrombopag, The serum concentration of Avatrombopag can be increased when it is combined with Canagliflozin.]
[L04AA37, baricitinib, Canagliflozin may increase the excretion rate of Baricitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[L01EE03, binimetinib, The serum concentration of Binimetinib can be increased when it is combined with Canagliflozin.]
[J01DD14, ceftibuten, Canagliflozin may increase the excretion rate of Ceftibuten which could result in a lower serum level and potentially a reduction in efficacy.]
[J01GB14, plazomicin, Canagliflozin may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Celiprolol.]
[H01CC03, elagolix, The serum concentration of Elagolix can be increased when it is combined with Canagliflozin.]
[L01XX62, ivosidenib, The metabolism of Canagliflozin can be increased when combined with Ivosidenib.]
[A16AX14, migalastat, Canagliflozin may increase the excretion rate of Migalastat which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AX17, stiripentol, The metabolism of Canagliflozin can be decreased when combined with Stiripentol.]
[B02BX07, lusutrombopag, The serum concentration of Lusutrombopag can be increased when it is combined with Canagliflozin.]
[L01EM04, duvelisib, The serum concentration of Duvelisib can be increased when it is combined with Canagliflozin.]
[L01EB07, dacomitinib, The serum concentration of Dacomitinib can be increased when it is combined with Canagliflozin.]
[J01AA14, sarecycline, The serum concentration of Canagliflozin can be increased when it is combined with Sarecycline.]
[J01AA15, omadacycline, The serum concentration of Omadacycline can be increased when it is combined with Canagliflozin.]
[S01GX12, cetirizine, Canagliflozin may increase the excretion rate of Cetirizine which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BB06, carbutamide, Canagliflozin may increase the hypoglycemic activities of Carbutamide.]
[D08AE05, chloroxylenol, Canagliflozin may increase the excretion rate of Chloroxylenol which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AC05, lornoxicam, The risk or severity of hyperkalemia can be increased when Lornoxicam is combined with Canagliflozin.]
[N07XX15, inotersen, Inotersen may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[L01XK04, talazoparib, The serum concentration of Talazoparib can be increased when it is combined with Canagliflozin.]
[R03BB08, revefenacin, The serum concentration of Revefenacin can be increased when it is combined with Canagliflozin.]
[L01AD01, carmustine, Canagliflozin may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX12, larotrectinib, The serum concentration of Larotrectinib can be increased when it is combined with Canagliflozin.]
[L01EX13, gilteritinib, The serum concentration of Gilteritinib can be increased when it is combined with Canagliflozin.]
[L01XJ03, glasdegib, The serum concentration of Glasdegib can be increased when it is combined with Canagliflozin.]
[A06AX05, prucalopride, The serum concentration of Prucalopride can be increased when it is combined with Canagliflozin.]
[C01BG07, cifenline, The risk or severity of hypoglycemia can be increased when Cibenzoline is combined with Canagliflozin.]
[C09AA08, cilazapril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Cilazapril.]
[B01AC23, cilostazol, Canagliflozin may increase the excretion rate of Cilostazol which could result in a lower serum level and potentially a reduction in efficacy.]
[J01FA09, clarithromycin, The metabolism of Canagliflozin can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, Canagliflozin may increase the excretion rate of Solriamfetol which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EN01, erdafitinib, The serum concentration of Canagliflozin can be increased when it is combined with Erdafitinib.]
[N05BA09, clobazam, The serum concentration of Clobazam can be increased when it is combined with Canagliflozin.]
[D07AB21, clocortolone, The risk or severity of hyperglycemia can be increased when Clocortolone is combined with Canagliflozin.]
[H02AB14, cloprednol, The risk or severity of hyperglycemia can be increased when Cloprednol is combined with Canagliflozin.]
[A06AB05, castor oil, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Castor oil.]
[C01EB09, ubidecarenone, The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Canagliflozin.]
[C09CA06, candesartan, The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Candesartan.]
[H02AB17, cortivazol, The risk or severity of hyperglycemia can be increased when Cortivazol is combined with Canagliflozin.]
[J01DC04, cefaclor, Canagliflozin may increase the excretion rate of Cefaclor which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DB05, cefadroxil, Canagliflozin may increase the excretion rate of Cefadroxil which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[L02BB06, darolutamide, The serum concentration of Darolutamide can be increased when it is combined with Canagliflozin.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J01DC05, cefotetan, Canagliflozin may increase the excretion rate of Cefotetan which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J01DD02, ceftazidime, Canagliflozin may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BX03, cicletanine, Cicletanine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J01DD04, ceftriaxone, Canagliflozin may increase the excretion rate of Ceftriaxone which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[L01EJ02, fedratinib, The serum concentration of Fedratinib can be increased when it is combined with Canagliflozin.]
[L01EX14, entrectinib, The serum concentration of Canagliflozin can be increased when it is combined with Entrectinib.]
[N07XX11, pitolisant, The serum concentration of Canagliflozin can be decreased when it is combined with Pitolisant.]
[J01XX12, lefamulin, Canagliflozin may decrease the excretion rate of Lefamulin which could result in a higher serum level.]
[N04CX01, istradefylline, The serum concentration of Canagliflozin can be increased when it is combined with Istradefylline.]
[C03AA09, cyclothiazide, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Cyclothiazide.]
[A10AE03, insulin, regular, pork, The risk or severity of hypoglycemia can be increased when Canagliflozin is combined with Insulin pork.]
[A06AB03, danthron, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Dantron.]
[J01XX09, daptomycin, The serum concentration of Daptomycin can be increased when it is combined with Canagliflozin.]
[J01DB01, cephalexin, Canagliflozin may increase the excretion rate of Cephalexin which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J01DB09, cephradine, Canagliflozin may increase the excretion rate of Cefradine which could result in a lower serum level and potentially a reduction in efficacy.]
[H02AB13, deflazacort, The risk or severity of hyperglycemia can be increased when Deflazacort is combined with Canagliflozin.]
[N02CC08, lasmiditan, The serum concentration of Canagliflozin can be increased when it is combined with Lasmiditan.]
[G03AC09, desogestrel, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Desogestrel.]
[N03AX25, cenobamate, The serum concentration of Canagliflozin can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, Givosiran may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[M09AX08, golodirsen, Canagliflozin may increase the excretion rate of Golodirsen which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Canagliflozin.]
[L01FX13, enfortumab vedotin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Canagliflozin.]
[S01XA12, dexpanthenol, Canagliflozin may increase the excretion rate of Dexpanthenol which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AX03, dezocine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Dezocine.]
[N05CM21, lemborexant, The serum concentration of Lemborexant can be increased when it is combined with Canagliflozin.]
[L01XX72, tazemetostat, The serum concentration of Tazemetostat can be increased when it is combined with Canagliflozin.]
[L04AA53, teprotumumab, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Teprotumumab.]
[N02CD06, rimegepant, The serum concentration of Rimegepant can be increased when it is combined with Canagliflozin.]
[S01AE06, gatifloxacin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Gatifloxacin.]
[J05AE05, amprenavir, The metabolism of Canagliflozin can be decreased when combined with Amprenavir.]
[L01EE04, selumetinib, The serum concentration of Selumetinib can be increased when it is combined with Canagliflozin.]
[R02AA03, dichlorobenzyl alcohol, Canagliflozin may increase the excretion rate of Dichlorobenzyl alcohol which could result in a lower serum level and potentially a reduction in efficacy.]
[G03DB08, dienogest, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Dienogest.]
[D07AC19, difluprednate, The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Canagliflozin.]
[N02AA08, dihydrocodeine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Dihydrocodeine.]
[M01AH02, rofecoxib, The risk or severity of hyperkalemia can be increased when Rofecoxib is combined with Canagliflozin.]
[C08CA16, clevidipine, Canagliflozin may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BD07, dronedarone, The metabolism of Canagliflozin can be decreased when combined with Dronedarone.]
[C02AA06, methoserpidine, Canagliflozin may increase the hypotensive activities of Methoserpidine.]
[L01EH03, tucatinib, Tucatinib may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[L01EX17, capmatinib, The serum concentration of Canagliflozin can be increased when it is combined with Capmatinib.]
[N04BX04, opicapone, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Opicapone.]
[D07XB03, fluprednidene, The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Canagliflozin.]
[M01AC04, droxicam, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Droxicam.]
[L01EX19, ripretinib, The serum concentration of Ripretinib can be increased when it is combined with Canagliflozin.]
[V08CA05, mangafodipir, Canagliflozin may increase the excretion rate of Mangafodipir which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BA14, loteprednol, The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Canagliflozin.]
[M02AA27, dexketoprofen, Canagliflozin may increase the excretion rate of Dexketoprofen which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA17, levamlodipine, The risk or severity of hypoglycemia can be increased when Levamlodipine is combined with Canagliflozin.]
[J05AX29, fostemsavir, The serum concentration of Fostemsavir can be increased when it is combined with Canagliflozin.]
[L01FX15, belantamab mafodotin, The serum concentration of Belantamab mafodotin can be increased when it is combined with Canagliflozin.]
[L04AC19, satralizumab, The serum concentration of Canagliflozin can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Oliceridine.]
[P01BA01, chloroquine, Canagliflozin may increase the excretion rate of Chloroquine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX23, pralsetinib, The serum concentration of Pralsetinib can be increased when it is combined with Canagliflozin.]
[C03AA04, chlorothiazide, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Chlorothiazide.]
[N05AA01, chlorpromazine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Chlorpromazine.]
[A10BB02, chlorpropamide, Canagliflozin may increase the hypoglycemic activities of Chlorpropamide.]
[C03BA04, chlorthalidone, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Chlorthalidone.]
[M03BB03, chlorzoxazone, Canagliflozin may increase the excretion rate of Chlorzoxazone which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA07, ethenzamide, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Ethenzamide.]
[N02BA03, choline salicylate, Choline salicylate may increase the hypoglycemic activities of Canagliflozin.]
[N06BX18, vinpocetine, The risk or severity of hypoglycemia can be increased when Vinpocetine is combined with Canagliflozin.]
[M01AB08, etodolac, Canagliflozin may increase the excretion rate of Etodolac which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA06, etofenamate, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Etofenamate.]
[B06AC06, berotralstat, The serum concentration of Berotralstat can be increased when it is combined with Canagliflozin.]
[A16AX20, lonafarnib, The metabolism of Canagliflozin can be decreased when combined with Lonafarnib.]
[L02BX04, relugolix, The serum concentration of Relugolix can be increased when it is combined with Canagliflozin.]
[M01AX25, chondroitin sulfates, Canagliflozin may increase the excretion rate of Chondroitin sulfate which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AD03, voclosporin, The serum concentration of Voclosporin can be increased when it is combined with Canagliflozin.]
[P03AX07, abametapir, The serum concentration of Canagliflozin can be increased when it is combined with Abametapir.]
[C01DX22, vericiguat, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Vericiguat.]
[L01EX21, tepotinib, The serum concentration of Tepotinib can be increased when it is combined with Canagliflozin.]
[L01EX25, umbralisib, The serum concentration of Canagliflozin can be increased when it is combined with Umbralisib.]
[V03AF12, trilaciclib, The serum concentration of Trilaciclib can be increased when it is combined with Canagliflozin.]
[M01AE05, fenbufen, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Fenbufen.]
[C01CA19, fenoldopam, Canagliflozin may increase the excretion rate of Fenoldopam which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD15, cefdinir, Canagliflozin may increase the excretion rate of Cefdinir which could result in a lower serum level and potentially a reduction in efficacy.]
[J01MB07, flumequine, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Flumequine.]
[R03BA03, flunisolide, The risk or severity of hyperglycemia can be increased when Flunisolide is combined with Canagliflozin.]
[S02BA08, fluocinolone acetonide, The risk or severity of hyperglycemia can be increased when Fluocinolone acetonide is combined with Canagliflozin.]
[N02BG07, flupirtine, Canagliflozin may increase the excretion rate of Flupirtine which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AF01, insulin, regular, human, The risk or severity of hypoglycemia can be increased when Canagliflozin is combined with Insulin human.]
[L01EK03, tivozanib, The serum concentration of Tivozanib can be increased when it is combined with Canagliflozin.]
[H04AA02, dasiglucagon, Canagliflozin may increase the hypotensive activities of Dasiglucagon.]
[L01FX22, loncastuximab tesirine, The serum concentration of Loncastuximab tesirine can be increased when it is combined with Canagliflozin.]
[A02BA01, cimetidine, Canagliflozin may increase the excretion rate of Cimetidine which could result in a lower serum level and potentially a reduction in efficacy.]
[V08CA04, gadoteridol, Canagliflozin may increase the excretion rate of Gadoteridol which could result in a lower serum level and potentially a reduction in efficacy.]
[N07CA02, cinnarizine, The risk or severity of hypoglycemia can be increased when Cinnarizine is combined with Canagliflozin.]
[J01MB06, cinoxacin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Canagliflozin can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Ciprofloxacin.]
[L01XA01, cisplatin, Canagliflozin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AB04, citalopram, The risk or severity of hypoglycemia can be increased when Citalopram is combined with Canagliflozin.]
[H01AC07, somapacitan, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Somapacitan.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AA48, belumosudil, The serum concentration of Canagliflozin can be increased when it is combined with Belumosudil.]
[H01AC09, lonapegsomatropin, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lonapegsomatropin.]
[V09AB03, ioflupane I-123, Canagliflozin may increase the excretion rate of Ioflupane I-123 which could result in a lower serum level and potentially a reduction in efficacy.]
[V09GA01, technetium Tc 99m sestamibi, The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Canagliflozin.]
[V09AA01, technetium Tc 99m exametazime, Canagliflozin may increase the excretion rate of Technetium Tc-99m exametazime which could result in a lower serum level and potentially a reduction in efficacy.]
[V09AX06, florbetaben f-18, Canagliflozin may increase the excretion rate of Florbetaben (18F) which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AG01, mefenamic acid, The metabolism of Canagliflozin can be decreased when combined with Mefenamic acid.]
[A10BB12, glimepiride, Canagliflozin may increase the hypoglycemic activities of Glimepiride.]
[A10BB08, gliquidone, Canagliflozin may increase the hypoglycemic activities of Gliquidone.]
[N06AX25, St. John's wort extract, The serum concentration of Canagliflozin can be decreased when it is combined with St. John's Wort.]
[L01EA06, asciminib, The serum concentration of Canagliflozin can be increased when it is combined with Asciminib.]
[J05AX10, maribavir, The serum concentration of Canagliflozin can be increased when it is combined with Maribavir.]
[D07AD01, clobetasol, The risk or severity of hyperglycemia can be increased when Clobetasol is combined with Canagliflozin.]
[D11AH08, abrocitinib, The serum concentration of Canagliflozin can be increased when it is combined with Abrocitinib.]
[J04BA01, clofazimine, The serum concentration of Canagliflozin can be increased when it is combined with Clofazimine.]
[B06AX04, mitapivat, The serum concentration of Canagliflozin can be increased when it is combined with Mitapivat.]
[N01BB10, levobupivacaine, Canagliflozin may increase the excretion rate of Levobupivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EJ03, pacritinib, The serum concentration of Canagliflozin can be increased when it is combined with Pacritinib.]
[G03GB02, clomiphene, The serum concentration of Clomifene can be increased when it is combined with Canagliflozin.]
[N06AA04, clomipramine, Clomipramine may decrease the hypoglycemic activities of Canagliflozin.]
[N03AE01, clonazepam, Canagliflozin may increase the excretion rate of Clonazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[S01EA04, clonidine, The risk or severity of adverse effects can be increased when Clonidine is combined with Canagliflozin.]
[C01EB24, mavacamten, The serum concentration of Canagliflozin can be decreased when it is combined with Mavacamten.]
[J05AH02, oseltamivir, Canagliflozin may increase the excretion rate of Oseltamivir which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BX16, tirzepatide, Canagliflozin may increase the hypoglycemic activities of Tirzepatide.]
[C03BA03, clopamide, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Clopamide.]
[N05AH02, clozapine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Clozapine.]
[L01EN04, futibatinib, The serum concentration of Futibatinib can be increased when it is combined with Canagliflozin.]
[A10BX01, guar gum, Canagliflozin may increase the hypoglycemic activities of Guar gum.]
[A10BK06, sotagliflozin, Canagliflozin may increase the hypoglycemic activities of Sotagliflozin.]
[J01GB12, arbekacin, Canagliflozin may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[D07AC12, halometasone, The risk or severity of hyperglycemia can be increased when Halometasone is combined with Canagliflozin.]
[H01AC08, somatrogon, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Somatrogon.]
[C02KB01, metyrosine, Canagliflozin may increase the hypotensive activities of Metyrosine.]
[M01AX13, proquazone, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Proquazone.]
[R05DA04, codeine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Codeine.]
[M04AC01, colchicine, The serum concentration of Colchicine can be increased when it is combined with Canagliflozin.]
[J01XB01, colistin, Canagliflozin may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Desflurane is combined with Canagliflozin.]
[A04AA03, tropisetron, Canagliflozin may increase the excretion rate of Tropisetron which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BX03, nateglinide, Canagliflozin may increase the hypoglycemic activities of Nateglinide.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Imidazole salicylate.]
[H01AC03, mecasermin, Canagliflozin may increase the hypoglycemic activities of Mecasermin.]
[A10AE04, insulin glargine, The risk or severity of hypoglycemia can be increased when Canagliflozin is combined with Insulin glargine.]
[J01FA15, telithromycin, The metabolism of Canagliflozin can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The risk or severity of hyperglycemia can be increased when Ciclesonide is combined with Canagliflozin.]
[B01AC10, indobufen, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Indobufen.]
[J05AB14, valganciclovir, Canagliflozin may increase the excretion rate of Valganciclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[C05BB03, invert sugar, Canagliflozin may increase the excretion rate of Invert sugar which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB09, iodixanol, Canagliflozin may increase the excretion rate of Iodixanol which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB05, iopromide, Canagliflozin may increase the excretion rate of Iopromide which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB07, ioversol, Canagliflozin may increase the excretion rate of Ioversol which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB12, ioxilan, Canagliflozin may increase the excretion rate of Ioxilan which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH03, valdecoxib, The risk or severity of hyperkalemia can be increased when Valdecoxib is combined with Canagliflozin.]
[H01AX01, pegvisomant, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Canagliflozin.]
[N02CC05, almotriptan, Canagliflozin may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH04, parecoxib, The risk or severity of hyperkalemia can be increased when Parecoxib is combined with Canagliflozin.]
[J02AC02, itraconazole, The metabolism of Canagliflozin can be decreased when combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Bemiparin.]
[S01AD03, acyclovir, Canagliflozin may increase the excretion rate of Acyclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA10, ketazolam, Canagliflozin may increase the excretion rate of Ketazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AA06, kebuzone, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Kebuzone.]
[J02AC04, posaconazole, The metabolism of Canagliflozin can be decreased when combined with Posaconazole.]
[C08CA09, lacidipine, Canagliflozin may increase the hypotensive activities of Lacidipine.]
[A06AD12, lactitol, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Lactitol.]
[N03AX09, lamotrigine, Canagliflozin may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BA03, cortisone, The risk or severity of hyperglycemia can be increased when Cortisone is combined with Canagliflozin.]
[N07BC04, lofexidine, Canagliflozin may increase the excretion rate of Lofexidine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AE04, lomefloxacin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Lomefloxacin.]
[M01AB09, lonazolac, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Lonazolac.]
[M02AA31, loxoprofen, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Loxoprofen.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[C09AA03, lisinopril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Lisinopril.]
[A06AD01, magnesium carbonate, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Magnesium carbonate.]
[C08CA11, manidipine, The risk or severity of hypoglycemia can be increased when Manidipine is combined with Canagliflozin.]
[S01BA08, medrysone, The risk or severity of hyperglycemia can be increased when Medrysone is combined with Canagliflozin.]
[C07AA14, mepindolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Mepindolol.]
[H02AB15, meprednisone, The risk or severity of hyperglycemia can be increased when Meprednisone is combined with Canagliflozin.]
[J01DH02, meropenem, Canagliflozin may increase the excretion rate of Meropenem which could result in a lower serum level and potentially a reduction in efficacy.]
[C04AX01, cyclandelate, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Canagliflozin.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, Canagliflozin may increase the excretion rate of Melperone which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA07, cyclopenthiazide, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Cyclopenthiazide.]
[A10BF02, miglitol, Canagliflozin may increase the hypoglycemic activities of Miglitol.]
[J05AF07, tenofovir disoproxil, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Canagliflozin.]
[N06AX07, minaprine, Minaprine may increase the orthostatic hypotensive activities of Canagliflozin.]
[S01XA18, cyclosporine, The serum concentration of Cyclosporine can be increased when it is combined with Canagliflozin.]
[N06AG02, moclobemide, Moclobemide may increase the orthostatic hypotensive activities of Canagliflozin.]
[C09AA13, moexipril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Moexipril.]
[C10AA07, rosuvastatin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Rosuvastatin.]
[M02AA02, mofebutazone, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Morniflumate.]
[C03XA02, conivaptan, The metabolism of Canagliflozin can be decreased when combined with Conivaptan.]
[C02AC05, moxonidine, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Moxonidine.]
[G04BE09, vardenafil, The serum concentration of Canagliflozin can be increased when it is combined with Vardenafil.]
[M01AH05, etoricoxib, The risk or severity of hyperkalemia can be increased when Etoricoxib is combined with Canagliflozin.]
[L01AX04, dacarbazine, Canagliflozin may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01DA01, dactinomycin, The serum concentration of Dactinomycin can be increased when it is combined with Canagliflozin.]
[G03XA01, danazol, The metabolism of Canagliflozin can be decreased when combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Canagliflozin.]
[C02CC04, debrisoquin, Canagliflozin may increase the hypotensive activities of Debrisoquine.]
[A04AD11, nabilone, The risk or severity of adverse effects can be increased when Nabilone is combined with Canagliflozin.]
[M01AX01, nabumetone, The risk or severity of hyperkalemia can be increased when Nabumetone is combined with Canagliflozin.]
[N07BB05, nalmefene, Canagliflozin may increase the excretion rate of Nalmefene which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA15, potassium lactate, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Potassium lactate.]
[C07AB12, nebivolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Nebivolol.]
[S01GX04, nedocromil, Canagliflozin may increase the excretion rate of Nedocromil which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX06, nefazodone, The metabolism of Canagliflozin can be decreased when combined with Nefazodone.]
[C01DX16, nicorandil, Nicorandil may increase the hypotensive activities of Canagliflozin.]
[L02BB02, nilutamide, Canagliflozin may increase the excretion rate of Nilutamide which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA23, theodrenaline, The risk or severity of Cardiac Arrhythmia can be increased when Theodrenaline is combined with Canagliflozin.]
[R05DA06, normethadone, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Normethadone.]
[B01AX05, fondaparinux, Canagliflozin may increase the excretion rate of Fondaparinux which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AB10, escitalopram, The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Canagliflozin.]
[A07EC03, olsalazine, Olsalazine may increase the hypoglycemic activities of Canagliflozin.]
[N06AA01, desipramine, Desipramine may decrease the hypoglycemic activities of Canagliflozin.]
[H01BA02, desmopressin, Canagliflozin may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BA11, desonide, The risk or severity of hyperglycemia can be increased when Desonide is combined with Canagliflozin.]
[D07XC02, desoximetasone, The risk or severity of hyperglycemia can be increased when Desoximetasone is combined with Canagliflozin.]
[V04CH02, indigo carmine, Canagliflozin may increase the excretion rate of Indigotindisulfonic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[H02AA03, desoxycorticosterone, The risk or severity of hyperglycemia can be increased when Desoxycortone is combined with Canagliflozin.]
[J01DH03, ertapenem, Canagliflozin may increase the excretion rate of Ertapenem which could result in a lower serum level and potentially a reduction in efficacy.]
[C09XA02, aliskiren, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Aliskiren.]
[M01AE12, oxaprozin, Canagliflozin may increase the excretion rate of Oxaprozin which could result in a lower serum level and potentially a reduction in efficacy.]
[S03BA01, dexamethasone, The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Canagliflozin.]
[N06BA02, dextroamphetamine, Canagliflozin may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AC01, dextromoramide, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Dextromoramide.]
[N06AB05, paroxetine, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Canagliflozin.]
[N07BC06, heroin, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Diamorphine.]
[C01DA05, pentaerythritol tetranitrate, Canagliflozin may increase the excretion rate of Pentaerythritol tetranitrate which could result in a lower serum level and potentially a reduction in efficacy.]
[P03AC04, permethrin, Canagliflozin may increase the excretion rate of Permethrin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA01, diazepam, Canagliflozin may increase the excretion rate of Diazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AH01, diazoxide, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Diazoxide.]
[N06AA08, dibenzepin, Dibenzepin may decrease the hypoglycemic activities of Canagliflozin.]
[R05DA08, pholcodine, Canagliflozin may increase the excretion rate of Pholcodine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01EC02, dichlorphenamide, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Diclofenamide.]
[S01BC03, diclofenac, The risk or severity of hyperkalemia can be increased when Diclofenac is combined with Canagliflozin.]
[J05AD01, foscarnet, Foscarnet may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[A03AA07, dicyclomine, Canagliflozin may increase the excretion rate of Dicyclomine which could result in a lower serum level and potentially a reduction in efficacy.]
[A07AB02, phthalylsulfathiazole, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Phthalylsulfathiazole.]
[J05AF02, didanosine, Canagliflozin may increase the excretion rate of Didanosine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02DG01, pinacidil, Canagliflozin may increase the hypotensive activities of Pinacidil.]
[A03AX04, pinaverium, The risk or severity of hypoglycemia can be increased when Pinaverium is combined with Canagliflozin.]
[A10BG03, pioglitazone, Canagliflozin may increase the hypoglycemic activities of Pioglitazone.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Pipamperone.]
[L01DC04, ixabepilone, The serum concentration of Canagliflozin can be increased when it is combined with Ixabepilone.]
[C03CA03, piretanide, The risk or severity of hypotension can be increased when Canagliflozin is combined with Piretanide.]
[C08CA03, isradipine, The metabolism of Canagliflozin can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Canagliflozin.]
[N02BA11, diflunisal, Diflunisal may increase the hypoglycemic activities of Canagliflozin.]
[C01AA04, digitoxin, The serum concentration of Digitoxin can be increased when it is combined with Canagliflozin.]
[C01AA05, digoxin, The serum concentration of Digoxin can be increased when it is combined with Canagliflozin.]
[C02DB01, dihydralazine, Canagliflozin may increase the hypotensive activities of Dihydralazine.]
[N02AA03, hydromorphone, Canagliflozin may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX04, lenalidomide, Canagliflozin may increase the excretion rate of Lenalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE08, atazanavir, The metabolism of Canagliflozin can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, Canagliflozin may increase the hypotensive activities of Treprostinil.]
[H03BC01, potassium perchlorate, Canagliflozin may increase the excretion rate of Potassium perchlorate which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB04, pralidoxime, Canagliflozin may increase the excretion rate of Pralidoxime which could result in a lower serum level and potentially a reduction in efficacy.]
[D07AC18, prednicarbate, The risk or severity of hyperglycemia can be increased when Prednicarbate is combined with Canagliflozin.]
[C08DB01, diltiazem, The metabolism of Canagliflozin can be decreased when combined with Diltiazem.]
[V03AB09, dimercaprol, Canagliflozin may increase the excretion rate of Dimercaprol which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AX03, dimethyl sulfoxide, Canagliflozin may increase the excretion rate of Dimethyl sulfoxide which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BB04, propyphenazone, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Proglumetacin.]
[C05CA03, diosmin, The serum concentration of Canagliflozin can be increased when it is combined with Diosmin.]
[A07DA01, diphenoxylate, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Diphenoxylate.]
[C09AA06, quinapril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Quinapril.]
[B01AC07, dipyridamole, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Canagliflozin.]
[N06AA23, quinupramine, Quinupramine may decrease the hypoglycemic activities of Canagliflozin.]
[C09AA05, ramipril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Ramipril.]
[S01XA23, sirolimus, The serum concentration of Sirolimus can be increased when it is combined with Canagliflozin.]
[S01AX06, resorcinol, Canagliflozin may increase the excretion rate of Resorcinol which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BA03, disopyramide, Canagliflozin may increase the hypoglycemic activities of Disopyramide.]
[S02AA12, rifamycin SV, The metabolism of Canagliflozin can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Canagliflozin can be increased when combined with Rifapentine.]
[D06AX11, rifaximin, The serum concentration of Rifaximin can be increased when it is combined with Canagliflozin.]
[N05AX08, risperidone, Canagliflozin may increase the hypotensive activities of Risperidone.]
[R06AE09, levocetirizine, Canagliflozin may increase the excretion rate of Levocetirizine which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB09, ropivacaine, Canagliflozin may increase the excretion rate of Ropivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01MB01, rosoxacin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Rosoxacin.]
[L01EX01, sunitinib, Canagliflozin may increase the hypoglycemic activities of Sunitinib.]
[A04AD12, aprepitant, The metabolism of Canagliflozin can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The serum concentration of Tolvaptan can be increased when it is combined with Canagliflozin.]
[L01XG01, bortezomib, The serum concentration of Bortezomib can be increased when it is combined with Canagliflozin.]
[J05AE07, fosamprenavir, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Fosamprenavir.]
[G04BE08, tadalafil, Canagliflozin may increase the excretion rate of Tadalafil which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC05, ketorolac, The risk or severity of hyperkalemia can be increased when Ketorolac is combined with Canagliflozin.]
[C02KX02, ambrisentan, The serum concentration of Ambrisentan can be increased when it is combined with Canagliflozin.]
[C01EB18, ranolazine, The serum concentration of Ranolazine can be increased when it is combined with Canagliflozin.]
[N02BA06, salsalate, The risk or severity of hyperkalemia can be increased when Salsalate is combined with Canagliflozin.]
[H05BA01, salmon calcitonin, Canagliflozin may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA07, dobutamine, Canagliflozin may increase the excretion rate of Dobutamine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA04, dopamine, Canagliflozin may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA16, dothiepin, Dosulepin may decrease the hypoglycemic activities of Canagliflozin.]
[N06AA12, doxepin, Doxepin may decrease the hypoglycemic activities of Canagliflozin.]
[A06AB06, sennosides, USP, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Sennosides.]
[L01DB01, doxorubicin, The serum concentration of Doxorubicin can be increased when it is combined with Canagliflozin.]
[J01AA02, doxycycline, Canagliflozin may increase the excretion rate of Doxycycline which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AB06, sertraline, The risk or severity of hypoglycemia can be increased when Sertraline is combined with Canagliflozin.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Sevoflurane is combined with Canagliflozin.]
[A08AA10, sibutramine, Canagliflozin may increase the excretion rate of Sibutramine which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AA01, simvastatin, The serum concentration of Canagliflozin can be increased when it is combined with Simvastatin.]
[V03AG05, sodium phosphate, Canagliflozin may increase the nephrotoxic activities of Sodium phosphate, monobasic.]
[A12CA02, sodium sulfate, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Sodium sulfate.]
[C09AA11, spirapril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Spirapril.]
[R03DA01, dyphylline, Canagliflozin may increase the excretion rate of Dyphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[A07AB04, succinylsulfathiazole, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Succinylsulfathiazole.]
[N02CC01, sumatriptan, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Sumatriptan.]
[V04CX07, edrophonium, Canagliflozin may increase the excretion rate of Edrophonium which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB13, talinolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Talinolol.]
[H01AA01, corticotropin, The risk or severity of hyperglycemia can be increased when Corticotropin is combined with Canagliflozin.]
[J01MA05, temafloxacin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Temafloxacin.]
[L01AX03, temozolomide, Canagliflozin may increase the excretion rate of Temozolomide which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AC02, tenoxicam, The risk or severity of hyperkalemia can be increased when Tenoxicam is combined with Canagliflozin.]
[G04CA03, terazosin, The risk or severity of adverse effects can be increased when Terazosin is combined with Canagliflozin.]
[G04BD05, terodiline, The risk or severity of hypoglycemia can be increased when Terodiline is combined with Canagliflozin.]
[C07AA16, tertatolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Tertatolol.]
[N06AX14, tianeptine, Tianeptine may decrease the hypoglycemic activities of Canagliflozin.]
[C09AA02, enalapril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Enalapril.]
[M01AG02, tolfenamic acid, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Tolfenamic acid.]
[N06AG03, toloxatone, Toloxatone may increase the orthostatic hypotensive activities of Canagliflozin.]
[N06BA09, atomoxetine, Canagliflozin may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AX11, topiramate, Canagliflozin may increase the excretion rate of Topiramate which could result in a lower serum level and potentially a reduction in efficacy.]
[L02BA02, toremifene, The serum concentration of Canagliflozin can be increased when it is combined with Toremifene.]
[C03CA04, torsemide, The risk or severity of hypotension can be increased when Canagliflozin is combined with Torasemide.]
[C09AA10, trandolapril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Trandolapril.]
[N05CC01, chloral hydrate, Canagliflozin may increase the excretion rate of Chloral hydrate which could result in a lower serum level and potentially a reduction in efficacy.]
[H02CA01, trilostane, The risk or severity of hyperglycemia can be increased when Trilostane is combined with Canagliflozin.]
[L02AE04, triptorelin, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Triptorelin.]
[C02CA06, urapidil, Canagliflozin may increase the hypotensive activities of Urapidil.]
[J01MA04, enoxacin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Enoxacin.]
[S01FB02, ephedrine, The risk or severity of Cardiac Arrhythmia can be increased when Ephedrine is combined with Canagliflozin.]
[N06AX16, venlafaxine, The risk or severity of hypoglycemia can be increased when Venlafaxine is combined with Canagliflozin.]
[S01GA03, xylometazoline, The risk or severity of hypoglycemia can be increased when Xylometazoline is combined with Canagliflozin.]
[C08CA12, mepirodipine, The metabolism of Canagliflozin can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Epinephrine.]
[C09AA15, zofenopril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Zofenopril.]
[M01AB04, zomepirac, The risk or severity of hyperkalemia can be increased when Zomepirac is combined with Canagliflozin.]
[N03AX15, zonisamide, The serum concentration of Canagliflozin can be increased when it is combined with Zonisamide.]
[A10AB06, insulin glulisine, human, The risk or severity of hypoglycemia can be increased when Canagliflozin is combined with Insulin glulisine.]
[L01XA02, carboplatin, Canagliflozin may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AC02, guanfacine, Canagliflozin may increase the excretion rate of Guanfacine which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC11, iloprost, The risk or severity of adverse effects can be increased when Iloprost is combined with Canagliflozin.]
[N02CA02, ergotamine, The metabolism of Canagliflozin can be decreased when combined with Ergotamine.]
[L03AX05, pidotimod, Canagliflozin may increase the excretion rate of Pidotimod which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA17, erythromycin, The metabolism of Canagliflozin can be decreased when combined with Erythromycin.]
[N05CD04, estazolam, Canagliflozin may increase the excretion rate of Estazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[A02BC02, pantoprazole, Canagliflozin may increase the excretion rate of Pantoprazole which could result in a lower serum level and potentially a reduction in efficacy.]
[G03CA03, estradiol, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Estradiol.]
[G03CA57, estrogens, conjugated (USP), Canagliflozin may increase the excretion rate of Conjugated estrogens which could result in a lower serum level and potentially a reduction in efficacy.]
[J04AK02, ethambutol, Canagliflozin may increase the excretion rate of Ethambutol which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA09, fluticasone furoate, The risk or severity of hyperglycemia can be increased when Fluticasone furoate is combined with Canagliflozin.]
[R03BA05, fluticasone, The risk or severity of hyperglycemia can be increased when Fluticasone is combined with Canagliflozin.]
[V08CA03, gadodiamide, Canagliflozin may increase the excretion rate of Gadodiamide which could result in a lower serum level and potentially a reduction in efficacy.]
[D07AC21, halobetasol, The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Canagliflozin.]
[L02AA03, ethinyl estradiol, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Ethinylestradiol.]
[V03AF05, amifostine, The risk or severity of adverse effects can be increased when Amifostine is combined with Canagliflozin.]
[C01BD05, ibutilide, Canagliflozin may increase the excretion rate of Ibutilide which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AD01, ethosuximide, The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Canagliflozin.]
[M01AC06, meloxicam, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Meloxicam.]
[S01XA06, ethylmorphine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Ethylmorphine.]
[N01AX07, etomidate, Canagliflozin may increase the excretion rate of Etomidate which could result in a lower serum level and potentially a reduction in efficacy.]
[L01CB01, etoposide, The serum concentration of Etoposide can be increased when it is combined with Canagliflozin.]
[L04AD02, tacrolimus, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Tacrolimus.]
[J01MA08, fleroxacin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Fleroxacin.]
[R06AX12, terfenadine, The metabolism of Canagliflozin can be decreased when combined with Terfenadine.]
[P01AX07, trimetrexate, Canagliflozin may increase the excretion rate of Trimetrexate which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX12, bupropion, Canagliflozin may increase the excretion rate of Bupropion which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AB08, fluvoxamine, The risk or severity of hypoglycemia can be increased when Fluvoxamine is combined with Canagliflozin.]
[L02AE02, leuprolide, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Leuprolide.]
[C10AA03, pravastatin, The serum concentration of Pravastatin can be increased when it is combined with Canagliflozin.]
[M01CB01, gold sodium thiomalate, Canagliflozin may increase the excretion rate of Sodium aurothiomalate which could result in a lower serum level and potentially a reduction in efficacy.]
[B05AA05, dextran, Canagliflozin may increase the excretion rate of Dextran which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AF02, dexrazoxane, Canagliflozin may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AA01, levocarnitine, Canagliflozin may increase the excretion rate of Levocarnitine which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA02, felodipine, The risk or severity of hypoglycemia can be increased when Felodipine is combined with Canagliflozin.]
[C08EA01, fendiline, The risk or severity of hypoglycemia can be increased when Fendiline is combined with Canagliflozin.]
[M01AE04, fenoprofen, The risk or severity of hyperkalemia can be increased when Fenoprofen is combined with Canagliflozin.]
[N02AB03, fentanyl, Canagliflozin may increase the excretion rate of Fentanyl which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CC02, albuterol, Canagliflozin may increase the excretion rate of Salbutamol which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BB06, clofarabine, Canagliflozin may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy.]
[N07AX03, cevimeline, Canagliflozin may increase the excretion rate of Cevimeline which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD02, flavoxate, Canagliflozin may increase the excretion rate of Flavoxate which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BG04, floctafenine, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Floctafenine.]
[J02AC01, fluconazole, The risk or severity of hypoglycemia can be increased when Canagliflozin is combined with Fluconazole.]
[J02AX01, flucytosine, Canagliflozin may increase the excretion rate of Flucytosine which could result in a lower serum level and potentially a reduction in efficacy.]
[H02AA02, fludrocortisone, The risk or severity of hyperglycemia can be increased when Fludrocortisone is combined with Canagliflozin.]
[V03AB25, flumazenil, Canagliflozin may increase the excretion rate of Flumazenil which could result in a lower serum level and potentially a reduction in efficacy.]
[D07XB01, flumethasone, The risk or severity of hyperglycemia can be increased when Flumethasone is combined with Canagliflozin.]
[N07CA03, flunarizine, The risk or severity of hypoglycemia can be increased when Flunarizine is combined with Canagliflozin.]
[D07AC08, fluocinonide, The risk or severity of hyperglycemia can be increased when Fluocinonide is combined with Canagliflozin.]
[N06AA14, melitracen, Melitracen may decrease the hypoglycemic activities of Canagliflozin.]
[H02AB03, fluocortolone, The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Canagliflozin.]
[V03AZ01, ethanol, Ethanol may increase the hypotensive activities of Canagliflozin.]
[L01BC09, floxuridine, Canagliflozin may increase the excretion rate of Floxuridine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01CB05, fluorometholone, The risk or severity of hyperglycemia can be increased when Fluorometholone is combined with Canagliflozin.]
[N06AB03, fluoxetine, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Canagliflozin.]
[G03BA01, fluoxymesterone, Fluoxymesterone may increase the hypoglycemic activities of Canagliflozin.]
[D07AC07, flurandrenolide, The risk or severity of hyperglycemia can be increased when Flurandrenolide is combined with Canagliflozin.]
[N05CD01, flurazepam, Canagliflozin may increase the excretion rate of Flurazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC04, flurbiprofen, Canagliflozin may increase the excretion rate of Flurbiprofen which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AG01, fluspirilene, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Canagliflozin.]
[L02BB01, flutamide, Canagliflozin may increase the excretion rate of Flutamide which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CX02, folic acid, Canagliflozin may increase the excretion rate of Folic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[S02AA17, fosfomycin, Canagliflozin may increase the excretion rate of Fosfomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[L01BC03, tegafur, Canagliflozin may increase the excretion rate of Tegafur which could result in a lower serum level and potentially a reduction in efficacy.]
[G01AX06, furazolidone, Furazolidone may increase the orthostatic hypotensive activities of Canagliflozin.]
[J05AE10, darunavir, The metabolism of Canagliflozin can be decreased when combined with Darunavir.]
[C03CA01, furosemide, The risk or severity of hypotension can be increased when Canagliflozin is combined with Furosemide.]
[N05CF04, eszopiclone, Canagliflozin may increase the excretion rate of Eszopiclone which could result in a lower serum level and potentially a reduction in efficacy.]
[C08DA02, gallopamil, The risk or severity of hypoglycemia can be increased when Gallopamil is combined with Canagliflozin.]
[S01AD09, ganciclovir, Canagliflozin may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AA04, barbexaclone, The serum concentration of Canagliflozin can be decreased when it is combined with Barbexaclone.]
[C10AB04, gemfibrozil, Canagliflozin may increase the excretion rate of Gemfibrozil which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XA03, telavancin, Canagliflozin may increase the excretion rate of Telavancin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EA02, dasatinib, The serum concentration of Dasatinib can be increased when it is combined with Canagliflozin.]
[N04BC06, cabergoline, The serum concentration of Cabergoline can be increased when it is combined with Canagliflozin.]
[A10BJ02, liraglutide, Canagliflozin may increase the hypoglycemic activities of Liraglutide.]
[N03AD03, methsuximide, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Canagliflozin.]
[N01AH02, alfentanil, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Alfentanil.]
[L01EH01, lapatinib, The serum concentration of Canagliflozin can be increased when it is combined with Lapatinib.]
[A10BB01, glyburide, Canagliflozin may increase the hypoglycemic activities of Glyburide.]
[A10BB09, gliclazide, Canagliflozin may increase the hypoglycemic activities of Gliclazide.]
[A10BB07, glipizide, Canagliflozin may increase the hypoglycemic activities of Glipizide.]
[N05CM18, dexmedetomidine, Canagliflozin may increase the excretion rate of Dexmedetomidine which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AX01, glycerin, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Glycerin.]
[C05AE01, nitroglycerin, The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Canagliflozin.]
[C02CA04, doxazosin, The risk or severity of adverse effects can be increased when Doxazosin is combined with Canagliflozin.]
[H01AB01, thyrotropin alfa, Thyrotropin alfa may decrease the hypoglycemic activities of Canagliflozin.]
[L01EX02, sorafenib, The serum concentration of Canagliflozin can be increased when it is combined with Sorafenib.]
[C07AB09, esmolol, The risk or severity of adverse effects can be increased when Esmolol is combined with Canagliflozin.]
[M01CB04, aurothioglucose, Canagliflozin may increase the excretion rate of Aurothioglucose which could result in a lower serum level and potentially a reduction in efficacy.]
[S01LA03, pegaptanib, Canagliflozin may increase the excretion rate of Pegaptanib which could result in a lower serum level and potentially a reduction in efficacy.]
[C09AA09, fosinopril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Fosinopril.]
[S01EX01, guanethidine, Canagliflozin may increase the excretion rate of Guanethidine which could result in a lower serum level and potentially a reduction in efficacy.]
[L02AE03, goserelin, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Goserelin.]
[D07AD02, halcinonide, The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Canagliflozin.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Canagliflozin.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Halothane is combined with Canagliflozin.]
[L02AE05, histrelin, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Histrelin.]
[N05AH04, quetiapine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Quetiapine.]
[N06BX13, idebenone, Canagliflozin may increase the excretion rate of Idebenone which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AD05, insulin aspart, human, The risk or severity of hypoglycemia can be increased when Canagliflozin is combined with Insulin aspart.]
[M04AA01, allopurinol, Canagliflozin may increase the excretion rate of Allopurinol which could result in a lower serum level and potentially a reduction in efficacy.]
[C09CA01, losartan, The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Losartan.]
[S01XA14, heparin, The risk or severity of hyperkalemia can be increased when Heparin is combined with Canagliflozin.]
[B05CB03, magnesium citrate, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Magnesium citrate.]
[G03DC01, allylestrenol, Canagliflozin may increase the excretion rate of Allylestrenol which could result in a lower serum level and potentially a reduction in efficacy.]
[A07EC02, mesalamine, Mesalazine may increase the hypoglycemic activities of Canagliflozin.]
[C01CE02, milrinone, Canagliflozin may increase the excretion rate of Milrinone which could result in a lower serum level and potentially a reduction in efficacy.]
[A12CD02, sodium monofluorophosphate, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Sodium fluorophosphate.]
[N05CA16, hexobarbital, The serum concentration of Canagliflozin can be decreased when it is combined with Hexobarbital.]
[C08CA10, nilvadipine, The metabolism of Canagliflozin can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of hypoglycemia can be increased when Nimesulide is combined with Canagliflozin.]
[C09AA04, perindopril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Perindopril.]
[C02DB02, hydralazine, Canagliflozin may increase the excretion rate of Hydralazine which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA03, hydrochlorothiazide, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Hydrochlorothiazide.]
[R05DA03, hydrocodone, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Hydrocodone.]
[S02BA01, hydrocortisone, The risk or severity of hyperglycemia can be increased when Hydrocortisone is combined with Canagliflozin.]
[D07AC16, hydrocortisone aceponate, The risk or severity of hyperglycemia can be increased when Hydrocortisone aceponate is combined with Canagliflozin.]
[D07AB11, hydrocortisone probutate, The risk or severity of hyperglycemia can be increased when Hydrocortisone probutate is combined with Canagliflozin.]
[C03AA02, hydroflumethiazide, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Hydroflumethiazide.]
[B05XA17, potassium acetate, Canagliflozin may increase the excretion rate of Potassium acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[S01XA07, aluminum potassium sulfate, Potassium alum may increase the hyperkalemic activities of Canagliflozin.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Canagliflozin may increase the excretion rate of Hydroxocobalamin which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD06, propiverine, Canagliflozin may increase the excretion rate of Propiverine which could result in a lower serum level and potentially a reduction in efficacy.]
[P01BA02, hydroxychloroquine, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Hydroxychloroquine.]
[B05AA07, hetastarch, Canagliflozin may increase the excretion rate of Hydroxyethyl Starch which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AC06, rilmenidine, Canagliflozin may increase the hypotensive activities of Rilmenidine.]
[S01BA13, rimexolone, The risk or severity of hyperglycemia can be increased when Rimexolone is combined with Canagliflozin.]
[R02AX02, ibuprofen, Canagliflozin may increase the excretion rate of Ibuprofen which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA08, sodium acetate, Canagliflozin may increase the excretion rate of Sodium acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AD21, sodium tartrate, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Sodium tartrate.]
[L01AA06, ifosfamide, Canagliflozin may increase the excretion rate of Ifosfamide which could result in a lower serum level and potentially a reduction in efficacy.]
[H01AC02, somatrem, Somatrem may decrease the hypoglycemic activities of Canagliflozin.]
[N01AH03, sufentanil, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Sufentanil.]
[N06AA02, imipramine, The serum concentration of Imipramine can be increased when it is combined with Canagliflozin.]
[L01CD01, paclitaxel, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Canagliflozin.]
[R01AD07, tixocortol, The risk or severity of hyperglycemia can be increased when Tixocortol is combined with Canagliflozin.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Tizanidine is combined with Canagliflozin.]
[L01CE01, topotecan, The serum concentration of Topotecan can be increased when it is combined with Canagliflozin.]
[C03BA11, indapamide, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Indapamide.]
[S01BC01, indomethacin, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Canagliflozin.]
[C02CA02, indoramin, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Indoramin.]
[A11HA07, inositol, Canagliflozin may increase the excretion rate of Inositol which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX17, milnacipran, The risk or severity of hypoglycemia can be increased when Milnacipran is combined with Canagliflozin.]
[S01XA28, varenicline, Canagliflozin may increase the excretion rate of Varenicline which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB08, articaine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Articaine.]
[A10BH01, sitagliptin, Canagliflozin may increase the hypoglycemic activities of Sitagliptin.]
[N05BA12, alprazolam, Canagliflozin may increase the excretion rate of Alprazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CH02, ramelteon, Canagliflozin may increase the excretion rate of Ramelteon which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BH02, vildagliptin, Canagliflozin may increase the hypoglycemic activities of Vildagliptin.]
[C07AA01, alprenolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Alprenolol.]
[C03BA02, quinethazone, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Quinethazone.]
[V03AB01, ipecac, Canagliflozin may increase the excretion rate of Ipecac which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA13, iprindole, Iprindole may decrease the hypoglycemic activities of Canagliflozin.]
[N06AF05, iproniazid, Iproniazid may increase the orthostatic hypotensive activities of Canagliflozin.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the orthostatic hypotensive activities of Canagliflozin.]
[C09AA16, imidapril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Imidapril.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Canagliflozin.]
[J04AC01, isoniazid, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Isoniazid.]
[J05AX05, inosine pranobex, Canagliflozin may increase the excretion rate of Inosine pranobex which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BJ01, exenatide, Canagliflozin may increase the hypoglycemic activities of Exenatide.]
[C01DA14, isosorbide mononitrate, Canagliflozin may increase the excretion rate of Isosorbide mononitrate which could result in a lower serum level and potentially a reduction in efficacy.]
[C05AE02, isosorbide dinitrate, The risk or severity of adverse effects can be increased when Isosorbide dinitrate is combined with Canagliflozin.]
[D10BA01, isotretinoin, Canagliflozin may increase the excretion rate of Isotretinoin which could result in a lower serum level and potentially a reduction in efficacy.]
[C04AA01, isoxsuprine, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Isoxsuprine.]
[S01AA24, kanamycin, Canagliflozin may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[H01AC01, somatropin, Somatotropin may decrease the hypoglycemic activities of Canagliflozin.]
[N01AX03, ketamine, Canagliflozin may increase the excretion rate of Ketamine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02KD01, ketanserin, Canagliflozin may increase the hypotensive activities of Ketanserin.]
[B01AC22, prasugrel, Canagliflozin may increase the excretion rate of Prasugrel which could result in a lower serum level and potentially a reduction in efficacy.]
[J02AB02, ketoconazole, The metabolism of Canagliflozin can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Canagliflozin can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Olanzapine.]
[M02AA10, ketoprofen, Canagliflozin may increase the excretion rate of Ketoprofen which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC03, deferasirox, The metabolism of Canagliflozin can be decreased when combined with Deferasirox.]
[S01GX08, ketotifen, The risk or severity of thrombocytopenia can be increased when Canagliflozin is combined with Ketotifen.]
[N04BC09, rotigotine, The risk or severity of adverse effects can be increased when Rotigotine is combined with Canagliflozin.]
[A16AX01, thioctic acid, The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Canagliflozin.]
[D10AX03, azelaic acid, Canagliflozin may increase the excretion rate of Azelaic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[J01MB02, nalidixic acid, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Nalidixic acid.]
[M01AE11, tiaprofenic acid, The risk or severity of hyperkalemia can be increased when Tiaprofenic acid is combined with Canagliflozin.]
[C07AG01, labetalol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Labetalol.]
[N04BB01, amantadine, Canagliflozin may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AA05, deserpidine, Canagliflozin may increase the hypotensive activities of Deserpidine.]
[A06AD11, lactulose, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Lactulose.]
[A06AX03, lubiprostone, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Lubiprostone.]
[C03CC01, ethacrynic acid, The risk or severity of hypotension can be increased when Canagliflozin is combined with Etacrynic acid.]
[G03AD01, levonorgestrel, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Levonorgestrel.]
[N04BA01, levodopa, The risk or severity of hypotension and orthostatic hypotension can be increased when Canagliflozin is combined with Levodopa.]
[C08EX01, lidoflazine, The risk or severity of hypoglycemia can be increased when Lidoflazine is combined with Canagliflozin.]
[S01AA21, amikacin, Canagliflozin may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA07, lofepramine, Lofepramine may decrease the hypoglycemic activities of Canagliflozin.]
[A07DA03, loperamide, The excretion of Loperamide can be decreased when combined with Canagliflozin.]
[N05BA06, lorazepam, Canagliflozin may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AA02, lovastatin, The metabolism of Canagliflozin can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, The serum concentration of Canagliflozin can be increased when it is combined with Loxapine.]
[L01EG01, temsirolimus, The serum concentration of Temsirolimus can be increased when it is combined with Canagliflozin.]
[B05XA11, magnesium chloride, Canagliflozin may increase the excretion rate of Magnesium chloride which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BX01, magnesium hydroxide, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Magnesium hydroxide.]
[A12CC10, magnesium oxide, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Magnesium oxide.]
[V04CC02, magnesium sulfate, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Magnesium sulfate.]
[L01BA05, pralatrexate, Canagliflozin may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EA03, nilotinib, The metabolism of Canagliflozin can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, The serum concentration of Mannitol can be increased when it is combined with Canagliflozin.]
[N06AA21, maprotiline, Canagliflozin may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.]
[C02BB01, mecamylamine, Canagliflozin may increase the excretion rate of Mecamylamine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA18, meclofenamic acid, Canagliflozin may increase the excretion rate of Meclofenamic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[C01AA08, medigoxin, Canagliflozin may decrease the excretion rate of Metildigoxin which could result in a higher serum level.]
[A06AB07, cascara sagrada, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Frangula purshiana bark.]
[P01BC02, mefloquine, The serum concentration of Canagliflozin can be increased when it is combined with Mefloquine.]
[C03BA05, mefruside, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Mefruside.]
[B01AB06, nadroparin, The risk or severity of hyperkalemia can be increased when Nadroparin is combined with Canagliflozin.]
[B01AB05, enoxaparin, The risk or severity of hyperkalemia can be increased when Enoxaparin is combined with Canagliflozin.]
[B01AB04, dalteparin, The risk or severity of hyperkalemia can be increased when Dalteparin is combined with Canagliflozin.]
[N06DX01, memantine, Canagliflozin may increase the excretion rate of Memantine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AB02, meperidine, Canagliflozin may increase the excretion rate of Meperidine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AA01, mephobarbital, The serum concentration of Canagliflozin can be decreased when it is combined with Methylphenobarbital.]
[N01BB03, mepivacaine, Canagliflozin may increase the excretion rate of Mepivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AX05, meptazinol, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Meptazinol.]
[G04BX16, tiopronin, Canagliflozin may increase the excretion rate of Tiopronin which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BC01, mersalyl, Canagliflozin may increase the excretion rate of Mersalyl which could result in a lower serum level and potentially a reduction in efficacy.]
[G03BB01, mesterolone, Mesterolone may increase the hypoglycemic activities of Canagliflozin.]
[N05AX13, paliperidone, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Paliperidone.]
[H01CB03, lanreotide, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lanreotide.]
[N07BC02, methadone, Canagliflozin may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BA03, methamphetamine, Canagliflozin may increase the excretion rate of Metamfetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF05, lamivudine, Canagliflozin may increase the excretion rate of Lamivudine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01EC05, methazolamide, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Methazolamide.]
[H03BB02, methimazole, The metabolism of Canagliflozin can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, Canagliflozin may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[N05CA15, methohexital, The serum concentration of Canagliflozin can be decreased when it is combined with Methohexital.]
[A11HA02, pyridoxine, Canagliflozin may increase the excretion rate of Pyridoxine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BG08, ziconotide, The risk or severity of CNS depression can be increased when Canagliflozin is combined with Ziconotide.]
[L04AX03, methotrexate, Canagliflozin may increase the excretion rate of Methotrexate which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AA02, methotrimeprazine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Methotrimeprazine.]
[D05BA02, methoxsalen, Canagliflozin may increase the excretion rate of Methoxsalen which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Methyclothiazide.]
[A06AC06, methylcellulose, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Methylcellulose.]
[C02AB01, methyldopa, Canagliflozin may increase the excretion rate of Methyldopa which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CG05, methylene blue, Methylene blue may increase the orthostatic hypotensive activities of Canagliflozin.]
[H02AB04, methylprednisolone, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Canagliflozin.]
[D07AC14, methylprednisolone aceponate, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Canagliflozin.]
[G03EK01, methyltestosterone, Canagliflozin may increase the excretion rate of Methyltestosterone which could result in a lower serum level and potentially a reduction in efficacy.]
[A03FA01, metoclopramide, Canagliflozin may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BA08, metolazone, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Metolazone.]
[C07AB02, metoprolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Metoprolol.]
[V04CD01, metyrapone, Canagliflozin may increase the excretion rate of Metyrapone which could result in a lower serum level and potentially a reduction in efficacy.]
[S02AA13, miconazole, The metabolism of Canagliflozin can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The risk or severity of hyperkalemia can be increased when Aminophenazone is combined with Canagliflozin.]
[B01AB07, parnaparin, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Parnaparin.]
[N05CD08, midazolam, Canagliflozin may increase the excretion rate of Midazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[G03XB01, mifepristone, Canagliflozin may increase the hypoglycemic activities of Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of hyperkalemia can be increased when Tinzaparin is combined with Canagliflozin.]
[A06AA01, mineral oil, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Mineral oil.]
[J05AH01, zanamivir, Canagliflozin may increase the excretion rate of Zanamivir which could result in a lower serum level and potentially a reduction in efficacy.]
[C09CA03, valsartan, The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Valsartan.]
[D11AX01, minoxidil, The risk or severity of adverse effects can be increased when Minoxidil is combined with Canagliflozin.]
[L01XX23, mitotane, The metabolism of Canagliflozin can be increased when combined with Mitotane.]
[L03AC01, aldesleukin, Canagliflozin may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BD01, amiodarone, The metabolism of Canagliflozin can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, Amitriptyline may decrease the hypoglycemic activities of Canagliflozin.]
[N02AA01, morphine, The serum concentration of Morphine can be increased when it is combined with Canagliflozin.]
[A04AA05, palonosetron, Canagliflozin may increase the excretion rate of Palonosetron which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[L04AB05, certolizumab pegol, Canagliflozin may increase the excretion rate of Certolizumab pegol which could result in a lower serum level and potentially a reduction in efficacy.]
[B02BX05, eltrombopag, The metabolism of Canagliflozin can be decreased when combined with Eltrombopag.]
[G04BA01, ammonium chloride, Canagliflozin may increase the excretion rate of Ammonium chloride which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX03, pazopanib, The serum concentration of Pazopanib can be increased when it is combined with Canagliflozin.]
[L04AA06, mycophenolic acid, Canagliflozin may increase the excretion rate of Mycophenolic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CA02, amobarbital, The serum concentration of Canagliflozin can be decreased when it is combined with Amobarbital.]
[G04CA04, silodosin, The excretion of Silodosin can be decreased when combined with Canagliflozin.]
[N06AA17, amoxapine, Amoxapine may decrease the hypoglycemic activities of Canagliflozin.]
[N03AB05, fosphenytoin, The serum concentration of Canagliflozin can be decreased when it is combined with Fosphenytoin.]
[C07AA12, nadolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Nadolol.]
[J01CA04, amoxicillin, Canagliflozin may increase the excretion rate of Amoxicillin which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BC04, ropinirole, The risk or severity of adverse effects can be increased when Ropinirole is combined with Canagliflozin.]
[N02AF02, nalbuphine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Nalbuphine.]
[V03AB15, naloxone, The metabolism of Canagliflozin can be decreased when combined with Naloxone.]
[N07BB04, naltrexone, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Naltrexone.]
[S01XA11, nandrolone, Nandrolone phenpropionate may increase the hypoglycemic activities of Canagliflozin.]
[N06BA01, amphetamine, Canagliflozin may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA12, naproxen, The risk or severity of hyperkalemia can be increased when Naproxen is combined with Canagliflozin.]
[A10BG01, troglitazone, Canagliflozin may increase the hypoglycemic activities of Troglitazone.]
[N06AX21, duloxetine, The risk or severity of orthostatic hypotension and syncope can be increased when Canagliflozin is combined with Duloxetine.]
[N04BX01, tolcapone, Canagliflozin may increase the excretion rate of Tolcapone which could result in a lower serum level and potentially a reduction in efficacy.]
[S03AA01, neomycin, Canagliflozin may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[N01AH06, remifentanil, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Remifentanil.]
[A10BX02, repaglinide, Canagliflozin may increase the hypoglycemic activities of Repaglinide.]
[C01CX08, levosimendan, The risk or severity of adverse effects can be increased when Levosimendan is combined with Canagliflozin.]
[B01AC17, tirofiban, Canagliflozin may increase the excretion rate of Tirofiban which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AX14, iloperidone, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Iloperidone.]
[J02AA01, amphotericin B, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Canagliflozin.]
[S01AA19, ampicillin, Canagliflozin may increase the excretion rate of Ampicillin which could result in a lower serum level and potentially a reduction in efficacy.]
[L03AX16, plerixafor, Canagliflozin may increase the excretion rate of Plerixafor which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA23, netilmicin, Canagliflozin may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The risk or severity of hypoglycemia can be increased when Desvenlafaxine is combined with Canagliflozin.]
[C09CA07, telmisartan, The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Telmisartan.]
[J05AB11, valacyclovir, Canagliflozin may increase the excretion rate of Valaciclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CE01, inamrinone, Canagliflozin may increase the excretion rate of Amrinone which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AD02, niacin, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Niacin.]
[N06AF02, nialamide, Nialamide may increase the orthostatic hypotensive activities of Canagliflozin.]
[C08CA04, nicardipine, The metabolism of Canagliflozin can be decreased when combined with Nicardipine.]
[C08CA05, nifedipine, Canagliflozin may increase the excretion rate of Nifedipine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA17, niflumic acid, The metabolism of Canagliflozin can be decreased when combined with Niflumic acid.]
[V03AB22, amyl nitrite, The risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Canagliflozin.]
[C08CA06, nimodipine, The risk or severity of hypoglycemia can be increased when Nimodipine is combined with Canagliflozin.]
[C08CA07, nisoldipine, Canagliflozin may increase the excretion rate of Nisoldipine which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA08, nitrendipine, The risk or severity of hypoglycemia can be increased when Nitrendipine is combined with Canagliflozin.]
[R07AX01, nitric oxide, Canagliflozin may increase the excretion rate of Nitric Oxide which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XE01, nitrofurantoin, Canagliflozin may increase the excretion rate of Nitrofurantoin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF03, zaleplon, Canagliflozin may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BC05, pramipexole, Canagliflozin may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.]
[C02DD01, nitroprusside, Canagliflozin may increase the excretion rate of Nitroprusside which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA03, norepinephrine, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Canagliflozin.]
[G03DC02, norethindrone, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Norethisterone.]
[S01AE02, norfloxacin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Norfloxacin.]
[C02KX01, bosentan, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Bosentan.]
[N06AA10, nortriptyline, The serum concentration of Nortriptyline can be increased when it is combined with Canagliflozin.]
[A16AX07, sapropterin, The serum concentration of Canagliflozin can be increased when it is combined with Sapropterin.]
[G02CA02, nylidrin, The risk or severity of hypoglycemia can be increased when Nylidrin is combined with Canagliflozin.]
[B01AB08, reviparin, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Reviparin.]
[H01CB02, octreotide, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Octreotide.]
[S02AA16, ofloxacin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Ofloxacin.]
[N06AA05, opipramol, Opipramol may decrease the hypoglycemic activities of Canagliflozin.]
[N02AA02, opium, Canagliflozin may increase the excretion rate of Opium which could result in a lower serum level and potentially a reduction in efficacy.]
[G04CA02, tamsulosin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Tamsulosin.]
[J01CF04, oxacillin, Canagliflozin may increase the excretion rate of Oxacillin which could result in a lower serum level and potentially a reduction in efficacy.]
[A14AA08, oxandrolone, Oxandrolone may increase the hypoglycemic activities of Canagliflozin.]
[N05BA04, oxazepam, Canagliflozin may increase the excretion rate of Oxazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[J01MB05, oxolinic acid, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Oxolinic acid.]
[C07AA02, oxprenolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Oxprenolol.]
[N02AA05, oxycodone, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Oxycodone.]
[A14AA05, oxymetholone, Oxymetholone may increase the hypoglycemic activities of Canagliflozin.]
[N02AA11, oxymorphone, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Oxymorphone.]
[S01BC02, oxyphenbutazone, The risk or severity of hyperkalemia can be increased when Oxyphenbutazone is combined with Canagliflozin.]
[J04AA01, aminosalicylic acid, Aminosalicylic acid may increase the hypoglycemic activities of Canagliflozin.]
[N05AH05, asenapine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Asenapine.]
[B01AB09, danaparoid, The risk or severity of hyperkalemia can be increased when Danaparoid is combined with Canagliflozin.]
[N02AX06, tapentadol, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Tapentadol.]
[J04AB30, capreomycin, Canagliflozin may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[G04BE02, papaverine, The risk or severity of adverse effects can be increased when Papaverine is combined with Canagliflozin.]
[H02AB05, paramethasone, The risk or severity of hyperglycemia can be increased when Paramethasone is combined with Canagliflozin.]
[C02KC01, pargyline, Pargyline may increase the orthostatic hypotensive activities of Canagliflozin.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J01MA03, pefloxacin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Pefloxacin.]
[G04BD11, fesoterodine, Canagliflozin may increase the excretion rate of Fesoterodine which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AA23, penbutolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of hypoglycemia can be increased when Penfluridol is combined with Canagliflozin.]
[J01CE09, penicillin G procaine, Canagliflozin may increase the excretion rate of Procaine benzylpenicillin which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AD01, pentazocine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Pentazocine.]
[N05CA01, pentobarbital, The serum concentration of Canagliflozin can be decreased when it is combined with Pentobarbital.]
[L01XX08, pentostatin, Canagliflozin may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, Canagliflozin may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[C08EX02, perhexiline, The risk or severity of hypoglycemia can be increased when Perhexiline is combined with Canagliflozin.]
[N02AD02, phenazocine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Phenazocine.]
[G04BX06, phenazopyridine, Canagliflozin may increase the excretion rate of Phenazopyridine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AF03, phenelzine, Phenelzine may increase the orthostatic hypotensive activities of Canagliflozin.]
[A10BA01, phenformin, Canagliflozin may increase the hypoglycemic activities of Phenformin.]
[N03AA02, phenobarbital, The serum concentration of Canagliflozin can be decreased when it is combined with Phenobarbital.]
[A06AB01, oxyphenisatin, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Oxyphenisatin.]
[N01AH04, phenoperidine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Phenoperidine.]
[C04AX02, phenoxybenzamine, The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Canagliflozin.]
[A08AA01, phentermine, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Phentermine.]
[V03AB36, phentolamine, Canagliflozin may increase the excretion rate of Phentolamine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA01, phenylbutazone, The risk or severity of hyperkalemia can be increased when Phenylbutazone is combined with Canagliflozin.]
[N03AB02, phenytoin, The serum concentration of Canagliflozin can be decreased when it is combined with Phenytoin.]
[S01AE05, levofloxacin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Levofloxacin.]
[B02BA01, vitamin K1, Canagliflozin may increase the excretion rate of Phylloquinone which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AB12, cidofovir, Canagliflozin may increase the excretion rate of Cidofovir which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CX01, mibefradil, The serum concentration of Canagliflozin can be increased when it is combined with Mibefradil.]
[C07AA03, pindolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Pindolol.]
[J01CA12, piperacillin, Canagliflozin may increase the excretion rate of Piperacillin which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE01, saquinavir, The metabolism of Canagliflozin can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Piperazine.]
[N05AC04, pipothiazine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Pipotiazine.]
[N06BX03, piracetam, Canagliflozin may increase the excretion rate of Piracetam which could result in a lower serum level and potentially a reduction in efficacy.]
[C09CA02, eprosartan, The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Eprosartan.]
[N02AC03, pirinitramide, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Piritramide.]
[S01BC06, piroxicam, Canagliflozin may increase the excretion rate of Piroxicam which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J01MA11, grepafloxacin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Grepafloxacin.]
[J05AG02, delavirdine, The metabolism of Canagliflozin can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Irbesartan.]
[A10BG02, rosiglitazone, Canagliflozin may increase the hypoglycemic activities of Rosiglitazone.]
[A06AD15, polyethylene glycols, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Polyethylene glycol.]
[C03AA05, polythiazide, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Polythiazide.]
[J05AE03, ritonavir, The metabolism of Canagliflozin can be increased when combined with Ritonavir.]
[A10BH03, saxagliptin, Canagliflozin may increase the hypoglycemic activities of Saxagliptin.]
[B05XA01, potassium chloride, Canagliflozin may increase the excretion rate of Potassium chloride which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB21, potassium iodide, Potassium Iodide may increase the hyperkalemic activities of Canagliflozin.]
[A10AD04, insulin lispro, The risk or severity of hypoglycemia can be increased when Canagliflozin is combined with Insulin lispro.]
[C07AB01, practolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Practolol.]
[C02CA01, prazosin, The risk or severity of adverse effects can be increased when Prazosin is combined with Canagliflozin.]
[S03BA02, prednisolone, The risk or severity of hyperglycemia can be increased when Prednisolone is combined with Canagliflozin.]
[H02AB07, prednisone, The risk or severity of hyperglycemia can be increased when Prednisone is combined with Canagliflozin.]
[C01DX02, prenylamine, The risk or severity of hypoglycemia can be increased when Prenylamine is combined with Canagliflozin.]
[P01BA03, primaquine, The metabolism of Canagliflozin can be decreased when combined with Primaquine.]
[N03AA03, primidone, The serum concentration of Canagliflozin can be decreased when it is combined with Primidone.]
[M04AB01, probenecid, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Probenecid.]
[C01BA02, procainamide, Canagliflozin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01HA05, procaine, Procaine may increase the orthostatic hypotensive activities of Canagliflozin.]
[L01XB01, procarbazine, Procarbazine may increase the orthostatic hypotensive activities of Canagliflozin.]
[C10AB05, fenofibrate, Canagliflozin may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.]
[G03DA04, progesterone, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Progesterone.]
[R06AD02, promethazine, Canagliflozin may increase the excretion rate of Promethazine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BC03, propafenone, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Propafenone.]
[A03AB05, propantheline, Canagliflozin may increase the excretion rate of Propantheline which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AX26, fexofenadine, The serum concentration of Fexofenadine can be increased when it is combined with Canagliflozin.]
[L01XH02, romidepsin, The serum concentration of Romidepsin can be increased when it is combined with Canagliflozin.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Propofol is combined with Canagliflozin.]
[N02AC04, propoxyphene, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Dextropropoxyphene.]
[C07AA05, propranolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Propranolol.]
[N02CC04, rizatriptan, Canagliflozin may increase the excretion rate of Rizatriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC09, epoprostenol, Canagliflozin may increase the excretion rate of Epoprostenol which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA11, protriptyline, Protriptyline may decrease the hypoglycemic activities of Canagliflozin.]
[R01BA02, pseudoephedrine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Pseudoephedrine.]
[N05AX12, aripiprazole, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Aripiprazole.]
[N07XX07, dalfampridine, Canagliflozin may increase the excretion rate of Dalfampridine which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CC01, pyrantel, Canagliflozin may increase the excretion rate of Pyrantel which could result in a lower serum level and potentially a reduction in efficacy.]
[J04AK01, pyrazinamide, Canagliflozin may increase the excretion rate of Pyrazinamide which could result in a lower serum level and potentially a reduction in efficacy.]
[A12BA05, potassium gluconate, Potassium gluconate may increase the hyperkalemic activities of Canagliflozin.]
[C01BA01, quinidine, The serum concentration of Quinidine can be increased when it is combined with Canagliflozin.]
[P01BC01, quinine, Canagliflozin may increase the hypoglycemic activities of Quinine.]
[D07AC10, diflorasone, The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Canagliflozin.]
[A02BA02, ranitidine, Canagliflozin may increase the excretion rate of Ranitidine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AA01, rescinnamine, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Rescinnamine.]
[C02AA02, reserpine, The serum concentration of Canagliflozin can be increased when it is combined with Reserpine.]
[J05AP01, ribavirin, Canagliflozin may increase the excretion rate of Ribavirin which could result in a lower serum level and potentially a reduction in efficacy.]
[J04AB02, rifampin, The serum concentration of Canagliflozin can be decreased when it is combined with Rifampicin.]
[N02BA05, salicylamide, The risk or severity of hyperkalemia can be increased when Salicylamide is combined with Canagliflozin.]
[A07EC01, sulfasalazine, Sulfasalazine may increase the hypoglycemic activities of Canagliflozin.]
[S01BC08, salicylic acid, Salicylic acid may increase the hypoglycemic activities of Canagliflozin.]
[N05CA06, secobarbital, The serum concentration of Canagliflozin can be decreased when it is combined with Secobarbital.]
[N04BD01, selegiline, Selegiline may increase the orthostatic hypotensive activities of Canagliflozin.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Obinutuzumab.]
[J01GB08, sisomicin, Canagliflozin may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Canagliflozin may increase the excretion rate of Sodium fluoride which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CC01, sorbitol, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Sorbitol.]
[C07AA07, sotalol, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Canagliflozin.]
[L01CD04, cabazitaxel, The serum concentration of Cabazitaxel can be increased when it is combined with Canagliflozin.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01FD03, ado-trastuzumab emtansine, The serum concentration of Trastuzumab emtansine can be increased when it is combined with Canagliflozin.]
[D07AB02, hydrocortisone butyrate, The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Canagliflozin.]
[S02DA03, antipyrine, The risk or severity of hyperkalemia can be increased when Antipyrine is combined with Canagliflozin.]
[A14AA02, stanozolol, Stanozolol may increase the hypoglycemic activities of Canagliflozin.]
[B01AD01, streptokinase, The risk or severity of adverse effects can be increased when Streptokinase is combined with Canagliflozin.]
[J01GA01, streptomycin, Canagliflozin may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[M03AB01, succinylcholine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Canagliflozin.]
[A02BX02, sucralfate, Canagliflozin may increase the excretion rate of Sucralfate which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CG01, sulbactam, Canagliflozin may increase the excretion rate of Sulbactam which could result in a lower serum level and potentially a reduction in efficacy.]
[J01EC02, sulfadiazine, Canagliflozin may increase the hypoglycemic activities of Sulfadiazine.]
[J01ED01, sulfadimethoxine, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Sulfadimethoxine.]
[A07AB03, sulfaguanidine, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Sulfaguanidine.]
[J01ED02, sulfalene, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Sulfametopyrazine.]
[J01ED07, sulfamerazine, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Sulfamerazine.]
[J01EB03, sulfamethazine, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Sulfamethazine.]
[S01AB01, sulfamethizole, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Sulfamethizole.]
[J01EC01, sulfamethoxazole, Canagliflozin may increase the hypoglycemic activities of Sulfamethoxazole.]
[J01ED05, sulfamethoxypyridazine, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Sulfamethoxypyridazine.]
[J01EC03, sulfamoxole, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Sulfamoxole.]
[J01EB04, sulfapyridine, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Sulfapyridine.]
[J01EB01, sulfisomidine, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Sulfaisodimidine.]
[S01AB02, sulfisoxazole, Canagliflozin may increase the hypoglycemic activities of Sulfisoxazole.]
[M01AB02, sulindac, The risk or severity of hyperkalemia can be increased when Sulindac is combined with Canagliflozin.]
[A10BB04, glibornuride, Canagliflozin may increase the hypoglycemic activities of Glibornuride.]
[A10BC01, glymidine, Canagliflozin may increase the hypoglycemic activities of Glymidine.]
[M01AX04, apazone, The risk or severity of hyperkalemia can be increased when Azapropazone is combined with Canagliflozin.]
[L02BA01, tamoxifen, The serum concentration of Canagliflozin can be increased when it is combined with Tamoxifen.]
[N05CD07, temazepam, Canagliflozin may increase the excretion rate of Temazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CC03, terbutaline, Canagliflozin may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AE07, dabigatran etexilate, The serum concentration of Dabigatran etexilate can be increased when it is combined with Canagliflozin.]
[G03BA03, testosterone, Canagliflozin may increase the excretion rate of Testosterone which could result in a lower serum level and potentially a reduction in efficacy.]
[S03AA02, tetracycline, Canagliflozin may increase the excretion rate of Tetracycline which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[N05AE05, lurasidone, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lurasidone.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Canagliflozin.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Thalidomide is combined with Canagliflozin.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CA02, thiabendazole, Canagliflozin may increase the excretion rate of Thiabendazole which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AD03, thiethylperazine, Canagliflozin may increase the excretion rate of Thiethylperazine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CA19, thiopental, The serum concentration of Canagliflozin can be decreased when it is combined with Thiopental.]
[N05AC02, thioridazine, The risk or severity of adverse effects can be increased when Thioridazine is combined with Canagliflozin.]
[G04BE06, moxisylyte, Canagliflozin may increase the excretion rate of Moxisylyte which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AL03, tiapride, Canagliflozin may increase the excretion rate of Tiapride which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC05, ticlopidine, Canagliflozin may increase the excretion rate of Ticlopidine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AX01, tilidine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Tilidine.]
[S01ED01, timolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Timolol.]
[P01AB02, tinidazole, Canagliflozin may increase the excretion rate of Tinidazole which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA12, tobramycin, Canagliflozin may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, Canagliflozin may increase the hypoglycemic activities of Tolazamide.]
[M02AX02, tolazoline, The risk or severity of adverse effects can be increased when Tolazoline is combined with Canagliflozin.]
[V04CA01, tolbutamide, Canagliflozin may increase the hypoglycemic activities of Tolbutamide.]
[M02AA21, tolmetin, The risk or severity of hyperkalemia can be increased when Tolmetin is combined with Canagliflozin.]
[N02AX02, tramadol, Canagliflozin may increase the excretion rate of Tramadol which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the orthostatic hypotensive activities of Canagliflozin.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Canagliflozin.]
[S01BA05, triamcinolone, The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Canagliflozin.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, Canagliflozin may increase the excretion rate of Triazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA06, trichlormethiazide, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Trichlormethiazide.]
[A16AX12, trientine, Canagliflozin may increase the excretion rate of Triethylenetetramine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AD02, trifluridine, Canagliflozin may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BA09, clobetasone, The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Canagliflozin.]
[S01BA10, alclometasone, The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Canagliflozin.]
[D07AC02, fluclorolone, The risk or severity of hyperglycemia can be increased when Fluclorolone is combined with Canagliflozin.]
[R03BA07, mometasone, The risk or severity of hyperglycemia can be increased when Mometasone is combined with Canagliflozin.]
[A03AA05, trimebutine, Canagliflozin may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AC02, trimethadione, The risk or severity of hypoglycemia can be increased when Trimethadione is combined with Canagliflozin.]
[C02BA01, trimethaphan, Canagliflozin may increase the hypotensive activities of Trimethaphan.]
[J01EA01, trimethoprim, Canagliflozin may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA06, trimipramine, The serum concentration of Trimipramine can be increased when it is combined with Canagliflozin.]
[J01FA08, troleandomycin, The metabolism of Canagliflozin can be decreased when combined with Troleandomycin.]
[C09CA09, azilsartan medoxomil, The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Azilsartan medoxomil.]
[R03DX07, roflumilast, Canagliflozin may increase the excretion rate of Roflumilast which could result in a lower serum level and potentially a reduction in efficacy.]
[L01FX04, ipilimumab, Canagliflozin may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX04, vandetanib, The serum concentration of Canagliflozin can be increased when it is combined with Vandetanib.]
[R02AA14, oxyquinoline, Canagliflozin may increase the excretion rate of Oxyquinoline which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BH05, linagliptin, Canagliflozin may increase the hypoglycemic activities of Linagliptin.]
[J05AP03, boceprevir, The metabolism of Canagliflozin can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Canagliflozin can be decreased when combined with Telaprevir.]
[S01AA28, vancomycin, Canagliflozin may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, Canagliflozin may increase the excretion rate of Ezogabine which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AF01, rivaroxaban, The serum concentration of Rivaroxaban can be increased when it is combined with Canagliflozin.]
[R03AC18, indacaterol, The serum concentration of Indacaterol can be increased when it is combined with Canagliflozin.]
[B01AC24, ticagrelor, The serum concentration of Canagliflozin can be increased when it is combined with Ticagrelor.]
[C08DA01, verapamil, The metabolism of Canagliflozin can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Canagliflozin can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The serum concentration of Vinblastine can be increased when it is combined with Canagliflozin.]
[C04AX07, vincamine, Canagliflozin may increase the hypotensive activities of Vincamine.]
[L01CA02, vincristine, The excretion of Vincristine can be decreased when combined with Canagliflozin.]
[B03BA01, vitamin B12, Canagliflozin may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AA03, warfarin, Canagliflozin may decrease the excretion rate of Warfarin which could result in a higher serum level.]
[C03BA10, xipamide, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Xipamide.]
[J05AE02, indinavir, The metabolism of Canagliflozin can be decreased when combined with Indinavir.]
[L01EC01, vemurafenib, The serum concentration of Canagliflozin can be increased when it is combined with Vemurafenib.]
[L01FX05, brentuximab vedotin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Canagliflozin.]
[M05BA05, tiludronic acid, Canagliflozin may increase the excretion rate of Tiludronic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[B06AC02, icatibant, Canagliflozin may increase the excretion rate of Icatibant which could result in a lower serum level and potentially a reduction in efficacy.]
[L01ED01, crizotinib, The serum concentration of Crizotinib can be increased when it is combined with Canagliflozin.]
[A02BC04, rabeprazole, Canagliflozin may increase the excretion rate of Rabeprazole which could result in a lower serum level and potentially a reduction in efficacy.]
[J01MA13, trovafloxacin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Trovafloxacin.]
[N05AE04, ziprasidone, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Ziprasidone.]
[G03AC10, drospirenone, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Drospirenone.]
[V03AC02, deferiprone, Canagliflozin may increase the excretion rate of Deferiprone which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA01, aspirin, The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Canagliflozin.]
[L01EJ01, ruxolitinib, Canagliflozin may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD07, tolterodine, Canagliflozin may increase the excretion rate of Tolterodine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DH04, doripenem, Canagliflozin may increase the excretion rate of Doripenem which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB03, atenolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Atenolol.]
[J02AC03, voriconazole, The metabolism of Canagliflozin can be decreased when combined with Voriconazole.]
[M01CB03, auranofin, Canagliflozin may increase the excretion rate of Auranofin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EK01, axitinib, The serum concentration of Axitinib can be increased when it is combined with Canagliflozin.]
[R07AX02, ivacaftor, The serum concentration of Canagliflozin can be increased when it is combined with Ivacaftor.]
[H02AB11, prednylidene, The risk or severity of hyperglycemia can be increased when Prednylidene is combined with Canagliflozin.]
[B03XA04, peginesatide, Canagliflozin may increase the excretion rate of Peginesatide which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC07, azacitidine, Canagliflozin may increase the excretion rate of Azacitidine which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX01, azathioprine, Canagliflozin may increase the excretion rate of Azathioprine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC05, gemcitabine, The serum concentration of Gemcitabine can be increased when it is combined with Canagliflozin.]
[J01DF01, aztreonam, Canagliflozin may increase the excretion rate of Aztreonam which could result in a lower serum level and potentially a reduction in efficacy.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Canagliflozin.]
[M03BX01, baclofen, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Baclofen.]
[A08AA11, lorcaserin, Canagliflozin may increase the excretion rate of Lorcaserin which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD12, mirabegron, The serum concentration of Canagliflozin can be increased when it is combined with Mirabegron.]
[L01XG02, carfilzomib, The serum concentration of Carfilzomib can be increased when it is combined with Canagliflozin.]
[V03AX03, cobicistat, The metabolism of Canagliflozin can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Canagliflozin can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Canagliflozin can be decreased when it is combined with Enzalutamide.]
[A06AX04, linaclotide, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Linaclotide.]
[L01EA04, bosutinib, The serum concentration of Bosutinib can be increased when it is combined with Canagliflozin.]
[H02AA01, aldosterone, The risk or severity of hyperglycemia can be increased when Aldosterone is combined with Canagliflozin.]
[L01EX05, regorafenib, The serum concentration of Regorafenib can be increased when it is combined with Canagliflozin.]
[N05CA04, barbital, The serum concentration of Canagliflozin can be decreased when it is combined with Barbital.]
[D02BA02, octinoxate, Canagliflozin may increase the excretion rate of Octinoxate which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE04, nelfinavir, The metabolism of Canagliflozin can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, The serum concentration of Bendamustine can be increased when it is combined with Canagliflozin.]
[N04BD02, rasagiline, Rasagiline may increase the orthostatic hypotensive activities of Canagliflozin.]
[C08CA13, lercanidipine, The risk or severity of hypoglycemia can be increased when Lercanidipine is combined with Canagliflozin.]
[V09IX04, fluorodeoxyglucose F18, Canagliflozin may increase the excretion rate of Fludeoxyglucose (18F) which could result in a lower serum level and potentially a reduction in efficacy.]
[H01CB05, pasireotide, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Pasireotide.]
[G04BE03, sildenafil, The serum concentration of Canagliflozin can be increased when it is combined with Sildenafil.]
[V08CA11, gadofosveset, Canagliflozin may increase the excretion rate of Gadofosveset trisodium which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EA05, ponatinib, The serum concentration of Canagliflozin can be increased when it is combined with Ponatinib.]
[B01AF02, apixaban, The serum concentration of Apixaban can be increased when it is combined with Canagliflozin.]
[A16AX08, teduglutide, Canagliflozin may increase the excretion rate of Teduglutide which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AX12, lomitapide, The serum concentration of Canagliflozin can be increased when it is combined with Lomitapide.]
[C04AX11, bencyclane, The risk or severity of hypoglycemia can be increased when Bencyclane is combined with Canagliflozin.]
[A10BH04, alogliptin, Canagliflozin may increase the hypoglycemic activities of Alogliptin.]
[A16AX09, glycerol phenylbutyrate, Canagliflozin may increase the excretion rate of Glycerol phenylbutyrate which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA01, bendroflumethiazide, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Bendroflumethiazide.]
[L04AX06, pomalidomide, The serum concentration of Pomalidomide can be increased when it is combined with Canagliflozin.]
[N02BA10, benorilate, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Benorilate.]
[S01AA13, fusidic acid, The metabolism of Canagliflozin can be decreased when combined with Fusidic acid.]
[J01MB04, pipemidic acid, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Pipemidic acid.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[V08AA01, diatrizoic acid, Canagliflozin may increase the excretion rate of Diatrizoate which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AA04, iothalamic acid, Canagliflozin may increase the excretion rate of Diatrizoate which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CM19, suvorexant, The serum concentration of Canagliflozin can be increased when it is combined with Suvorexant.]
[A16AX10, eliglustat, The serum concentration of Canagliflozin can be increased when it is combined with Eliglustat.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[A06AB04, phenolphthalein, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Phenolphthalein.]
[A10BJ05, dulaglutide, Canagliflozin may increase the hypoglycemic activities of Dulaglutide.]
[A06AH03, naloxegol, The serum concentration of Naloxegol can be increased when it is combined with Canagliflozin.]
[L01EX09, nintedanib, The serum concentration of Nintedanib can be increased when it is combined with Canagliflozin.]
[A06AG02, bisacodyl, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Bisacodyl.]
[S03AA06, gentamicin, Canagliflozin may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[J05AP09, dasabuvir, The serum concentration of Dasabuvir can be increased when it is combined with Canagliflozin.]
[B01AF03, edoxaban, The serum concentration of Edoxaban can be increased when it is combined with Canagliflozin.]
[L01EF01, palbociclib, The serum concentration of Canagliflozin can be increased when it is combined with Palbociclib.]
[L01EX08, lenvatinib, The serum concentration of Lenvatinib can be increased when it is combined with Canagliflozin.]
[L01XH03, panobinostat, The serum concentration of Panobinostat can be increased when it is combined with Canagliflozin.]
[J05AP07, daclatasvir, The serum concentration of Canagliflozin can be increased when it is combined with Daclatasvir.]
[N02BE01, acetaminophen, Canagliflozin may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy.]
[L01DC01, bleomycin, Canagliflozin may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AP06, asunaprevir, The serum concentration of Canagliflozin can be increased when it is combined with Asunaprevir.]
[A07DA06, eluxadoline, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Eluxadoline.]
[N05AX16, brexpiprazole, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Brexpiprazole.]
[A04AD14, rolapitant, The serum concentration of Canagliflozin can be increased when it is combined with Rolapitant.]
[G02CX02, flibanserin, The serum concentration of Canagliflozin can be increased when it is combined with Flibanserin.]
[A06AD03, magnesium peroxide, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Magnesium peroxide.]
[A10BF01, acarbose, Canagliflozin may increase the hypoglycemic activities of Acarbose.]
[M02AA25, aceclofenac, Canagliflozin may increase the excretion rate of Aceclofenac which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AB11, acemetacin, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Acemetacin.]
[S01EC01, acetazolamide, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Acetazolamide.]
[A10AE06, insulin degludec, The risk or severity of hypoglycemia can be increased when Canagliflozin is combined with Insulin degludec.]
[V03AB37, idarucizumab, Canagliflozin may increase the excretion rate of Idarucizumab which could result in a lower serum level and potentially a reduction in efficacy.]
[J02AC05, isavuconazole, The serum concentration of Canagliflozin can be increased when it is combined with Isavuconazole.]
[L01EB04, osimertinib, The serum concentration of Osimertinib can be increased when it is combined with Canagliflozin.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Canagliflozin.]
[L01EE02, cobimetinib, The serum concentration of Cobimetinib can be increased when it is combined with Canagliflozin.]
[L01XG03, ixazomib, Canagliflozin may increase the excretion rate of Ixazomib which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC27, selexipag, The serum concentration of Selexipag can be increased when it is combined with Canagliflozin.]
[A10BB31, acetohexamide, Canagliflozin may increase the hypoglycemic activities of Acetohexamide.]
[M04AB05, lesinurad, Canagliflozin may increase the excretion rate of Lesinurad which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AP10, elbasvir, The serum concentration of Elbasvir can be increased when it is combined with Canagliflozin.]
[J05AP11, grazoprevir, The serum concentration of Grazoprevir can be increased when it is combined with Canagliflozin.]
[M01AE16, alminoprofen, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Alminoprofen.]
[N02BA02, aloxiprin, Aloxiprin may increase the hypoglycemic activities of Canagliflozin.]
[N03AX23, brivaracetam, Canagliflozin may increase the excretion rate of Brivaracetam which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XX52, venetoclax, The serum concentration of Venetoclax can be increased when it is combined with Canagliflozin.]
[N05BA08, bromazepam, Canagliflozin may increase the excretion rate of Bromazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BC01, bromocriptine, Canagliflozin may increase the hypoglycemic activities of Bromocriptine.]
[A02AD05, aluminum magnesium silicate, Canagliflozin may increase the excretion rate of Almasilate which could result in a lower serum level and potentially a reduction in efficacy.]
[D07AC11, amcinonide, The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Canagliflozin.]
[N06AA19, amineptin, Amineptine may decrease the hypoglycemic activities of Canagliflozin.]
[C08CA01, amlodipine, The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Canagliflozin.]
[C03CA02, bumetanide, The risk or severity of hypotension can be increased when Canagliflozin is combined with Bumetanide.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Canagliflozin.]
[C07AA19, bupranolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Bupranolol.]
[N07BC01, buprenorphine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Buprenorphine.]
[L02AE01, buserelin, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Buserelin.]
[N05BE01, buspirone, Canagliflozin may increase the excretion rate of Buspirone which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XX27, arsenic trioxide, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Arsenic trioxide.]
[M02AA03, clofezone, Canagliflozin may increase the excretion rate of Rabeprazole which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AF01, butorphanol, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Butorphanol.]
[J01MA09, sparfloxacin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Sparfloxacin.]
[A06AX07, plecanatide, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Plecanatide.]
[L01EF02, ribociclib, The metabolism of Canagliflozin can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, Balsalazide may increase the hypoglycemic activities of Canagliflozin.]
[A06AH05, naldemedine, Canagliflozin may increase the excretion rate of Naldemedine which could result in a lower serum level and potentially a reduction in efficacy.]
[N07XX16, deutetrabenazine, Canagliflozin may increase the excretion rate of Deutetrabenazine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BF02, pregabalin, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Canagliflozin.]
[C09AA07, benazepril, The risk or severity of hypoglycemia can be increased when Benazepril is combined with Canagliflozin.]
[A10BX06, benfluorex, Canagliflozin may increase the hypoglycemic activities of Benfluorex.]
[P01CA02, benznidazole, Canagliflozin may increase the excretion rate of Benznidazole which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XX08, linezolid, Linezolid may increase the orthostatic hypotensive activities of Canagliflozin.]
[J05AF06, abacavir, Canagliflozin may increase the excretion rate of Abacavir which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE09, tipranavir, The metabolism of Canagliflozin can be decreased when combined with Tipranavir.]
[N07XX13, valbenazine, Canagliflozin may increase the excretion rate of Valbenazine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX10, midostaurin, The metabolism of Canagliflozin can be decreased when combined with Midostaurin.]
[N04BD03, safinamide, Safinamide may increase the orthostatic hypotensive activities of Canagliflozin.]
[J01MA23, delafloxacin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Delafloxacin.]
[B01AF04, betrixaban, The serum concentration of Betrixaban can be increased when it is combined with Canagliflozin.]
[L01BC06, capecitabine, Canagliflozin may increase the excretion rate of Capecitabine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XX59, enasidenib, The serum concentration of Canagliflozin can be increased when it is combined with Enasidenib.]
[L01EH02, neratinib, The serum concentration of Canagliflozin can be increased when it is combined with Neratinib.]
[L01FB01, inotuzumab ozogamicin, The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Canagliflozin.]
[L01XH01, vorinostat, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Vorinostat.]
[L01EM02, copanlisib, The serum concentration of Copanlisib can be increased when it is combined with Canagliflozin.]
[L01EF03, abemaciclib, The serum concentration of Abemaciclib can be increased when it is combined with Canagliflozin.]
[C07AB07, bisoprolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Bisoprolol.]
[J05AG03, efavirenz, The serum concentration of Canagliflozin can be decreased when it is combined with Efavirenz.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[C07AA17, bopindolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Bopindolol.]
[C01DX19, nesiritide, The risk or severity of adverse effects can be increased when Nesiritide is combined with Canagliflozin.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, The risk or severity of hyperglycemia can be increased when Budesonide is combined with Canagliflozin.]
[M01AB07, bumadizone, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Bumadizone.]
[N06AA15, butriptyline, Butriptyline may decrease the hypoglycemic activities of Canagliflozin.]
[C01AA02, acetyldigoxins, Canagliflozin may decrease the excretion rate of Acetyldigoxin which could result in a higher serum level.]
[A10BJ06, semaglutide, Canagliflozin may increase the hypoglycemic activities of Semaglutide.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Ertugliflozin.]
[R06AX18, acrivastine, Canagliflozin may increase the excretion rate of Acrivastine which could result in a lower serum level and potentially a reduction in efficacy.]
[C09AA01, captopril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Captopril.]
[L02BB05, apalutamide, The serum concentration of Canagliflozin can be decreased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Canagliflozin can be increased when combined with Carbamazepine.]
[A06AC08, calcium polycarbophil, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Calcium polycarbophil.]
[C07AG02, carvedilol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Carvedilol.]
[B02BX09, fostamatinib, The risk or severity of hypotension can be increased when Fostamatinib is combined with Canagliflozin.]
[N03AX24, cannabidiol, The metabolism of Canagliflozin can be decreased when combined with Cannabidiol.]
[B02BX08, avatrombopag, The serum concentration of Avatrombopag can be increased when it is combined with Canagliflozin.]
[L04AA37, baricitinib, Canagliflozin may increase the excretion rate of Baricitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[L01EE03, binimetinib, The serum concentration of Binimetinib can be increased when it is combined with Canagliflozin.]
[J01DD14, ceftibuten, Canagliflozin may increase the excretion rate of Ceftibuten which could result in a lower serum level and potentially a reduction in efficacy.]
[J01GB14, plazomicin, Canagliflozin may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Celiprolol.]
[H01CC03, elagolix, The serum concentration of Elagolix can be increased when it is combined with Canagliflozin.]
[L01XX62, ivosidenib, The metabolism of Canagliflozin can be increased when combined with Ivosidenib.]
[A16AX14, migalastat, Canagliflozin may increase the excretion rate of Migalastat which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AX17, stiripentol, The metabolism of Canagliflozin can be decreased when combined with Stiripentol.]
[B02BX07, lusutrombopag, The serum concentration of Lusutrombopag can be increased when it is combined with Canagliflozin.]
[L01EM04, duvelisib, The serum concentration of Duvelisib can be increased when it is combined with Canagliflozin.]
[L01EB07, dacomitinib, The serum concentration of Dacomitinib can be increased when it is combined with Canagliflozin.]
[J01AA14, sarecycline, The serum concentration of Canagliflozin can be increased when it is combined with Sarecycline.]
[J01AA15, omadacycline, The serum concentration of Omadacycline can be increased when it is combined with Canagliflozin.]
[S01GX12, cetirizine, Canagliflozin may increase the excretion rate of Cetirizine which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BB06, carbutamide, Canagliflozin may increase the hypoglycemic activities of Carbutamide.]
[D08AE05, chloroxylenol, Canagliflozin may increase the excretion rate of Chloroxylenol which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AC05, lornoxicam, The risk or severity of hyperkalemia can be increased when Lornoxicam is combined with Canagliflozin.]
[N07XX15, inotersen, Inotersen may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[L01XK04, talazoparib, The serum concentration of Talazoparib can be increased when it is combined with Canagliflozin.]
[R03BB08, revefenacin, The serum concentration of Revefenacin can be increased when it is combined with Canagliflozin.]
[L01AD01, carmustine, Canagliflozin may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX12, larotrectinib, The serum concentration of Larotrectinib can be increased when it is combined with Canagliflozin.]
[L01EX13, gilteritinib, The serum concentration of Gilteritinib can be increased when it is combined with Canagliflozin.]
[L01XJ03, glasdegib, The serum concentration of Glasdegib can be increased when it is combined with Canagliflozin.]
[A06AX05, prucalopride, The serum concentration of Prucalopride can be increased when it is combined with Canagliflozin.]
[C01BG07, cifenline, The risk or severity of hypoglycemia can be increased when Cibenzoline is combined with Canagliflozin.]
[C09AA08, cilazapril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Cilazapril.]
[B01AC23, cilostazol, Canagliflozin may increase the excretion rate of Cilostazol which could result in a lower serum level and potentially a reduction in efficacy.]
[J01FA09, clarithromycin, The metabolism of Canagliflozin can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, Canagliflozin may increase the excretion rate of Solriamfetol which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EN01, erdafitinib, The serum concentration of Canagliflozin can be increased when it is combined with Erdafitinib.]
[N05BA09, clobazam, The serum concentration of Clobazam can be increased when it is combined with Canagliflozin.]
[D07AB21, clocortolone, The risk or severity of hyperglycemia can be increased when Clocortolone is combined with Canagliflozin.]
[H02AB14, cloprednol, The risk or severity of hyperglycemia can be increased when Cloprednol is combined with Canagliflozin.]
[A06AB05, castor oil, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Castor oil.]
[C01EB09, ubidecarenone, The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Canagliflozin.]
[C09CA06, candesartan, The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Candesartan.]
[H02AB17, cortivazol, The risk or severity of hyperglycemia can be increased when Cortivazol is combined with Canagliflozin.]
[J01DC04, cefaclor, Canagliflozin may increase the excretion rate of Cefaclor which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DB05, cefadroxil, Canagliflozin may increase the excretion rate of Cefadroxil which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[L02BB06, darolutamide, The serum concentration of Darolutamide can be increased when it is combined with Canagliflozin.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J01DC05, cefotetan, Canagliflozin may increase the excretion rate of Cefotetan which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J01DD02, ceftazidime, Canagliflozin may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BX03, cicletanine, Cicletanine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J01DD04, ceftriaxone, Canagliflozin may increase the excretion rate of Ceftriaxone which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[L01EJ02, fedratinib, The serum concentration of Fedratinib can be increased when it is combined with Canagliflozin.]
[L01EX14, entrectinib, The serum concentration of Canagliflozin can be increased when it is combined with Entrectinib.]
[N07XX11, pitolisant, The serum concentration of Canagliflozin can be decreased when it is combined with Pitolisant.]
[J01XX12, lefamulin, Canagliflozin may decrease the excretion rate of Lefamulin which could result in a higher serum level.]
[N04CX01, istradefylline, The serum concentration of Canagliflozin can be increased when it is combined with Istradefylline.]
[C03AA09, cyclothiazide, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Cyclothiazide.]
[A10AE03, insulin, regular, pork, The risk or severity of hypoglycemia can be increased when Canagliflozin is combined with Insulin pork.]
[A06AB03, danthron, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Dantron.]
[J01XX09, daptomycin, The serum concentration of Daptomycin can be increased when it is combined with Canagliflozin.]
[J01DB01, cephalexin, Canagliflozin may increase the excretion rate of Cephalexin which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J01DB09, cephradine, Canagliflozin may increase the excretion rate of Cefradine which could result in a lower serum level and potentially a reduction in efficacy.]
[H02AB13, deflazacort, The risk or severity of hyperglycemia can be increased when Deflazacort is combined with Canagliflozin.]
[N02CC08, lasmiditan, The serum concentration of Canagliflozin can be increased when it is combined with Lasmiditan.]
[G03AC09, desogestrel, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Desogestrel.]
[N03AX25, cenobamate, The serum concentration of Canagliflozin can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, Givosiran may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[M09AX08, golodirsen, Canagliflozin may increase the excretion rate of Golodirsen which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Canagliflozin.]
[L01FX13, enfortumab vedotin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Canagliflozin.]
[S01XA12, dexpanthenol, Canagliflozin may increase the excretion rate of Dexpanthenol which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AX03, dezocine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Dezocine.]
[N05CM21, lemborexant, The serum concentration of Lemborexant can be increased when it is combined with Canagliflozin.]
[L01XX72, tazemetostat, The serum concentration of Tazemetostat can be increased when it is combined with Canagliflozin.]
[L04AA53, teprotumumab, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Teprotumumab.]
[N02CD06, rimegepant, The serum concentration of Rimegepant can be increased when it is combined with Canagliflozin.]
[S01AE06, gatifloxacin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Gatifloxacin.]
[J05AE05, amprenavir, The metabolism of Canagliflozin can be decreased when combined with Amprenavir.]
[L01EE04, selumetinib, The serum concentration of Selumetinib can be increased when it is combined with Canagliflozin.]
[R02AA03, dichlorobenzyl alcohol, Canagliflozin may increase the excretion rate of Dichlorobenzyl alcohol which could result in a lower serum level and potentially a reduction in efficacy.]
[G03DB08, dienogest, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Dienogest.]
[D07AC19, difluprednate, The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Canagliflozin.]
[N02AA08, dihydrocodeine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Dihydrocodeine.]
[M01AH02, rofecoxib, The risk or severity of hyperkalemia can be increased when Rofecoxib is combined with Canagliflozin.]
[C08CA16, clevidipine, Canagliflozin may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BD07, dronedarone, The metabolism of Canagliflozin can be decreased when combined with Dronedarone.]
[C02AA06, methoserpidine, Canagliflozin may increase the hypotensive activities of Methoserpidine.]
[L01EH03, tucatinib, Tucatinib may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[L01EX17, capmatinib, The serum concentration of Canagliflozin can be increased when it is combined with Capmatinib.]
[N04BX04, opicapone, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Opicapone.]
[D07XB03, fluprednidene, The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Canagliflozin.]
[M01AC04, droxicam, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Droxicam.]
[L01EX19, ripretinib, The serum concentration of Ripretinib can be increased when it is combined with Canagliflozin.]
[V08CA05, mangafodipir, Canagliflozin may increase the excretion rate of Mangafodipir which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BA14, loteprednol, The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Canagliflozin.]
[M02AA27, dexketoprofen, Canagliflozin may increase the excretion rate of Dexketoprofen which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA17, levamlodipine, The risk or severity of hypoglycemia can be increased when Levamlodipine is combined with Canagliflozin.]
[J05AX29, fostemsavir, The serum concentration of Fostemsavir can be increased when it is combined with Canagliflozin.]
[L01FX15, belantamab mafodotin, The serum concentration of Belantamab mafodotin can be increased when it is combined with Canagliflozin.]
[L04AC19, satralizumab, The serum concentration of Canagliflozin can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Oliceridine.]
[P01BA01, chloroquine, Canagliflozin may increase the excretion rate of Chloroquine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX23, pralsetinib, The serum concentration of Pralsetinib can be increased when it is combined with Canagliflozin.]
[C03AA04, chlorothiazide, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Chlorothiazide.]
[N05AA01, chlorpromazine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Chlorpromazine.]
[A10BB02, chlorpropamide, Canagliflozin may increase the hypoglycemic activities of Chlorpropamide.]
[C03BA04, chlorthalidone, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Chlorthalidone.]
[M03BB03, chlorzoxazone, Canagliflozin may increase the excretion rate of Chlorzoxazone which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA07, ethenzamide, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Ethenzamide.]
[N02BA03, choline salicylate, Choline salicylate may increase the hypoglycemic activities of Canagliflozin.]
[N06BX18, vinpocetine, The risk or severity of hypoglycemia can be increased when Vinpocetine is combined with Canagliflozin.]
[M01AB08, etodolac, Canagliflozin may increase the excretion rate of Etodolac which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA06, etofenamate, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Etofenamate.]
[B06AC06, berotralstat, The serum concentration of Berotralstat can be increased when it is combined with Canagliflozin.]
[A16AX20, lonafarnib, The metabolism of Canagliflozin can be decreased when combined with Lonafarnib.]
[L02BX04, relugolix, The serum concentration of Relugolix can be increased when it is combined with Canagliflozin.]
[M01AX25, chondroitin sulfates, Canagliflozin may increase the excretion rate of Chondroitin sulfate which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AD03, voclosporin, The serum concentration of Voclosporin can be increased when it is combined with Canagliflozin.]
[P03AX07, abametapir, The serum concentration of Canagliflozin can be increased when it is combined with Abametapir.]
[C01DX22, vericiguat, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Vericiguat.]
[L01EX21, tepotinib, The serum concentration of Tepotinib can be increased when it is combined with Canagliflozin.]
[L01EX25, umbralisib, The serum concentration of Canagliflozin can be increased when it is combined with Umbralisib.]
[V03AF12, trilaciclib, The serum concentration of Trilaciclib can be increased when it is combined with Canagliflozin.]
[M01AE05, fenbufen, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Fenbufen.]
[C01CA19, fenoldopam, Canagliflozin may increase the excretion rate of Fenoldopam which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD15, cefdinir, Canagliflozin may increase the excretion rate of Cefdinir which could result in a lower serum level and potentially a reduction in efficacy.]
[J01MB07, flumequine, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Flumequine.]
[R03BA03, flunisolide, The risk or severity of hyperglycemia can be increased when Flunisolide is combined with Canagliflozin.]
[S02BA08, fluocinolone acetonide, The risk or severity of hyperglycemia can be increased when Fluocinolone acetonide is combined with Canagliflozin.]
[N02BG07, flupirtine, Canagliflozin may increase the excretion rate of Flupirtine which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AF01, insulin, regular, human, The risk or severity of hypoglycemia can be increased when Canagliflozin is combined with Insulin human.]
[L01EK03, tivozanib, The serum concentration of Tivozanib can be increased when it is combined with Canagliflozin.]
[H04AA02, dasiglucagon, Canagliflozin may increase the hypotensive activities of Dasiglucagon.]
[L01FX22, loncastuximab tesirine, The serum concentration of Loncastuximab tesirine can be increased when it is combined with Canagliflozin.]
[A02BA01, cimetidine, Canagliflozin may increase the excretion rate of Cimetidine which could result in a lower serum level and potentially a reduction in efficacy.]
[V08CA04, gadoteridol, Canagliflozin may increase the excretion rate of Gadoteridol which could result in a lower serum level and potentially a reduction in efficacy.]
[N07CA02, cinnarizine, The risk or severity of hypoglycemia can be increased when Cinnarizine is combined with Canagliflozin.]
[J01MB06, cinoxacin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Canagliflozin can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Ciprofloxacin.]
[L01XA01, cisplatin, Canagliflozin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AB04, citalopram, The risk or severity of hypoglycemia can be increased when Citalopram is combined with Canagliflozin.]
[H01AC07, somapacitan, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Somapacitan.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AA48, belumosudil, The serum concentration of Canagliflozin can be increased when it is combined with Belumosudil.]
[H01AC09, lonapegsomatropin, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lonapegsomatropin.]
[M01AG01, mefenamic acid, The metabolism of Canagliflozin can be decreased when combined with Mefenamic acid.]
[A10BB12, glimepiride, Canagliflozin may increase the hypoglycemic activities of Glimepiride.]
[A10BB08, gliquidone, Canagliflozin may increase the hypoglycemic activities of Gliquidone.]
[N06AX25, St. John's wort extract, The serum concentration of Canagliflozin can be decreased when it is combined with St. John's Wort.]
[L01EA06, asciminib, The serum concentration of Canagliflozin can be increased when it is combined with Asciminib.]
[J05AX10, maribavir, The serum concentration of Canagliflozin can be increased when it is combined with Maribavir.]
[D07AD01, clobetasol, The risk or severity of hyperglycemia can be increased when Clobetasol is combined with Canagliflozin.]
[D11AH08, abrocitinib, The serum concentration of Canagliflozin can be increased when it is combined with Abrocitinib.]
[J04BA01, clofazimine, The serum concentration of Canagliflozin can be increased when it is combined with Clofazimine.]
[B06AX04, mitapivat, The serum concentration of Canagliflozin can be increased when it is combined with Mitapivat.]
[N01BB10, levobupivacaine, Canagliflozin may increase the excretion rate of Levobupivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EJ03, pacritinib, The serum concentration of Canagliflozin can be increased when it is combined with Pacritinib.]
[G03GB02, clomiphene, The serum concentration of Clomifene can be increased when it is combined with Canagliflozin.]
[N06AA04, clomipramine, Clomipramine may decrease the hypoglycemic activities of Canagliflozin.]
[N03AE01, clonazepam, Canagliflozin may increase the excretion rate of Clonazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[S01EA04, clonidine, The risk or severity of adverse effects can be increased when Clonidine is combined with Canagliflozin.]
[C01EB24, mavacamten, The serum concentration of Canagliflozin can be decreased when it is combined with Mavacamten.]
[J05AH02, oseltamivir, Canagliflozin may increase the excretion rate of Oseltamivir which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BX16, tirzepatide, Canagliflozin may increase the hypoglycemic activities of Tirzepatide.]
[C03BA03, clopamide, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Clopamide.]
[N05AH02, clozapine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Clozapine.]
[L01EN04, futibatinib, The serum concentration of Futibatinib can be increased when it is combined with Canagliflozin.]
[A10BX01, guar gum, Canagliflozin may increase the hypoglycemic activities of Guar gum.]
[A10BK06, sotagliflozin, Canagliflozin may increase the hypoglycemic activities of Sotagliflozin.]
[J01GB12, arbekacin, Canagliflozin may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[D07AC12, halometasone, The risk or severity of hyperglycemia can be increased when Halometasone is combined with Canagliflozin.]
[H01AC08, somatrogon, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Somatrogon.]
[C02KB01, metyrosine, Canagliflozin may increase the hypotensive activities of Metyrosine.]
[M01AX13, proquazone, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Proquazone.]
[R05DA04, codeine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Codeine.]
[M04AC01, colchicine, The serum concentration of Colchicine can be increased when it is combined with Canagliflozin.]
[J01XB01, colistin, Canagliflozin may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Desflurane is combined with Canagliflozin.]
[A04AA03, tropisetron, Canagliflozin may increase the excretion rate of Tropisetron which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BX03, nateglinide, Canagliflozin may increase the hypoglycemic activities of Nateglinide.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Imidazole salicylate.]
[H01AC03, mecasermin, Canagliflozin may increase the hypoglycemic activities of Mecasermin.]
[A10AE04, insulin glargine, The risk or severity of hypoglycemia can be increased when Canagliflozin is combined with Insulin glargine.]
[J01FA15, telithromycin, The metabolism of Canagliflozin can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The risk or severity of hyperglycemia can be increased when Ciclesonide is combined with Canagliflozin.]
[B01AC10, indobufen, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Indobufen.]
[J05AB14, valganciclovir, Canagliflozin may increase the excretion rate of Valganciclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[C05BB03, invert sugar, Canagliflozin may increase the excretion rate of Invert sugar which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB09, iodixanol, Canagliflozin may increase the excretion rate of Iodixanol which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB05, iopromide, Canagliflozin may increase the excretion rate of Iopromide which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB07, ioversol, Canagliflozin may increase the excretion rate of Ioversol which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB12, ioxilan, Canagliflozin may increase the excretion rate of Ioxilan which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH03, valdecoxib, The risk or severity of hyperkalemia can be increased when Valdecoxib is combined with Canagliflozin.]
[H01AX01, pegvisomant, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Canagliflozin.]
[N02CC05, almotriptan, Canagliflozin may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH04, parecoxib, The risk or severity of hyperkalemia can be increased when Parecoxib is combined with Canagliflozin.]
[J02AC02, itraconazole, The metabolism of Canagliflozin can be decreased when combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Bemiparin.]
[S01AD03, acyclovir, Canagliflozin may increase the excretion rate of Acyclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA10, ketazolam, Canagliflozin may increase the excretion rate of Ketazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AA06, kebuzone, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Kebuzone.]
[J02AC04, posaconazole, The metabolism of Canagliflozin can be decreased when combined with Posaconazole.]
[C08CA09, lacidipine, Canagliflozin may increase the hypotensive activities of Lacidipine.]
[A06AD12, lactitol, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Lactitol.]
[N03AX09, lamotrigine, Canagliflozin may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BA03, cortisone, The risk or severity of hyperglycemia can be increased when Cortisone is combined with Canagliflozin.]
[N07BC04, lofexidine, Canagliflozin may increase the excretion rate of Lofexidine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AE04, lomefloxacin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Lomefloxacin.]
[M01AB09, lonazolac, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Lonazolac.]
[M02AA31, loxoprofen, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Loxoprofen.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[C09AA03, lisinopril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Lisinopril.]
[A06AD01, magnesium carbonate, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Magnesium carbonate.]
[C08CA11, manidipine, The risk or severity of hypoglycemia can be increased when Manidipine is combined with Canagliflozin.]
[S01BA08, medrysone, The risk or severity of hyperglycemia can be increased when Medrysone is combined with Canagliflozin.]
[C07AA14, mepindolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Mepindolol.]
[H02AB15, meprednisone, The risk or severity of hyperglycemia can be increased when Meprednisone is combined with Canagliflozin.]
[J01DH02, meropenem, Canagliflozin may increase the excretion rate of Meropenem which could result in a lower serum level and potentially a reduction in efficacy.]
[C04AX01, cyclandelate, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Canagliflozin.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, Canagliflozin may increase the excretion rate of Melperone which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA07, cyclopenthiazide, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Cyclopenthiazide.]
[A10BF02, miglitol, Canagliflozin may increase the hypoglycemic activities of Miglitol.]
[J05AF07, tenofovir disoproxil, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Canagliflozin.]
[N06AX07, minaprine, Minaprine may increase the orthostatic hypotensive activities of Canagliflozin.]
[S01XA18, cyclosporine, The serum concentration of Cyclosporine can be increased when it is combined with Canagliflozin.]
[N06AG02, moclobemide, Moclobemide may increase the orthostatic hypotensive activities of Canagliflozin.]
[C09AA13, moexipril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Moexipril.]
[C10AA07, rosuvastatin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Rosuvastatin.]
[M02AA02, mofebutazone, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Morniflumate.]
[C03XA02, conivaptan, The metabolism of Canagliflozin can be decreased when combined with Conivaptan.]
[C02AC05, moxonidine, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Moxonidine.]
[G04BE09, vardenafil, The serum concentration of Canagliflozin can be increased when it is combined with Vardenafil.]
[M01AH05, etoricoxib, The risk or severity of hyperkalemia can be increased when Etoricoxib is combined with Canagliflozin.]
[L01AX04, dacarbazine, Canagliflozin may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01DA01, dactinomycin, The serum concentration of Dactinomycin can be increased when it is combined with Canagliflozin.]
[G03XA01, danazol, The metabolism of Canagliflozin can be decreased when combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Canagliflozin.]
[C02CC04, debrisoquin, Canagliflozin may increase the hypotensive activities of Debrisoquine.]
[A04AD11, nabilone, The risk or severity of adverse effects can be increased when Nabilone is combined with Canagliflozin.]
[M01AX01, nabumetone, The risk or severity of hyperkalemia can be increased when Nabumetone is combined with Canagliflozin.]
[N07BB05, nalmefene, Canagliflozin may increase the excretion rate of Nalmefene which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA15, potassium lactate, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Potassium lactate.]
[C07AB12, nebivolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Nebivolol.]
[S01GX04, nedocromil, Canagliflozin may increase the excretion rate of Nedocromil which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX06, nefazodone, The metabolism of Canagliflozin can be decreased when combined with Nefazodone.]
[C01DX16, nicorandil, Nicorandil may increase the hypotensive activities of Canagliflozin.]
[L02BB02, nilutamide, Canagliflozin may increase the excretion rate of Nilutamide which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA23, theodrenaline, The risk or severity of Cardiac Arrhythmia can be increased when Theodrenaline is combined with Canagliflozin.]
[R05DA06, normethadone, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Normethadone.]
[B01AX05, fondaparinux, Canagliflozin may increase the excretion rate of Fondaparinux which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AB10, escitalopram, The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Canagliflozin.]
[A07EC03, olsalazine, Olsalazine may increase the hypoglycemic activities of Canagliflozin.]
[N06AA01, desipramine, Desipramine may decrease the hypoglycemic activities of Canagliflozin.]
[H01BA02, desmopressin, Canagliflozin may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BA11, desonide, The risk or severity of hyperglycemia can be increased when Desonide is combined with Canagliflozin.]
[D07XC02, desoximetasone, The risk or severity of hyperglycemia can be increased when Desoximetasone is combined with Canagliflozin.]
[V04CH02, indigo carmine, Canagliflozin may increase the excretion rate of Indigotindisulfonic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[H02AA03, desoxycorticosterone, The risk or severity of hyperglycemia can be increased when Desoxycortone is combined with Canagliflozin.]
[J01DH03, ertapenem, Canagliflozin may increase the excretion rate of Ertapenem which could result in a lower serum level and potentially a reduction in efficacy.]
[C09XA02, aliskiren, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Aliskiren.]
[M01AE12, oxaprozin, Canagliflozin may increase the excretion rate of Oxaprozin which could result in a lower serum level and potentially a reduction in efficacy.]
[S03BA01, dexamethasone, The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Canagliflozin.]
[N06BA02, dextroamphetamine, Canagliflozin may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AC01, dextromoramide, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Dextromoramide.]
[N06AB05, paroxetine, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Canagliflozin.]
[N07BC06, heroin, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Diamorphine.]
[C01DA05, pentaerythritol tetranitrate, Canagliflozin may increase the excretion rate of Pentaerythritol tetranitrate which could result in a lower serum level and potentially a reduction in efficacy.]
[P03AC04, permethrin, Canagliflozin may increase the excretion rate of Permethrin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA01, diazepam, Canagliflozin may increase the excretion rate of Diazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AH01, diazoxide, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Diazoxide.]
[N06AA08, dibenzepin, Dibenzepin may decrease the hypoglycemic activities of Canagliflozin.]
[R05DA08, pholcodine, Canagliflozin may increase the excretion rate of Pholcodine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01EC02, dichlorphenamide, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Diclofenamide.]
[S01BC03, diclofenac, The risk or severity of hyperkalemia can be increased when Diclofenac is combined with Canagliflozin.]
[J05AD01, foscarnet, Foscarnet may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[A03AA07, dicyclomine, Canagliflozin may increase the excretion rate of Dicyclomine which could result in a lower serum level and potentially a reduction in efficacy.]
[A07AB02, phthalylsulfathiazole, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Phthalylsulfathiazole.]
[J05AF02, didanosine, Canagliflozin may increase the excretion rate of Didanosine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02DG01, pinacidil, Canagliflozin may increase the hypotensive activities of Pinacidil.]
[A03AX04, pinaverium, The risk or severity of hypoglycemia can be increased when Pinaverium is combined with Canagliflozin.]
[A10BG03, pioglitazone, Canagliflozin may increase the hypoglycemic activities of Pioglitazone.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Pipamperone.]
[L01DC04, ixabepilone, The serum concentration of Canagliflozin can be increased when it is combined with Ixabepilone.]
[C03CA03, piretanide, The risk or severity of hypotension can be increased when Canagliflozin is combined with Piretanide.]
[C08CA03, isradipine, The metabolism of Canagliflozin can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Canagliflozin.]
[N02BA11, diflunisal, Diflunisal may increase the hypoglycemic activities of Canagliflozin.]
[C01AA04, digitoxin, The serum concentration of Digitoxin can be increased when it is combined with Canagliflozin.]
[C01AA05, digoxin, The serum concentration of Digoxin can be increased when it is combined with Canagliflozin.]
[C02DB01, dihydralazine, Canagliflozin may increase the hypotensive activities of Dihydralazine.]
[N02AA03, hydromorphone, Canagliflozin may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX04, lenalidomide, Canagliflozin may increase the excretion rate of Lenalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE08, atazanavir, The metabolism of Canagliflozin can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, Canagliflozin may increase the hypotensive activities of Treprostinil.]
[H03BC01, potassium perchlorate, Canagliflozin may increase the excretion rate of Potassium perchlorate which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB04, pralidoxime, Canagliflozin may increase the excretion rate of Pralidoxime which could result in a lower serum level and potentially a reduction in efficacy.]
[D07AC18, prednicarbate, The risk or severity of hyperglycemia can be increased when Prednicarbate is combined with Canagliflozin.]
[C08DB01, diltiazem, The metabolism of Canagliflozin can be decreased when combined with Diltiazem.]
[V03AB09, dimercaprol, Canagliflozin may increase the excretion rate of Dimercaprol which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AX03, dimethyl sulfoxide, Canagliflozin may increase the excretion rate of Dimethyl sulfoxide which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BB04, propyphenazone, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Proglumetacin.]
[C05CA03, diosmin, The serum concentration of Canagliflozin can be increased when it is combined with Diosmin.]
[A07DA01, diphenoxylate, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Diphenoxylate.]
[C09AA06, quinapril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Quinapril.]
[B01AC07, dipyridamole, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Canagliflozin.]
[N06AA23, quinupramine, Quinupramine may decrease the hypoglycemic activities of Canagliflozin.]
[C09AA05, ramipril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Ramipril.]
[S01XA23, sirolimus, The serum concentration of Sirolimus can be increased when it is combined with Canagliflozin.]
[S01AX06, resorcinol, Canagliflozin may increase the excretion rate of Resorcinol which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BA03, disopyramide, Canagliflozin may increase the hypoglycemic activities of Disopyramide.]
[S02AA12, rifamycin SV, The metabolism of Canagliflozin can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Canagliflozin can be increased when combined with Rifapentine.]
[D06AX11, rifaximin, The serum concentration of Rifaximin can be increased when it is combined with Canagliflozin.]
[N05AX08, risperidone, Canagliflozin may increase the hypotensive activities of Risperidone.]
[R06AE09, levocetirizine, Canagliflozin may increase the excretion rate of Levocetirizine which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB09, ropivacaine, Canagliflozin may increase the excretion rate of Ropivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01MB01, rosoxacin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Rosoxacin.]
[L01EX01, sunitinib, Canagliflozin may increase the hypoglycemic activities of Sunitinib.]
[A04AD12, aprepitant, The metabolism of Canagliflozin can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The serum concentration of Tolvaptan can be increased when it is combined with Canagliflozin.]
[L01XG01, bortezomib, The serum concentration of Bortezomib can be increased when it is combined with Canagliflozin.]
[J05AE07, fosamprenavir, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Fosamprenavir.]
[G04BE08, tadalafil, Canagliflozin may increase the excretion rate of Tadalafil which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC05, ketorolac, The risk or severity of hyperkalemia can be increased when Ketorolac is combined with Canagliflozin.]
[C02KX02, ambrisentan, The serum concentration of Ambrisentan can be increased when it is combined with Canagliflozin.]
[C01EB18, ranolazine, The serum concentration of Ranolazine can be increased when it is combined with Canagliflozin.]
[N02BA06, salsalate, The risk or severity of hyperkalemia can be increased when Salsalate is combined with Canagliflozin.]
[H05BA01, salmon calcitonin, Canagliflozin may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA07, dobutamine, Canagliflozin may increase the excretion rate of Dobutamine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA04, dopamine, Canagliflozin may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA16, dothiepin, Dosulepin may decrease the hypoglycemic activities of Canagliflozin.]
[N06AA12, doxepin, Doxepin may decrease the hypoglycemic activities of Canagliflozin.]
[A06AB06, sennosides, USP, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Sennosides.]
[L01DB01, doxorubicin, The serum concentration of Doxorubicin can be increased when it is combined with Canagliflozin.]
[J01AA02, doxycycline, Canagliflozin may increase the excretion rate of Doxycycline which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AB06, sertraline, The risk or severity of hypoglycemia can be increased when Sertraline is combined with Canagliflozin.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Sevoflurane is combined with Canagliflozin.]
[A08AA10, sibutramine, Canagliflozin may increase the excretion rate of Sibutramine which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AA01, simvastatin, The serum concentration of Canagliflozin can be increased when it is combined with Simvastatin.]
[V03AG05, sodium phosphate, Canagliflozin may increase the nephrotoxic activities of Sodium phosphate, monobasic.]
[A12CA02, sodium sulfate, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Sodium sulfate.]
[C09AA11, spirapril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Spirapril.]
[R03DA01, dyphylline, Canagliflozin may increase the excretion rate of Dyphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[A07AB04, succinylsulfathiazole, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Succinylsulfathiazole.]
[N02CC01, sumatriptan, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Sumatriptan.]
[V04CX07, edrophonium, Canagliflozin may increase the excretion rate of Edrophonium which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB13, talinolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Talinolol.]
[H01AA01, corticotropin, The risk or severity of hyperglycemia can be increased when Corticotropin is combined with Canagliflozin.]
[J01MA05, temafloxacin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Temafloxacin.]
[L01AX03, temozolomide, Canagliflozin may increase the excretion rate of Temozolomide which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AC02, tenoxicam, The risk or severity of hyperkalemia can be increased when Tenoxicam is combined with Canagliflozin.]
[G04CA03, terazosin, The risk or severity of adverse effects can be increased when Terazosin is combined with Canagliflozin.]
[G04BD05, terodiline, The risk or severity of hypoglycemia can be increased when Terodiline is combined with Canagliflozin.]
[C07AA16, tertatolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Tertatolol.]
[N06AX14, tianeptine, Tianeptine may decrease the hypoglycemic activities of Canagliflozin.]
[C09AA02, enalapril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Enalapril.]
[M01AG02, tolfenamic acid, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Tolfenamic acid.]
[N06AG03, toloxatone, Toloxatone may increase the orthostatic hypotensive activities of Canagliflozin.]
[N06BA09, atomoxetine, Canagliflozin may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AX11, topiramate, Canagliflozin may increase the excretion rate of Topiramate which could result in a lower serum level and potentially a reduction in efficacy.]
[L02BA02, toremifene, The serum concentration of Canagliflozin can be increased when it is combined with Toremifene.]
[C03CA04, torsemide, The risk or severity of hypotension can be increased when Canagliflozin is combined with Torasemide.]
[C09AA10, trandolapril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Trandolapril.]
[N05CC01, chloral hydrate, Canagliflozin may increase the excretion rate of Chloral hydrate which could result in a lower serum level and potentially a reduction in efficacy.]
[H02CA01, trilostane, The risk or severity of hyperglycemia can be increased when Trilostane is combined with Canagliflozin.]
[L02AE04, triptorelin, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Triptorelin.]
[C02CA06, urapidil, Canagliflozin may increase the hypotensive activities of Urapidil.]
[J01MA04, enoxacin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Enoxacin.]
[S01FB02, ephedrine, The risk or severity of Cardiac Arrhythmia can be increased when Ephedrine is combined with Canagliflozin.]
[N06AX16, venlafaxine, The risk or severity of hypoglycemia can be increased when Venlafaxine is combined with Canagliflozin.]
[S01GA03, xylometazoline, The risk or severity of hypoglycemia can be increased when Xylometazoline is combined with Canagliflozin.]
[C08CA12, mepirodipine, The metabolism of Canagliflozin can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Epinephrine.]
[C09AA15, zofenopril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Zofenopril.]
[M01AB04, zomepirac, The risk or severity of hyperkalemia can be increased when Zomepirac is combined with Canagliflozin.]
[N03AX15, zonisamide, The serum concentration of Canagliflozin can be increased when it is combined with Zonisamide.]
[A10AB06, insulin glulisine, human, The risk or severity of hypoglycemia can be increased when Canagliflozin is combined with Insulin glulisine.]
[L01XA02, carboplatin, Canagliflozin may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AC02, guanfacine, Canagliflozin may increase the excretion rate of Guanfacine which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC11, iloprost, The risk or severity of adverse effects can be increased when Iloprost is combined with Canagliflozin.]
[N02CA02, ergotamine, The metabolism of Canagliflozin can be decreased when combined with Ergotamine.]
[L03AX05, pidotimod, Canagliflozin may increase the excretion rate of Pidotimod which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA17, erythromycin, The metabolism of Canagliflozin can be decreased when combined with Erythromycin.]
[N05CD04, estazolam, Canagliflozin may increase the excretion rate of Estazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[A02BC02, pantoprazole, Canagliflozin may increase the excretion rate of Pantoprazole which could result in a lower serum level and potentially a reduction in efficacy.]
[G03CA03, estradiol, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Estradiol.]
[G03CA57, estrogens, conjugated (USP), Canagliflozin may increase the excretion rate of Conjugated estrogens which could result in a lower serum level and potentially a reduction in efficacy.]
[J04AK02, ethambutol, Canagliflozin may increase the excretion rate of Ethambutol which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA09, fluticasone furoate, The risk or severity of hyperglycemia can be increased when Fluticasone furoate is combined with Canagliflozin.]
[R03BA05, fluticasone, The risk or severity of hyperglycemia can be increased when Fluticasone is combined with Canagliflozin.]
[V08CA03, gadodiamide, Canagliflozin may increase the excretion rate of Gadodiamide which could result in a lower serum level and potentially a reduction in efficacy.]
[D07AC21, halobetasol, The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Canagliflozin.]
[L02AA03, ethinyl estradiol, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Ethinylestradiol.]
[V03AF05, amifostine, The risk or severity of adverse effects can be increased when Amifostine is combined with Canagliflozin.]
[C01BD05, ibutilide, Canagliflozin may increase the excretion rate of Ibutilide which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AD01, ethosuximide, The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Canagliflozin.]
[M01AC06, meloxicam, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Meloxicam.]
[S01XA06, ethylmorphine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Ethylmorphine.]
[N01AX07, etomidate, Canagliflozin may increase the excretion rate of Etomidate which could result in a lower serum level and potentially a reduction in efficacy.]
[L01CB01, etoposide, The serum concentration of Etoposide can be increased when it is combined with Canagliflozin.]
[L04AD02, tacrolimus, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Tacrolimus.]
[J01MA08, fleroxacin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Fleroxacin.]
[R06AX12, terfenadine, The metabolism of Canagliflozin can be decreased when combined with Terfenadine.]
[P01AX07, trimetrexate, Canagliflozin may increase the excretion rate of Trimetrexate which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX12, bupropion, Canagliflozin may increase the excretion rate of Bupropion which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AB08, fluvoxamine, The risk or severity of hypoglycemia can be increased when Fluvoxamine is combined with Canagliflozin.]
[L02AE02, leuprolide, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Leuprolide.]
[C10AA03, pravastatin, The serum concentration of Pravastatin can be increased when it is combined with Canagliflozin.]
[M01CB01, gold sodium thiomalate, Canagliflozin may increase the excretion rate of Sodium aurothiomalate which could result in a lower serum level and potentially a reduction in efficacy.]
[B05AA05, dextran, Canagliflozin may increase the excretion rate of Dextran which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AF02, dexrazoxane, Canagliflozin may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AA01, levocarnitine, Canagliflozin may increase the excretion rate of Levocarnitine which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA02, felodipine, The risk or severity of hypoglycemia can be increased when Felodipine is combined with Canagliflozin.]
[C08EA01, fendiline, The risk or severity of hypoglycemia can be increased when Fendiline is combined with Canagliflozin.]
[M01AE04, fenoprofen, The risk or severity of hyperkalemia can be increased when Fenoprofen is combined with Canagliflozin.]
[N02AB03, fentanyl, Canagliflozin may increase the excretion rate of Fentanyl which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CC02, albuterol, Canagliflozin may increase the excretion rate of Salbutamol which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BB06, clofarabine, Canagliflozin may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy.]
[N07AX03, cevimeline, Canagliflozin may increase the excretion rate of Cevimeline which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD02, flavoxate, Canagliflozin may increase the excretion rate of Flavoxate which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BG04, floctafenine, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Floctafenine.]
[J02AC01, fluconazole, The risk or severity of hypoglycemia can be increased when Canagliflozin is combined with Fluconazole.]
[J02AX01, flucytosine, Canagliflozin may increase the excretion rate of Flucytosine which could result in a lower serum level and potentially a reduction in efficacy.]
[H02AA02, fludrocortisone, The risk or severity of hyperglycemia can be increased when Fludrocortisone is combined with Canagliflozin.]
[V03AB25, flumazenil, Canagliflozin may increase the excretion rate of Flumazenil which could result in a lower serum level and potentially a reduction in efficacy.]
[D07XB01, flumethasone, The risk or severity of hyperglycemia can be increased when Flumethasone is combined with Canagliflozin.]
[N07CA03, flunarizine, The risk or severity of hypoglycemia can be increased when Flunarizine is combined with Canagliflozin.]
[D07AC08, fluocinonide, The risk or severity of hyperglycemia can be increased when Fluocinonide is combined with Canagliflozin.]
[N06AA14, melitracen, Melitracen may decrease the hypoglycemic activities of Canagliflozin.]
[H02AB03, fluocortolone, The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Canagliflozin.]
[V03AZ01, ethanol, Ethanol may increase the hypotensive activities of Canagliflozin.]
[L01BC09, floxuridine, Canagliflozin may increase the excretion rate of Floxuridine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01CB05, fluorometholone, The risk or severity of hyperglycemia can be increased when Fluorometholone is combined with Canagliflozin.]
[N06AB03, fluoxetine, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Canagliflozin.]
[G03BA01, fluoxymesterone, Fluoxymesterone may increase the hypoglycemic activities of Canagliflozin.]
[D07AC07, flurandrenolide, The risk or severity of hyperglycemia can be increased when Flurandrenolide is combined with Canagliflozin.]
[N05CD01, flurazepam, Canagliflozin may increase the excretion rate of Flurazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC04, flurbiprofen, Canagliflozin may increase the excretion rate of Flurbiprofen which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AG01, fluspirilene, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Canagliflozin.]
[L02BB01, flutamide, Canagliflozin may increase the excretion rate of Flutamide which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CX02, folic acid, Canagliflozin may increase the excretion rate of Folic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[S02AA17, fosfomycin, Canagliflozin may increase the excretion rate of Fosfomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[L01BC03, tegafur, Canagliflozin may increase the excretion rate of Tegafur which could result in a lower serum level and potentially a reduction in efficacy.]
[G01AX06, furazolidone, Furazolidone may increase the orthostatic hypotensive activities of Canagliflozin.]
[J05AE10, darunavir, The metabolism of Canagliflozin can be decreased when combined with Darunavir.]
[C03CA01, furosemide, The risk or severity of hypotension can be increased when Canagliflozin is combined with Furosemide.]
[N05CF04, eszopiclone, Canagliflozin may increase the excretion rate of Eszopiclone which could result in a lower serum level and potentially a reduction in efficacy.]
[C08DA02, gallopamil, The risk or severity of hypoglycemia can be increased when Gallopamil is combined with Canagliflozin.]
[S01AD09, ganciclovir, Canagliflozin may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AA04, barbexaclone, The serum concentration of Canagliflozin can be decreased when it is combined with Barbexaclone.]
[C10AB04, gemfibrozil, Canagliflozin may increase the excretion rate of Gemfibrozil which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XA03, telavancin, Canagliflozin may increase the excretion rate of Telavancin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EA02, dasatinib, The serum concentration of Dasatinib can be increased when it is combined with Canagliflozin.]
[N04BC06, cabergoline, The serum concentration of Cabergoline can be increased when it is combined with Canagliflozin.]
[A10BJ02, liraglutide, Canagliflozin may increase the hypoglycemic activities of Liraglutide.]
[N03AD03, methsuximide, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Canagliflozin.]
[N01AH02, alfentanil, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Alfentanil.]
[L01EH01, lapatinib, The serum concentration of Canagliflozin can be increased when it is combined with Lapatinib.]
[A10BB01, glyburide, Canagliflozin may increase the hypoglycemic activities of Glyburide.]
[A10BB09, gliclazide, Canagliflozin may increase the hypoglycemic activities of Gliclazide.]
[A10BB07, glipizide, Canagliflozin may increase the hypoglycemic activities of Glipizide.]
[N05CM18, dexmedetomidine, Canagliflozin may increase the excretion rate of Dexmedetomidine which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AX01, glycerin, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Glycerin.]
[C05AE01, nitroglycerin, The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Canagliflozin.]
[C02CA04, doxazosin, The risk or severity of adverse effects can be increased when Doxazosin is combined with Canagliflozin.]
[H01AB01, thyrotropin alfa, Thyrotropin alfa may decrease the hypoglycemic activities of Canagliflozin.]
[L01EX02, sorafenib, The serum concentration of Canagliflozin can be increased when it is combined with Sorafenib.]
[C07AB09, esmolol, The risk or severity of adverse effects can be increased when Esmolol is combined with Canagliflozin.]
[M01CB04, aurothioglucose, Canagliflozin may increase the excretion rate of Aurothioglucose which could result in a lower serum level and potentially a reduction in efficacy.]
[S01LA03, pegaptanib, Canagliflozin may increase the excretion rate of Pegaptanib which could result in a lower serum level and potentially a reduction in efficacy.]
[C09AA09, fosinopril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Fosinopril.]
[S01EX01, guanethidine, Canagliflozin may increase the excretion rate of Guanethidine which could result in a lower serum level and potentially a reduction in efficacy.]
[L02AE03, goserelin, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Goserelin.]
[D07AD02, halcinonide, The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Canagliflozin.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Canagliflozin.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Halothane is combined with Canagliflozin.]
[L02AE05, histrelin, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Histrelin.]
[N05AH04, quetiapine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Quetiapine.]
[N06BX13, idebenone, Canagliflozin may increase the excretion rate of Idebenone which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AD05, insulin aspart, human, The risk or severity of hypoglycemia can be increased when Canagliflozin is combined with Insulin aspart.]
[M04AA01, allopurinol, Canagliflozin may increase the excretion rate of Allopurinol which could result in a lower serum level and potentially a reduction in efficacy.]
[C09CA01, losartan, The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Losartan.]
[S01XA14, heparin, The risk or severity of hyperkalemia can be increased when Heparin is combined with Canagliflozin.]
[B05CB03, magnesium citrate, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Magnesium citrate.]
[G03DC01, allylestrenol, Canagliflozin may increase the excretion rate of Allylestrenol which could result in a lower serum level and potentially a reduction in efficacy.]
[A07EC02, mesalamine, Mesalazine may increase the hypoglycemic activities of Canagliflozin.]
[C01CE02, milrinone, Canagliflozin may increase the excretion rate of Milrinone which could result in a lower serum level and potentially a reduction in efficacy.]
[A12CD02, sodium monofluorophosphate, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Sodium fluorophosphate.]
[N05CA16, hexobarbital, The serum concentration of Canagliflozin can be decreased when it is combined with Hexobarbital.]
[C08CA10, nilvadipine, The metabolism of Canagliflozin can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of hypoglycemia can be increased when Nimesulide is combined with Canagliflozin.]
[C09AA04, perindopril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Perindopril.]
[C02DB02, hydralazine, Canagliflozin may increase the excretion rate of Hydralazine which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA03, hydrochlorothiazide, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Hydrochlorothiazide.]
[R05DA03, hydrocodone, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Hydrocodone.]
[S02BA01, hydrocortisone, The risk or severity of hyperglycemia can be increased when Hydrocortisone is combined with Canagliflozin.]
[D07AC16, hydrocortisone aceponate, The risk or severity of hyperglycemia can be increased when Hydrocortisone aceponate is combined with Canagliflozin.]
[D07AB11, hydrocortisone probutate, The risk or severity of hyperglycemia can be increased when Hydrocortisone probutate is combined with Canagliflozin.]
[C03AA02, hydroflumethiazide, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Hydroflumethiazide.]
[B05XA17, potassium acetate, Canagliflozin may increase the excretion rate of Potassium acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[S01XA07, aluminum potassium sulfate, Potassium alum may increase the hyperkalemic activities of Canagliflozin.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Canagliflozin may increase the excretion rate of Hydroxocobalamin which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD06, propiverine, Canagliflozin may increase the excretion rate of Propiverine which could result in a lower serum level and potentially a reduction in efficacy.]
[P01BA02, hydroxychloroquine, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Hydroxychloroquine.]
[B05AA07, hetastarch, Canagliflozin may increase the excretion rate of Hydroxyethyl Starch which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AC06, rilmenidine, Canagliflozin may increase the hypotensive activities of Rilmenidine.]
[S01BA13, rimexolone, The risk or severity of hyperglycemia can be increased when Rimexolone is combined with Canagliflozin.]
[R02AX02, ibuprofen, Canagliflozin may increase the excretion rate of Ibuprofen which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA08, sodium acetate, Canagliflozin may increase the excretion rate of Sodium acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AD21, sodium tartrate, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Sodium tartrate.]
[L01AA06, ifosfamide, Canagliflozin may increase the excretion rate of Ifosfamide which could result in a lower serum level and potentially a reduction in efficacy.]
[H01AC02, somatrem, Somatrem may decrease the hypoglycemic activities of Canagliflozin.]
[N01AH03, sufentanil, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Sufentanil.]
[N06AA02, imipramine, The serum concentration of Imipramine can be increased when it is combined with Canagliflozin.]
[L01CD01, paclitaxel, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Canagliflozin.]
[R01AD07, tixocortol, The risk or severity of hyperglycemia can be increased when Tixocortol is combined with Canagliflozin.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Tizanidine is combined with Canagliflozin.]
[L01CE01, topotecan, The serum concentration of Topotecan can be increased when it is combined with Canagliflozin.]
[C03BA11, indapamide, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Indapamide.]
[S01BC01, indomethacin, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Canagliflozin.]
[C02CA02, indoramin, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Indoramin.]
[A11HA07, inositol, Canagliflozin may increase the excretion rate of Inositol which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX17, milnacipran, The risk or severity of hypoglycemia can be increased when Milnacipran is combined with Canagliflozin.]
[S01XA28, varenicline, Canagliflozin may increase the excretion rate of Varenicline which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB08, articaine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Articaine.]
[A10BH01, sitagliptin, Canagliflozin may increase the hypoglycemic activities of Sitagliptin.]
[N05BA12, alprazolam, Canagliflozin may increase the excretion rate of Alprazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CH02, ramelteon, Canagliflozin may increase the excretion rate of Ramelteon which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BH02, vildagliptin, Canagliflozin may increase the hypoglycemic activities of Vildagliptin.]
[C07AA01, alprenolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Alprenolol.]
[C03BA02, quinethazone, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Quinethazone.]
[V03AB01, ipecac, Canagliflozin may increase the excretion rate of Ipecac which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA13, iprindole, Iprindole may decrease the hypoglycemic activities of Canagliflozin.]
[N06AF05, iproniazid, Iproniazid may increase the orthostatic hypotensive activities of Canagliflozin.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the orthostatic hypotensive activities of Canagliflozin.]
[C09AA16, imidapril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Imidapril.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Canagliflozin.]
[J04AC01, isoniazid, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Isoniazid.]
[J05AX05, inosine pranobex, Canagliflozin may increase the excretion rate of Inosine pranobex which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BJ01, exenatide, Canagliflozin may increase the hypoglycemic activities of Exenatide.]
[C01DA14, isosorbide mononitrate, Canagliflozin may increase the excretion rate of Isosorbide mononitrate which could result in a lower serum level and potentially a reduction in efficacy.]
[C05AE02, isosorbide dinitrate, The risk or severity of adverse effects can be increased when Isosorbide dinitrate is combined with Canagliflozin.]
[D10BA01, isotretinoin, Canagliflozin may increase the excretion rate of Isotretinoin which could result in a lower serum level and potentially a reduction in efficacy.]
[C04AA01, isoxsuprine, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Isoxsuprine.]
[S01AA24, kanamycin, Canagliflozin may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[H01AC01, somatropin, Somatotropin may decrease the hypoglycemic activities of Canagliflozin.]
[N01AX03, ketamine, Canagliflozin may increase the excretion rate of Ketamine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02KD01, ketanserin, Canagliflozin may increase the hypotensive activities of Ketanserin.]
[B01AC22, prasugrel, Canagliflozin may increase the excretion rate of Prasugrel which could result in a lower serum level and potentially a reduction in efficacy.]
[J02AB02, ketoconazole, The metabolism of Canagliflozin can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Canagliflozin can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Olanzapine.]
[M02AA10, ketoprofen, Canagliflozin may increase the excretion rate of Ketoprofen which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC03, deferasirox, The metabolism of Canagliflozin can be decreased when combined with Deferasirox.]
[S01GX08, ketotifen, The risk or severity of thrombocytopenia can be increased when Canagliflozin is combined with Ketotifen.]
[N04BC09, rotigotine, The risk or severity of adverse effects can be increased when Rotigotine is combined with Canagliflozin.]
[A16AX01, thioctic acid, The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Canagliflozin.]
[D10AX03, azelaic acid, Canagliflozin may increase the excretion rate of Azelaic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[J01MB02, nalidixic acid, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Nalidixic acid.]
[M01AE11, tiaprofenic acid, The risk or severity of hyperkalemia can be increased when Tiaprofenic acid is combined with Canagliflozin.]
[C07AG01, labetalol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Labetalol.]
[N04BB01, amantadine, Canagliflozin may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AA05, deserpidine, Canagliflozin may increase the hypotensive activities of Deserpidine.]
[A06AD11, lactulose, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Lactulose.]
[A06AX03, lubiprostone, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Lubiprostone.]
[C03CC01, ethacrynic acid, The risk or severity of hypotension can be increased when Canagliflozin is combined with Etacrynic acid.]
[G03AD01, levonorgestrel, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Levonorgestrel.]
[N04BA01, levodopa, The risk or severity of hypotension and orthostatic hypotension can be increased when Canagliflozin is combined with Levodopa.]
[C08EX01, lidoflazine, The risk or severity of hypoglycemia can be increased when Lidoflazine is combined with Canagliflozin.]
[S01AA21, amikacin, Canagliflozin may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA07, lofepramine, Lofepramine may decrease the hypoglycemic activities of Canagliflozin.]
[A07DA03, loperamide, The excretion of Loperamide can be decreased when combined with Canagliflozin.]
[N05BA06, lorazepam, Canagliflozin may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AA02, lovastatin, The metabolism of Canagliflozin can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, The serum concentration of Canagliflozin can be increased when it is combined with Loxapine.]
[L01EG01, temsirolimus, The serum concentration of Temsirolimus can be increased when it is combined with Canagliflozin.]
[B05XA11, magnesium chloride, Canagliflozin may increase the excretion rate of Magnesium chloride which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BX01, magnesium hydroxide, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Magnesium hydroxide.]
[A12CC10, magnesium oxide, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Magnesium oxide.]
[V04CC02, magnesium sulfate, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Magnesium sulfate.]
[L01BA05, pralatrexate, Canagliflozin may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EA03, nilotinib, The metabolism of Canagliflozin can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, The serum concentration of Mannitol can be increased when it is combined with Canagliflozin.]
[N06AA21, maprotiline, Canagliflozin may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.]
[C02BB01, mecamylamine, Canagliflozin may increase the excretion rate of Mecamylamine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA18, meclofenamic acid, Canagliflozin may increase the excretion rate of Meclofenamic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[C01AA08, medigoxin, Canagliflozin may decrease the excretion rate of Metildigoxin which could result in a higher serum level.]
[A06AB07, cascara sagrada, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Frangula purshiana bark.]
[P01BC02, mefloquine, The serum concentration of Canagliflozin can be increased when it is combined with Mefloquine.]
[C03BA05, mefruside, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Mefruside.]
[B01AB06, nadroparin, The risk or severity of hyperkalemia can be increased when Nadroparin is combined with Canagliflozin.]
[B01AB05, enoxaparin, The risk or severity of hyperkalemia can be increased when Enoxaparin is combined with Canagliflozin.]
[B01AB04, dalteparin, The risk or severity of hyperkalemia can be increased when Dalteparin is combined with Canagliflozin.]
[N06DX01, memantine, Canagliflozin may increase the excretion rate of Memantine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AB02, meperidine, Canagliflozin may increase the excretion rate of Meperidine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AA01, mephobarbital, The serum concentration of Canagliflozin can be decreased when it is combined with Methylphenobarbital.]
[N01BB03, mepivacaine, Canagliflozin may increase the excretion rate of Mepivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AX05, meptazinol, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Meptazinol.]
[G04BX16, tiopronin, Canagliflozin may increase the excretion rate of Tiopronin which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BC01, mersalyl, Canagliflozin may increase the excretion rate of Mersalyl which could result in a lower serum level and potentially a reduction in efficacy.]
[G03BB01, mesterolone, Mesterolone may increase the hypoglycemic activities of Canagliflozin.]
[N05AX13, paliperidone, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Paliperidone.]
[H01CB03, lanreotide, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lanreotide.]
[N07BC02, methadone, Canagliflozin may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BA03, methamphetamine, Canagliflozin may increase the excretion rate of Metamfetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF05, lamivudine, Canagliflozin may increase the excretion rate of Lamivudine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01EC05, methazolamide, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Methazolamide.]
[H03BB02, methimazole, The metabolism of Canagliflozin can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, Canagliflozin may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[N05CA15, methohexital, The serum concentration of Canagliflozin can be decreased when it is combined with Methohexital.]
[A11HA02, pyridoxine, Canagliflozin may increase the excretion rate of Pyridoxine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BG08, ziconotide, The risk or severity of CNS depression can be increased when Canagliflozin is combined with Ziconotide.]
[L04AX03, methotrexate, Canagliflozin may increase the excretion rate of Methotrexate which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AA02, methotrimeprazine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Methotrimeprazine.]
[D05BA02, methoxsalen, Canagliflozin may increase the excretion rate of Methoxsalen which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Methyclothiazide.]
[A06AC06, methylcellulose, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Methylcellulose.]
[C02AB01, methyldopa, Canagliflozin may increase the excretion rate of Methyldopa which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CG05, methylene blue, Methylene blue may increase the orthostatic hypotensive activities of Canagliflozin.]
[H02AB04, methylprednisolone, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Canagliflozin.]
[D07AC14, methylprednisolone aceponate, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Canagliflozin.]
[G03EK01, methyltestosterone, Canagliflozin may increase the excretion rate of Methyltestosterone which could result in a lower serum level and potentially a reduction in efficacy.]
[A03FA01, metoclopramide, Canagliflozin may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BA08, metolazone, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Metolazone.]
[C07AB02, metoprolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Metoprolol.]
[V04CD01, metyrapone, Canagliflozin may increase the excretion rate of Metyrapone which could result in a lower serum level and potentially a reduction in efficacy.]
[S02AA13, miconazole, The metabolism of Canagliflozin can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The risk or severity of hyperkalemia can be increased when Aminophenazone is combined with Canagliflozin.]
[B01AB07, parnaparin, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Parnaparin.]
[N05CD08, midazolam, Canagliflozin may increase the excretion rate of Midazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[G03XB01, mifepristone, Canagliflozin may increase the hypoglycemic activities of Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of hyperkalemia can be increased when Tinzaparin is combined with Canagliflozin.]
[A06AA01, mineral oil, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Mineral oil.]
[J05AH01, zanamivir, Canagliflozin may increase the excretion rate of Zanamivir which could result in a lower serum level and potentially a reduction in efficacy.]
[C09CA03, valsartan, The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Valsartan.]
[D11AX01, minoxidil, The risk or severity of adverse effects can be increased when Minoxidil is combined with Canagliflozin.]
[L01XX23, mitotane, The metabolism of Canagliflozin can be increased when combined with Mitotane.]
[L03AC01, aldesleukin, Canagliflozin may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BD01, amiodarone, The metabolism of Canagliflozin can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, Amitriptyline may decrease the hypoglycemic activities of Canagliflozin.]
[N02AA01, morphine, The serum concentration of Morphine can be increased when it is combined with Canagliflozin.]
[A04AA05, palonosetron, Canagliflozin may increase the excretion rate of Palonosetron which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[L04AB05, certolizumab pegol, Canagliflozin may increase the excretion rate of Certolizumab pegol which could result in a lower serum level and potentially a reduction in efficacy.]
[B02BX05, eltrombopag, The metabolism of Canagliflozin can be decreased when combined with Eltrombopag.]
[G04BA01, ammonium chloride, Canagliflozin may increase the excretion rate of Ammonium chloride which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX03, pazopanib, The serum concentration of Pazopanib can be increased when it is combined with Canagliflozin.]
[L04AA06, mycophenolic acid, Canagliflozin may increase the excretion rate of Mycophenolic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CA02, amobarbital, The serum concentration of Canagliflozin can be decreased when it is combined with Amobarbital.]
[G04CA04, silodosin, The excretion of Silodosin can be decreased when combined with Canagliflozin.]
[N06AA17, amoxapine, Amoxapine may decrease the hypoglycemic activities of Canagliflozin.]
[N03AB05, fosphenytoin, The serum concentration of Canagliflozin can be decreased when it is combined with Fosphenytoin.]
[C07AA12, nadolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Nadolol.]
[J01CA04, amoxicillin, Canagliflozin may increase the excretion rate of Amoxicillin which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BC04, ropinirole, The risk or severity of adverse effects can be increased when Ropinirole is combined with Canagliflozin.]
[N02AF02, nalbuphine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Nalbuphine.]
[V03AB15, naloxone, The metabolism of Canagliflozin can be decreased when combined with Naloxone.]
[N07BB04, naltrexone, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Naltrexone.]
[S01XA11, nandrolone, Nandrolone phenpropionate may increase the hypoglycemic activities of Canagliflozin.]
[N06BA01, amphetamine, Canagliflozin may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA12, naproxen, The risk or severity of hyperkalemia can be increased when Naproxen is combined with Canagliflozin.]
[A10BG01, troglitazone, Canagliflozin may increase the hypoglycemic activities of Troglitazone.]
[N06AX21, duloxetine, The risk or severity of orthostatic hypotension and syncope can be increased when Canagliflozin is combined with Duloxetine.]
[N04BX01, tolcapone, Canagliflozin may increase the excretion rate of Tolcapone which could result in a lower serum level and potentially a reduction in efficacy.]
[S03AA01, neomycin, Canagliflozin may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[N01AH06, remifentanil, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Remifentanil.]
[A10BX02, repaglinide, Canagliflozin may increase the hypoglycemic activities of Repaglinide.]
[C01CX08, levosimendan, The risk or severity of adverse effects can be increased when Levosimendan is combined with Canagliflozin.]
[B01AC17, tirofiban, Canagliflozin may increase the excretion rate of Tirofiban which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AX14, iloperidone, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Iloperidone.]
[J02AA01, amphotericin B, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Canagliflozin.]
[S01AA19, ampicillin, Canagliflozin may increase the excretion rate of Ampicillin which could result in a lower serum level and potentially a reduction in efficacy.]
[L03AX16, plerixafor, Canagliflozin may increase the excretion rate of Plerixafor which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA23, netilmicin, Canagliflozin may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The risk or severity of hypoglycemia can be increased when Desvenlafaxine is combined with Canagliflozin.]
[C09CA07, telmisartan, The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Telmisartan.]
[J05AB11, valacyclovir, Canagliflozin may increase the excretion rate of Valaciclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CE01, inamrinone, Canagliflozin may increase the excretion rate of Amrinone which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AD02, niacin, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Niacin.]
[N06AF02, nialamide, Nialamide may increase the orthostatic hypotensive activities of Canagliflozin.]
[C08CA04, nicardipine, The metabolism of Canagliflozin can be decreased when combined with Nicardipine.]
[C08CA05, nifedipine, Canagliflozin may increase the excretion rate of Nifedipine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA17, niflumic acid, The metabolism of Canagliflozin can be decreased when combined with Niflumic acid.]
[V03AB22, amyl nitrite, The risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Canagliflozin.]
[C08CA06, nimodipine, The risk or severity of hypoglycemia can be increased when Nimodipine is combined with Canagliflozin.]
[C08CA07, nisoldipine, Canagliflozin may increase the excretion rate of Nisoldipine which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA08, nitrendipine, The risk or severity of hypoglycemia can be increased when Nitrendipine is combined with Canagliflozin.]
[R07AX01, nitric oxide, Canagliflozin may increase the excretion rate of Nitric Oxide which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XE01, nitrofurantoin, Canagliflozin may increase the excretion rate of Nitrofurantoin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF03, zaleplon, Canagliflozin may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BC05, pramipexole, Canagliflozin may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.]
[C02DD01, nitroprusside, Canagliflozin may increase the excretion rate of Nitroprusside which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA03, norepinephrine, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Canagliflozin.]
[G03DC02, norethindrone, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Norethisterone.]
[S01AE02, norfloxacin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Norfloxacin.]
[C02KX01, bosentan, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Bosentan.]
[N06AA10, nortriptyline, The serum concentration of Nortriptyline can be increased when it is combined with Canagliflozin.]
[A16AX07, sapropterin, The serum concentration of Canagliflozin can be increased when it is combined with Sapropterin.]
[G02CA02, nylidrin, The risk or severity of hypoglycemia can be increased when Nylidrin is combined with Canagliflozin.]
[B01AB08, reviparin, The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Reviparin.]
[H01CB02, octreotide, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Octreotide.]
[S02AA16, ofloxacin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Ofloxacin.]
[N06AA05, opipramol, Opipramol may decrease the hypoglycemic activities of Canagliflozin.]
[N02AA02, opium, Canagliflozin may increase the excretion rate of Opium which could result in a lower serum level and potentially a reduction in efficacy.]
[G04CA02, tamsulosin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Tamsulosin.]
[J01CF04, oxacillin, Canagliflozin may increase the excretion rate of Oxacillin which could result in a lower serum level and potentially a reduction in efficacy.]
[A14AA08, oxandrolone, Oxandrolone may increase the hypoglycemic activities of Canagliflozin.]
[N05BA04, oxazepam, Canagliflozin may increase the excretion rate of Oxazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[J01MB05, oxolinic acid, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Oxolinic acid.]
[C07AA02, oxprenolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Oxprenolol.]
[N02AA05, oxycodone, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Oxycodone.]
[A14AA05, oxymetholone, Oxymetholone may increase the hypoglycemic activities of Canagliflozin.]
[N02AA11, oxymorphone, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Oxymorphone.]
[S01BC02, oxyphenbutazone, The risk or severity of hyperkalemia can be increased when Oxyphenbutazone is combined with Canagliflozin.]
[J04AA01, aminosalicylic acid, Aminosalicylic acid may increase the hypoglycemic activities of Canagliflozin.]
[N05AH05, asenapine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Asenapine.]
[B01AB09, danaparoid, The risk or severity of hyperkalemia can be increased when Danaparoid is combined with Canagliflozin.]
[N02AX06, tapentadol, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Tapentadol.]
[J04AB30, capreomycin, Canagliflozin may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[G04BE02, papaverine, The risk or severity of adverse effects can be increased when Papaverine is combined with Canagliflozin.]
[H02AB05, paramethasone, The risk or severity of hyperglycemia can be increased when Paramethasone is combined with Canagliflozin.]
[C02KC01, pargyline, Pargyline may increase the orthostatic hypotensive activities of Canagliflozin.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J01MA03, pefloxacin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Pefloxacin.]
[G04BD11, fesoterodine, Canagliflozin may increase the excretion rate of Fesoterodine which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AA23, penbutolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of hypoglycemia can be increased when Penfluridol is combined with Canagliflozin.]
[J01CE09, penicillin G procaine, Canagliflozin may increase the excretion rate of Procaine benzylpenicillin which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AD01, pentazocine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Pentazocine.]
[N05CA01, pentobarbital, The serum concentration of Canagliflozin can be decreased when it is combined with Pentobarbital.]
[L01XX08, pentostatin, Canagliflozin may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, Canagliflozin may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[C08EX02, perhexiline, The risk or severity of hypoglycemia can be increased when Perhexiline is combined with Canagliflozin.]
[N02AD02, phenazocine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Phenazocine.]
[G04BX06, phenazopyridine, Canagliflozin may increase the excretion rate of Phenazopyridine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AF03, phenelzine, Phenelzine may increase the orthostatic hypotensive activities of Canagliflozin.]
[A10BA01, phenformin, Canagliflozin may increase the hypoglycemic activities of Phenformin.]
[N03AA02, phenobarbital, The serum concentration of Canagliflozin can be decreased when it is combined with Phenobarbital.]
[A06AB01, oxyphenisatin, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Oxyphenisatin.]
[N01AH04, phenoperidine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Phenoperidine.]
[C04AX02, phenoxybenzamine, The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Canagliflozin.]
[A08AA01, phentermine, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Phentermine.]
[V03AB36, phentolamine, Canagliflozin may increase the excretion rate of Phentolamine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA01, phenylbutazone, The risk or severity of hyperkalemia can be increased when Phenylbutazone is combined with Canagliflozin.]
[N03AB02, phenytoin, The serum concentration of Canagliflozin can be decreased when it is combined with Phenytoin.]
[S01AE05, levofloxacin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Levofloxacin.]
[B02BA01, vitamin K1, Canagliflozin may increase the excretion rate of Phylloquinone which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AB12, cidofovir, Canagliflozin may increase the excretion rate of Cidofovir which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CX01, mibefradil, The serum concentration of Canagliflozin can be increased when it is combined with Mibefradil.]
[C07AA03, pindolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Pindolol.]
[J01CA12, piperacillin, Canagliflozin may increase the excretion rate of Piperacillin which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE01, saquinavir, The metabolism of Canagliflozin can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Piperazine.]
[N05AC04, pipothiazine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Pipotiazine.]
[N06BX03, piracetam, Canagliflozin may increase the excretion rate of Piracetam which could result in a lower serum level and potentially a reduction in efficacy.]
[C09CA02, eprosartan, The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Eprosartan.]
[N02AC03, pirinitramide, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Piritramide.]
[S01BC06, piroxicam, Canagliflozin may increase the excretion rate of Piroxicam which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[J01MA11, grepafloxacin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Grepafloxacin.]
[J05AG02, delavirdine, The metabolism of Canagliflozin can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Irbesartan.]
[A10BG02, rosiglitazone, Canagliflozin may increase the hypoglycemic activities of Rosiglitazone.]
[A06AD15, polyethylene glycols, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Polyethylene glycol.]
[C03AA05, polythiazide, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Polythiazide.]
[J05AE03, ritonavir, The metabolism of Canagliflozin can be increased when combined with Ritonavir.]
[A10BH03, saxagliptin, Canagliflozin may increase the hypoglycemic activities of Saxagliptin.]
[B05XA01, potassium chloride, Canagliflozin may increase the excretion rate of Potassium chloride which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB21, potassium iodide, Potassium Iodide may increase the hyperkalemic activities of Canagliflozin.]
[A10AD04, insulin lispro, The risk or severity of hypoglycemia can be increased when Canagliflozin is combined with Insulin lispro.]
[C07AB01, practolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Practolol.]
[C02CA01, prazosin, The risk or severity of adverse effects can be increased when Prazosin is combined with Canagliflozin.]
[S03BA02, prednisolone, The risk or severity of hyperglycemia can be increased when Prednisolone is combined with Canagliflozin.]
[H02AB07, prednisone, The risk or severity of hyperglycemia can be increased when Prednisone is combined with Canagliflozin.]
[C01DX02, prenylamine, The risk or severity of hypoglycemia can be increased when Prenylamine is combined with Canagliflozin.]
[P01BA03, primaquine, The metabolism of Canagliflozin can be decreased when combined with Primaquine.]
[N03AA03, primidone, The serum concentration of Canagliflozin can be decreased when it is combined with Primidone.]
[M04AB01, probenecid, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Probenecid.]
[C01BA02, procainamide, Canagliflozin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01HA05, procaine, Procaine may increase the orthostatic hypotensive activities of Canagliflozin.]
[L01XB01, procarbazine, Procarbazine may increase the orthostatic hypotensive activities of Canagliflozin.]
[C10AB05, fenofibrate, Canagliflozin may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.]
[G03DA04, progesterone, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Progesterone.]
[R06AD02, promethazine, Canagliflozin may increase the excretion rate of Promethazine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BC03, propafenone, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Propafenone.]
[A03AB05, propantheline, Canagliflozin may increase the excretion rate of Propantheline which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AX26, fexofenadine, The serum concentration of Fexofenadine can be increased when it is combined with Canagliflozin.]
[L01XH02, romidepsin, The serum concentration of Romidepsin can be increased when it is combined with Canagliflozin.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Propofol is combined with Canagliflozin.]
[N02AC04, propoxyphene, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Dextropropoxyphene.]
[C07AA05, propranolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Propranolol.]
[N02CC04, rizatriptan, Canagliflozin may increase the excretion rate of Rizatriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC09, epoprostenol, Canagliflozin may increase the excretion rate of Epoprostenol which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA11, protriptyline, Protriptyline may decrease the hypoglycemic activities of Canagliflozin.]
[R01BA02, pseudoephedrine, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Pseudoephedrine.]
[N05AX12, aripiprazole, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Aripiprazole.]
[N07XX07, dalfampridine, Canagliflozin may increase the excretion rate of Dalfampridine which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CC01, pyrantel, Canagliflozin may increase the excretion rate of Pyrantel which could result in a lower serum level and potentially a reduction in efficacy.]
[J04AK01, pyrazinamide, Canagliflozin may increase the excretion rate of Pyrazinamide which could result in a lower serum level and potentially a reduction in efficacy.]
[A12BA05, potassium gluconate, Potassium gluconate may increase the hyperkalemic activities of Canagliflozin.]
[C01BA01, quinidine, The serum concentration of Quinidine can be increased when it is combined with Canagliflozin.]
[P01BC01, quinine, Canagliflozin may increase the hypoglycemic activities of Quinine.]
[D07AC10, diflorasone, The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Canagliflozin.]
[A02BA02, ranitidine, Canagliflozin may increase the excretion rate of Ranitidine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AA01, rescinnamine, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Rescinnamine.]
[C02AA02, reserpine, The serum concentration of Canagliflozin can be increased when it is combined with Reserpine.]
[J05AP01, ribavirin, Canagliflozin may increase the excretion rate of Ribavirin which could result in a lower serum level and potentially a reduction in efficacy.]
[J04AB02, rifampin, The serum concentration of Canagliflozin can be decreased when it is combined with Rifampicin.]
[N02BA05, salicylamide, The risk or severity of hyperkalemia can be increased when Salicylamide is combined with Canagliflozin.]
[A07EC01, sulfasalazine, Sulfasalazine may increase the hypoglycemic activities of Canagliflozin.]
[S01BC08, salicylic acid, Salicylic acid may increase the hypoglycemic activities of Canagliflozin.]
[N05CA06, secobarbital, The serum concentration of Canagliflozin can be decreased when it is combined with Secobarbital.]
[N04BD01, selegiline, Selegiline may increase the orthostatic hypotensive activities of Canagliflozin.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Obinutuzumab.]
[J01GB08, sisomicin, Canagliflozin may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Canagliflozin may increase the excretion rate of Sodium fluoride which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CC01, sorbitol, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Sorbitol.]
[C07AA07, sotalol, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Canagliflozin.]
[L01CD04, cabazitaxel, The serum concentration of Cabazitaxel can be increased when it is combined with Canagliflozin.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.]
[J01MA15, gemifloxacin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Gemifloxacin.]
[S01AE07, moxifloxacin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Moxifloxacin.]
[A06AX06, tegaserod, The serum concentration of Tegaserod can be increased when it is combined with Canagliflozin.]
[H03AA04, tiratricol, Tiratricol may decrease the hypoglycemic activities of Canagliflozin.]
[A10AE05, insulin detemir, The risk or severity of hypoglycemia can be increased when Canagliflozin is combined with Insulin detemir.]
[A10BX05, pramlintide, Canagliflozin may increase the hypoglycemic activities of Pramlintide.]
[L03AA12, ancestim, Canagliflozin may increase the excretion rate of Ancestim which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH01, celecoxib, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Celecoxib.]
[L04AA18, everolimus, The serum concentration of Everolimus can be increased when it is combined with Canagliflozin.]
[N04AC01, benztropine, Canagliflozin may increase the excretion rate of Benzatropine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EC02, dabrafenib, The serum concentration of Canagliflozin can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, Canagliflozin may increase the excretion rate of Benzydamine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EE01, trametinib, Canagliflozin may increase the excretion rate of Trametinib which could result in a lower serum level and potentially a reduction in efficacy.]
[V09AX05, florbetapir F-18, Canagliflozin may increase the excretion rate of Florbetapir (18F) which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EB03, afatinib, The serum concentration of Afatinib can be increased when it is combined with Canagliflozin.]
[N06AX28, levomilnacipran, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Canagliflozin.]
[J05AJ03, dolutegravir, The serum concentration of Dolutegravir can be increased when it is combined with Canagliflozin.]
[C08EA02, bepridil, The risk or severity of hypoglycemia can be increased when Bepridil is combined with Canagliflozin.]
[C02KX05, riociguat, The serum concentration of Riociguat can be increased when it is combined with Canagliflozin.]
[A10BJ03, lixisenatide, Canagliflozin may increase the hypoglycemic activities of Lixisenatide.]
[C02KX04, macitentan, Canagliflozin may increase the excretion rate of Macitentan which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX26, vortioxetine, Canagliflozin may increase the excretion rate of Vortioxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[G03AC08, etonogestrel, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Etonogestrel.]
[J05AP05, simeprevir, The metabolism of Canagliflozin can be decreased when combined with Simeprevir.]
[J05AP08, sofosbuvir, The serum concentration of Sofosbuvir can be increased when it is combined with Canagliflozin.]
[A10BK01, dapagliflozin, Dapagliflozin may increase the hypoglycemic activities of Canagliflozin.]
[C01CA27, droxidopa, Canagliflozin may increase the excretion rate of Droxidopa which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB04, acebutolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Acebutolol.]
[N05CH03, tasimelteon, Canagliflozin may increase the excretion rate of Tasimelteon which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AA07, metreleptin, The metabolism of Canagliflozin can be increased when combined with Metreleptin.]
[L04AA32, apremilast, Canagliflozin may increase the excretion rate of Apremilast which could result in a lower serum level and potentially a reduction in efficacy.]
[L02BG02, formestane, Canagliflozin may increase the excretion rate of Formestane which could result in a lower serum level and potentially a reduction in efficacy.]
[S03BA03, betamethasone, The risk or severity of hyperglycemia can be increased when Betamethasone is combined with Canagliflozin.]
[S01ED02, betaxolol, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Betaxolol.]
[V03AB34, fomepizole, Canagliflozin may increase the excretion rate of Fomepizole which could result in a lower serum level and potentially a reduction in efficacy.]
[C02CC01, bethanidine, Canagliflozin may increase the hypotensive activities of Bethanidine.]
[A10BJ04, albiglutide, Canagliflozin may increase the hypoglycemic activities of Albiglutide.]
[L01ED02, ceritinib, The serum concentration of Ceritinib can be increased when it is combined with Canagliflozin.]
[B01AC26, vorapaxar, The serum concentration of Canagliflozin can be increased when it is combined with Vorapaxar.]
[L01XH04, belinostat, The serum concentration of Belinostat can be increased when it is combined with Canagliflozin.]
[L01EM01, idelalisib, The serum concentration of Idelalisib can be increased when it is combined with Canagliflozin.]
[A10BK03, empagliflozin, Empagliflozin may increase the diuretic activities of Canagliflozin.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[L01FD03, ado-trastuzumab emtansine, The serum concentration of Trastuzumab emtansine can be increased when it is combined with Canagliflozin.]
[V09AB03, ioflupane I-123, Canagliflozin may increase the excretion rate of Ioflupane I-123 which could result in a lower serum level and potentially a reduction in efficacy.]
[V09GA01, technetium Tc 99m sestamibi, The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Canagliflozin.]
[V09AA01, technetium Tc 99m exametazime, Canagliflozin may increase the excretion rate of Technetium Tc-99m exametazime which could result in a lower serum level and potentially a reduction in efficacy.]
[V09AX06, florbetaben f-18, Canagliflozin may increase the excretion rate of Florbetaben (18F) which could result in a lower serum level and potentially a reduction in efficacy.]
[D07AB02, hydrocortisone butyrate, The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Canagliflozin.]
[S02DA03, antipyrine, Antipyrine may decrease the excretion rate of Metformin which could result in a higher serum level.]
[A14AA02, stanozolol, Stanozolol may increase the hypoglycemic activities of Metformin.]
[J01GA01, streptomycin, Metformin may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[A02BX02, sucralfate, Metformin may decrease the excretion rate of Sucralfate which could result in a higher serum level.]
[J01CG01, sulbactam, Metformin may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, The risk or severity of hypoglycemia can be increased when Sulfadiazine is combined with Metformin.]
[J01ED01, sulfadimethoxine, The therapeutic efficacy of Metformin can be increased when used in combination with Sulfadimethoxine.]
[A07AB03, sulfaguanidine, The therapeutic efficacy of Metformin can be increased when used in combination with Sulfaguanidine.]
[J01ED02, sulfalene, The therapeutic efficacy of Metformin can be increased when used in combination with Sulfametopyrazine.]
[J01ED07, sulfamerazine, The therapeutic efficacy of Metformin can be increased when used in combination with Sulfamerazine.]
[J01EB03, sulfamethazine, The therapeutic efficacy of Metformin can be increased when used in combination with Sulfamethazine.]
[S01AB01, sulfamethizole, The therapeutic efficacy of Metformin can be increased when used in combination with Sulfamethizole.]
[J01EC01, sulfamethoxazole, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Metformin.]
[J01ED05, sulfamethoxypyridazine, The therapeutic efficacy of Metformin can be increased when used in combination with Sulfamethoxypyridazine.]
[J01EC03, sulfamoxole, The therapeutic efficacy of Metformin can be increased when used in combination with Sulfamoxole.]
[J01EB04, sulfapyridine, The therapeutic efficacy of Metformin can be increased when used in combination with Sulfapyridine.]
[J01EB01, sulfisomidine, The therapeutic efficacy of Metformin can be increased when used in combination with Sulfaisodimidine.]
[S01AB02, sulfisoxazole, The risk or severity of hypoglycemia can be increased when Sulfisoxazole is combined with Metformin.]
[M01AB02, sulindac, Sulindac may decrease the excretion rate of Metformin which could result in a higher serum level.]
[A10BB04, glibornuride, The risk or severity of hypoglycemia can be increased when Metformin is combined with Glibornuride.]
[A10BC01, glymidine, The therapeutic efficacy of Metformin can be increased when used in combination with Glymidine.]
[M01AX04, apazone, Azapropazone may decrease the excretion rate of Metformin which could result in a higher serum level.]
[N05CD07, temazepam, Temazepam may decrease the excretion rate of Metformin which could result in a higher serum level.]
[R03CC03, terbutaline, Metformin may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[B01AE07, dabigatran etexilate, Metformin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.]
[G03BA03, testosterone, Testosterone may increase the hypoglycemic activities of Metformin.]
[S03AA02, tetracycline, Metformin may decrease the excretion rate of Tetracycline which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Metformin which could result in a higher serum level.]
[N05AE05, lurasidone, The therapeutic efficacy of Metformin can be decreased when used in combination with Lurasidone.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CA02, thiabendazole, Metformin may decrease the excretion rate of Thiabendazole which could result in a higher serum level.]
[A11DA01, thiamine, The serum concentration of Metformin can be increased when it is combined with Thiamine.]
[R06AD03, thiethylperazine, Metformin may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.]
[G04BE06, moxisylyte, Metformin may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[N05AL03, tiapride, Metformin may decrease the excretion rate of Tiapride which could result in a higher serum level.]
[B01AC05, ticlopidine, Ticlopidine may decrease the excretion rate of Metformin which could result in a higher serum level.]
[S01ED01, timolol, The therapeutic efficacy of Metformin can be increased when used in combination with Timolol.]
[P01AB02, tinidazole, Metformin may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[S01AA12, tobramycin, Metformin may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, The risk or severity of hypoglycemia can be increased when Tolazamide is combined with Metformin.]
[V04CA01, tolbutamide, The risk or severity of hypoglycemia can be increased when Tolbutamide is combined with Metformin.]
[M02AA21, tolmetin, Tolmetin may decrease the excretion rate of Metformin which could result in a higher serum level.]
[N02AX02, tramadol, Tramadol may decrease the excretion rate of Metformin which could result in a higher serum level.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the hypoglycemic activities of Metformin.]
[S01BA05, triamcinolone, The therapeutic efficacy of Metformin can be decreased when used in combination with Triamcinolone.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, Metformin may decrease the excretion rate of Triazolam which could result in a higher serum level.]
[C03AA06, trichlormethiazide, The therapeutic efficacy of Metformin can be decreased when used in combination with Trichlormethiazide.]
[A16AX12, trientine, Metformin may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[S01AD02, trifluridine, Metformin may decrease the excretion rate of Trifluridine which could result in a higher serum level.]
[S01BA09, clobetasone, The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Metformin.]
[S01BA10, alclometasone, The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Metformin.]
[D07AC02, fluclorolone, The risk or severity of hyperglycemia can be increased when Fluclorolone is combined with Metformin.]
[R03BA07, mometasone, The therapeutic efficacy of Metformin can be decreased when used in combination with Mometasone.]
[A03AA05, trimebutine, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Metformin.]
[N03AC02, trimethadione, The risk or severity of hypoglycemia can be increased when Trimethadione is combined with Metformin.]
[J01EA01, trimethoprim, The serum concentration of Metformin can be increased when it is combined with Trimethoprim.]
[N06AA06, trimipramine, Trimipramine may decrease the hypoglycemic activities of Metformin.]
[R03DX07, roflumilast, Metformin may decrease the excretion rate of Roflumilast which could result in a higher serum level.]
[L01FX04, ipilimumab, Metformin may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[L01EX04, vandetanib, The serum concentration of Metformin can be increased when it is combined with Vandetanib.]
[R02AA14, oxyquinoline, Metformin may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[S01AA28, vancomycin, Metformin may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, Metformin may decrease the excretion rate of Ezogabine which could result in a higher serum level.]
[B01AF01, rivaroxaban, Metformin may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.]
[C08DA01, verapamil, The excretion of Metformin can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, Metformin may decrease the excretion rate of Viloxazine which could result in a higher serum level.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Metformin which could result in a higher serum level.]
[B01AA03, warfarin, Metformin may decrease the excretion rate of Warfarin which could result in a higher serum level.]
[C03BA10, xipamide, The therapeutic efficacy of Metformin can be increased when used in combination with Xipamide.]
[J05AE02, indinavir, The therapeutic efficacy of Metformin can be decreased when used in combination with Indinavir.]
[L01EC01, vemurafenib, The therapeutic efficacy of Metformin can be increased when used in combination with Vemurafenib.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Metformin which could result in a higher serum level.]
[M05BA05, tiludronic acid, Metformin may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.]
[B06AC02, icatibant, Metformin may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[L01ED01, crizotinib, The serum concentration of Metformin can be increased when it is combined with Crizotinib.]
[A02BC04, rabeprazole, Metformin may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[J01MA13, trovafloxacin, The therapeutic efficacy of Metformin can be increased when used in combination with Trovafloxacin.]
[N05AE04, ziprasidone, The therapeutic efficacy of Metformin can be decreased when used in combination with Ziprasidone.]
[G03AC10, drospirenone, The therapeutic efficacy of Metformin can be decreased when used in combination with Drospirenone.]
[V03AC02, deferiprone, Metformin may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[N02BA01, aspirin, The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Metformin.]
[L01EJ01, ruxolitinib, Metformin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[G04BD07, tolterodine, Metformin may decrease the excretion rate of Tolterodine which could result in a higher serum level.]
[J01DH04, doripenem, Metformin may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[C07AB03, atenolol, The serum concentration of Metformin can be increased when it is combined with Atenolol.]
[M01CB03, auranofin, Metformin may decrease the excretion rate of Auranofin which could result in a higher serum level.]
[H02AB11, prednylidene, The therapeutic efficacy of Metformin can be decreased when used in combination with Prednylidene.]
[B03XA04, peginesatide, Metformin may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, Metformin may decrease the excretion rate of Azacitidine which could result in a higher serum level.]
[L04AX01, azathioprine, Metformin may decrease the excretion rate of Azathioprine which could result in a higher serum level.]
[L01BC05, gemcitabine, Metformin may decrease the excretion rate of Gemcitabine which could result in a higher serum level.]
[J01DF01, aztreonam, Metformin may decrease the excretion rate of Aztreonam which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Metformin which could result in a higher serum level.]
[M03BX01, baclofen, The therapeutic efficacy of Metformin can be decreased when used in combination with Baclofen.]
[A08AA11, lorcaserin, Metformin may decrease the excretion rate of Lorcaserin which could result in a higher serum level.]
[G04BD12, mirabegron, Metformin may decrease the excretion rate of Mirabegron which could result in a higher serum level.]
[L02BB04, enzalutamide, Metformin may decrease the excretion rate of Enzalutamide which could result in a higher serum level.]
[H02AA01, aldosterone, The risk or severity of hyperglycemia can be increased when Aldosterone is combined with Metformin.]
[D02BA02, octinoxate, Metformin may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, The therapeutic efficacy of Metformin can be decreased when used in combination with Nelfinavir.]
[N04BD02, rasagiline, Rasagiline may increase the hypoglycemic activities of Metformin.]
[C08CA13, lercanidipine, The risk or severity of hypoglycemia can be increased when Lercanidipine is combined with Metformin.]
[V09IX04, fluorodeoxyglucose F18, Metformin may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[H01CB05, pasireotide, The therapeutic efficacy of Metformin can be decreased when used in combination with Pasireotide.]
[V08CA11, gadofosveset, Metformin may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[A16AX08, teduglutide, Metformin may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[C04AX11, bencyclane, The risk or severity of hypoglycemia can be increased when Bencyclane is combined with Metformin.]
[A16AX09, glycerol phenylbutyrate, Metformin may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.]
[C03AA01, bendroflumethiazide, The therapeutic efficacy of Metformin can be decreased when used in combination with Bendroflumethiazide.]
[L04AX06, pomalidomide, Metformin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N02BA10, benorilate, Benorilate may decrease the excretion rate of Metformin which could result in a higher serum level.]
[J01MA15, gemifloxacin, The therapeutic efficacy of Metformin can be increased when used in combination with Gemifloxacin.]
[S01AE07, moxifloxacin, The therapeutic efficacy of Metformin can be increased when used in combination with Moxifloxacin.]
[H03AA04, tiratricol, The therapeutic efficacy of Metformin can be decreased when used in combination with Tiratricol.]
[A10AE05, insulin detemir, The risk or severity of adverse effects can be increased when Insulin detemir is combined with Metformin.]
[A10BX05, pramlintide, The risk or severity of hypoglycemia can be increased when Pramlintide is combined with Metformin.]
[L03AA12, ancestim, Metformin may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, The therapeutic efficacy of Metformin can be increased when used in combination with Celecoxib.]
[L04AA18, everolimus, The therapeutic efficacy of Metformin can be decreased when used in combination with Everolimus.]
[N04AC01, benztropine, Benzatropine may decrease the excretion rate of Metformin which could result in a higher serum level.]
[L01EC02, dabrafenib, The therapeutic efficacy of Metformin can be decreased when used in combination with Dabrafenib.]
[R02AX03, benzydamine, Benzydamine may decrease the excretion rate of Metformin which could result in a higher serum level.]
[L01EE01, trametinib, Metformin may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[V09AX05, florbetapir F-18, Metformin may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[N06AX28, levomilnacipran, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Metformin.]
[J05AJ03, dolutegravir, The serum concentration of Metformin can be increased when it is combined with Dolutegravir.]
[C08EA02, bepridil, The risk or severity of hypoglycemia can be increased when Bepridil is combined with Metformin.]
[A10BJ03, lixisenatide, The risk or severity of hypoglycemia can be increased when Metformin is combined with Lixisenatide.]
[C02KX04, macitentan, Metformin may decrease the excretion rate of Macitentan which could result in a higher serum level.]
[N06AX26, vortioxetine, Metformin may decrease the excretion rate of Vortioxetine which could result in a higher serum level.]
[G03AC08, etonogestrel, The therapeutic efficacy of Metformin can be decreased when used in combination with Etonogestrel.]
[J05AP05, simeprevir, The therapeutic efficacy of Metformin can be increased when used in combination with Simeprevir.]
[J05AP08, sofosbuvir, Metformin may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[C01CA27, droxidopa, Metformin may decrease the excretion rate of Droxidopa which could result in a higher serum level.]
[C07AB04, acebutolol, The therapeutic efficacy of Metformin can be increased when used in combination with Acebutolol.]
[N05CH03, tasimelteon, Metformin may decrease the excretion rate of Tasimelteon which could result in a higher serum level.]
[L04AA32, apremilast, Metformin may decrease the excretion rate of Apremilast which could result in a higher serum level.]
[L02BG02, formestane, Metformin may decrease the excretion rate of Formestane which could result in a higher serum level.]
[S03BA03, betamethasone, The therapeutic efficacy of Metformin can be decreased when used in combination with Betamethasone.]
[S01ED02, betaxolol, The therapeutic efficacy of Metformin can be increased when used in combination with Betaxolol.]
[V03AB34, fomepizole, Metformin may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[A10BJ04, albiglutide, The risk or severity of hypoglycemia can be increased when Metformin is combined with Albiglutide.]
[L01ED02, ceritinib, The therapeutic efficacy of Metformin can be decreased when used in combination with Ceritinib.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Metformin which could result in a higher serum level.]
[D11AA01, glycopyrronium, The serum concentration of Metformin can be increased when it is combined with Glycopyrronium.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Metformin which could result in a higher serum level.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Metformin which could result in a higher serum level.]
[A10BJ05, dulaglutide, The risk or severity of hypoglycemia can be increased when Metformin is combined with Dulaglutide.]
[S03AA06, gentamicin, Metformin may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[B01AF03, edoxaban, Metformin may decrease the excretion rate of Edoxaban which could result in a higher serum level.]
[L01EX08, lenvatinib, The serum concentration of Metformin can be increased when it is combined with Lenvatinib.]
[L01DC01, bleomycin, Bleomycin may decrease the excretion rate of Metformin which could result in a higher serum level.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Metformin which could result in a higher serum level.]
[N05AX16, brexpiprazole, The therapeutic efficacy of Metformin can be decreased when used in combination with Brexpiprazole.]
[A10BF01, acarbose, The risk or severity of hypoglycemia can be increased when Acarbose is combined with Metformin.]
[M02AA25, aceclofenac, Aceclofenac may decrease the excretion rate of Metformin which could result in a higher serum level.]
[M01AB11, acemetacin, Acemetacin may decrease the excretion rate of Metformin which could result in a higher serum level.]
[S01EC01, acetazolamide, The risk or severity of lactic acidosis can be increased when Acetazolamide is combined with Metformin.]
[A10AE06, insulin degludec, The risk or severity of adverse effects can be increased when Insulin degludec is combined with Metformin.]
[V03AB37, idarucizumab, Metformin may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[J02AC05, isavuconazole, The serum concentration of Metformin can be increased when it is combined with Isavuconazole.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Metformin.]
[L01XG03, ixazomib, Metformin may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[A10BB31, acetohexamide, The risk or severity of hypoglycemia can be increased when Metformin is combined with Acetohexamide.]
[M04AB05, lesinurad, Metformin may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[M01AE16, alminoprofen, Alminoprofen may decrease the excretion rate of Metformin which could result in a higher serum level.]
[N02BA02, aloxiprin, Aloxiprin may increase the hypoglycemic activities of Metformin.]
[N03AX23, brivaracetam, Metformin may decrease the excretion rate of Brivaracetam which could result in a higher serum level.]
[N05BA08, bromazepam, Metformin may decrease the excretion rate of Bromazepam which could result in a higher serum level.]
[N04BC01, bromocriptine, The risk or severity of hypoglycemia can be increased when Metformin is combined with Bromocriptine.]
[A02AD05, aluminum magnesium silicate, Metformin may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[D07AC11, amcinonide, The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Metformin.]
[N06AA19, amineptin, Amineptine may decrease the hypoglycemic activities of Metformin.]
[C08CA01, amlodipine, The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Metformin.]
[C03CA02, bumetanide, The therapeutic efficacy of Metformin can be decreased when used in combination with Bumetanide.]
[N01BB01, bupivacaine, Metformin may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[C07AA19, bupranolol, The therapeutic efficacy of Metformin can be increased when used in combination with Bupranolol.]
[L02AE01, buserelin, The therapeutic efficacy of Metformin can be decreased when used in combination with Buserelin.]
[N05BE01, buspirone, Metformin may decrease the excretion rate of Buspirone which could result in a higher serum level.]
[L01XX27, arsenic trioxide, The therapeutic efficacy of Metformin can be decreased when used in combination with Arsenic trioxide.]
[M02AA03, clofezone, Metformin may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[J01MA09, sparfloxacin, The therapeutic efficacy of Metformin can be increased when used in combination with Sparfloxacin.]
[A07EC04, balsalazide, Balsalazide may increase the hypoglycemic activities of Metformin.]
[A06AH05, naldemedine, Metformin may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, Metformin may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.]
[N02BF02, pregabalin, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Metformin.]
[C09AA07, benazepril, The risk or severity of hypoglycemia can be increased when Benazepril is combined with Metformin.]
[A10BX06, benfluorex, The risk or severity of hypoglycemia can be increased when Metformin is combined with Benfluorex.]
[P01CA02, benznidazole, Metformin may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[J01XX08, linezolid, Linezolid may increase the hypoglycemic activities of Metformin.]
[J05AF06, abacavir, Metformin may decrease the excretion rate of Abacavir which could result in a higher serum level.]
[J05AE09, tipranavir, The therapeutic efficacy of Metformin can be decreased when used in combination with Tipranavir.]
[N07XX13, valbenazine, Metformin may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[L01ED04, brigatinib, The excretion of Metformin can be decreased when combined with Brigatinib.]
[N04BD03, safinamide, Safinamide may increase the hypoglycemic activities of Metformin.]
[J01MA23, delafloxacin, The therapeutic efficacy of Metformin can be increased when used in combination with Delafloxacin.]
[L01BC06, capecitabine, Metformin may decrease the excretion rate of Capecitabine which could result in a higher serum level.]
[L01XX59, enasidenib, The serum concentration of Metformin can be increased when it is combined with Enasidenib.]
[L01XH01, vorinostat, The therapeutic efficacy of Metformin can be decreased when used in combination with Vorinostat.]
[L01EM02, copanlisib, The excretion of Metformin can be decreased when combined with Copanlisib.]
[L01EF03, abemaciclib, The excretion of Abemaciclib can be decreased when combined with Metformin.]
[C07AB07, bisoprolol, The therapeutic efficacy of Metformin can be increased when used in combination with Bisoprolol.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Metformin which could result in a higher serum level.]
[C07AA17, bopindolol, The therapeutic efficacy of Metformin can be increased when used in combination with Bopindolol.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, The risk or severity of hyperglycemia can be increased when Budesonide is combined with Metformin.]
[M01AB07, bumadizone, Bumadizone may decrease the excretion rate of Metformin which could result in a higher serum level.]
[N06AA15, butriptyline, Butriptyline may decrease the hypoglycemic activities of Metformin.]
[C01AA02, acetyldigoxins, The serum concentration of Acetyldigoxin can be increased when it is combined with Metformin.]
[A10BJ06, semaglutide, The risk or severity of hypoglycemia can be increased when Metformin is combined with Semaglutide.]
[R06AX18, acrivastine, Metformin may decrease the excretion rate of Acrivastine which could result in a higher serum level.]
[C09AA01, captopril, The risk or severity of lactic acidosis can be increased when Captopril is combined with Metformin.]
[L02BB05, apalutamide, The serum concentration of Metformin can be increased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, Metformin may decrease the excretion rate of Carbamazepine which could result in a higher serum level.]
[C07AG02, carvedilol, The therapeutic efficacy of Metformin can be increased when used in combination with Carvedilol.]
[L04AA37, baricitinib, The excretion of Baricitinib can be decreased when combined with Metformin.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Metformin which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Metformin which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Metformin which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Metformin which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Metformin which could result in a higher serum level.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Metformin which could result in a higher serum level.]
[J01GB14, plazomicin, Metformin may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, The therapeutic efficacy of Metformin can be increased when used in combination with Celiprolol.]
[P01BA07, tafenoquine, The serum concentration of Metformin can be increased when it is combined with Tafenoquine.]
[A16AX14, migalastat, Metformin may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, Metformin may decrease the excretion rate of Stiripentol which could result in a higher serum level.]
[S01GX12, cetirizine, Metformin may decrease the excretion rate of Cetirizine which could result in a higher serum level.]
[A10BB06, carbutamide, The risk or severity of hypoglycemia can be increased when Metformin is combined with Carbutamide.]
[D08AE05, chloroxylenol, Metformin may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[M01AC05, lornoxicam, Lornoxicam may decrease the excretion rate of Metformin which could result in a higher serum level.]
[N07XX15, inotersen, Inotersen may decrease the excretion rate of Metformin which could result in a higher serum level.]
[L01AD01, carmustine, Carmustine may decrease the excretion rate of Metformin which could result in a higher serum level.]
[L01EX13, gilteritinib, The excretion of Metformin can be decreased when combined with Gilteritinib.]
[L01XJ03, glasdegib, The excretion of Metformin can be decreased when combined with Glasdegib.]
[A06AX05, prucalopride, Metformin may decrease the excretion rate of Prucalopride which could result in a higher serum level.]
[C01BG07, cifenline, The risk or severity of hypoglycemia can be increased when Cibenzoline is combined with Metformin.]
[C09AA08, cilazapril, The risk or severity of lactic acidosis can be increased when Cilazapril is combined with Metformin.]
[B01AC23, cilostazol, Metformin may decrease the excretion rate of Cilostazol which could result in a higher serum level.]
[N06BA14, solriamfetol, Metformin may decrease the excretion rate of Solriamfetol which could result in a higher serum level.]
[L01EN01, erdafitinib, The serum concentration of Metformin can be increased when it is combined with Erdafitinib.]
[N05BA09, clobazam, Metformin may decrease the excretion rate of Clobazam which could result in a higher serum level.]
[D07AB21, clocortolone, The risk or severity of hyperglycemia can be increased when Clocortolone is combined with Metformin.]
[H02AB14, cloprednol, The therapeutic efficacy of Metformin can be decreased when used in combination with Cloprednol.]
[C01EB09, ubidecarenone, The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Metformin.]
[H02AB17, cortivazol, The therapeutic efficacy of Metformin can be decreased when used in combination with Cortivazol.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Metformin which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Metformin which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Metformin which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Metformin which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Metformin which could result in a higher serum level.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Metformin which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Metformin which could result in a higher serum level.]
[L01EX15, pexidartinib, The excretion of Metformin can be decreased when combined with Pexidartinib.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Metformin which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Metformin which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Metformin which could result in a higher serum level.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Metformin which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Metformin which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Metformin which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Metformin which could result in a higher serum level.]
[C03BX03, cicletanine, Cicletanine may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Metformin which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Metformin which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Metformin which could result in a higher serum level.]
[L01EJ02, fedratinib, The excretion of Metformin can be decreased when combined with Fedratinib.]
[N07XX11, pitolisant, Metformin may decrease the excretion rate of Pitolisant which could result in a higher serum level.]
[N04CX01, istradefylline, The excretion of Metformin can be decreased when combined with Istradefylline.]
[C03AA09, cyclothiazide, The therapeutic efficacy of Metformin can be decreased when used in combination with Cyclothiazide.]
[A10AE03, insulin, regular, pork, The risk or severity of adverse effects can be increased when Insulin pork is combined with Metformin.]
[J01XX09, daptomycin, Daptomycin may decrease the excretion rate of Metformin which could result in a higher serum level.]
[J01DB01, cephalexin, Cephalexin may decrease the excretion rate of Metformin which could result in a higher serum level.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Metformin which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Metformin which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Metformin which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Metformin which could result in a higher serum level.]
[H02AB13, deflazacort, The therapeutic efficacy of Metformin can be decreased when used in combination with Deflazacort.]
[G03AC09, desogestrel, The therapeutic efficacy of Metformin can be decreased when used in combination with Desogestrel.]
[A16AX16, givosiran, Givosiran may decrease the excretion rate of Metformin which could result in a higher serum level.]
[M09AX08, golodirsen, Metformin may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[S01XA12, dexpanthenol, Metformin may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[L01XX72, tazemetostat, The excretion of Metformin can be decreased when combined with Tazemetostat.]
[L04AA53, teprotumumab, The therapeutic efficacy of Metformin can be decreased when used in combination with Teprotumumab.]
[J05AB16, remdesivir, The excretion of Metformin can be decreased when combined with Remdesivir.]
[S01AE06, gatifloxacin, The therapeutic efficacy of Metformin can be increased when used in combination with Gatifloxacin.]
[R02AA03, dichlorobenzyl alcohol, Metformin may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, The therapeutic efficacy of Metformin can be decreased when used in combination with Dienogest.]
[D07AC19, difluprednate, The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Metformin.]
[M01AH02, rofecoxib, Rofecoxib may decrease the excretion rate of Metformin which could result in a higher serum level.]
[C08CA16, clevidipine, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Metformin.]
[C01BD07, dronedarone, The serum concentration of Metformin can be increased when it is combined with Dronedarone.]
[L01EH03, tucatinib, The serum concentration of Metformin can be increased when it is combined with Tucatinib.]
[L01EX17, capmatinib, The excretion of Metformin can be decreased when combined with Capmatinib.]
[D07XB03, fluprednidene, The therapeutic efficacy of Metformin can be decreased when used in combination with Fluprednidene.]
[G04BD09, trospium, The serum concentration of Trospium can be decreased when it is combined with Metformin.]
[M01AC04, droxicam, Droxicam may decrease the excretion rate of Metformin which could result in a higher serum level.]
[L01EX19, ripretinib, The excretion of Metformin can be decreased when combined with Ripretinib.]
[V08CA05, mangafodipir, Metformin may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[L01EX22, selpercatinib, The excretion of Metformin can be decreased when combined with Selpercatinib.]
[S01BA14, loteprednol, The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Metformin.]
[M02AA27, dexketoprofen, Dexketoprofen may decrease the excretion rate of Metformin which could result in a higher serum level.]
[C08CA17, levamlodipine, The risk or severity of hypoglycemia can be increased when Levamlodipine is combined with Metformin.]
[M09AX10, risdiplam, The serum concentration of Metformin can be increased when it is combined with Risdiplam.]
[P01BA01, chloroquine, Metformin may decrease the excretion rate of Chloroquine which could result in a higher serum level.]
[L01EX23, pralsetinib, The excretion of Metformin can be decreased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, The therapeutic efficacy of Metformin can be decreased when used in combination with Chlorothiazide.]
[R06AB04, chlorpheniramine, The serum concentration of Metformin can be increased when it is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The therapeutic efficacy of Metformin can be decreased when used in combination with Chlorpromazine.]
[A10BB02, chlorpropamide, The risk or severity of hypoglycemia can be increased when Chlorpropamide is combined with Metformin.]
[C03BA04, chlorthalidone, The therapeutic efficacy of Metformin can be decreased when used in combination with Chlorthalidone.]
[M03BB03, chlorzoxazone, Metformin may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.]
[N02BA07, ethenzamide, Ethenzamide may decrease the excretion rate of Metformin which could result in a higher serum level.]
[N02BA03, choline salicylate, Choline salicylate may increase the hypoglycemic activities of Metformin.]
[N06BX18, vinpocetine, The risk or severity of hypoglycemia can be increased when Vinpocetine is combined with Metformin.]
[M01AB08, etodolac, Etodolac may decrease the excretion rate of Metformin which could result in a higher serum level.]
[M02AA06, etofenamate, Etofenamate may decrease the excretion rate of Metformin which could result in a higher serum level.]
[M01AX25, chondroitin sulfates, Metformin may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[V03AF12, trilaciclib, The serum concentration of Metformin can be increased when it is combined with Trilaciclib.]
[M01AE05, fenbufen, Fenbufen may decrease the excretion rate of Metformin which could result in a higher serum level.]
[C01CA19, fenoldopam, Metformin may decrease the excretion rate of Fenoldopam which could result in a higher serum level.]
[J01DD15, cefdinir, Metformin may decrease the excretion rate of Cefdinir which could result in a higher serum level.]
[J01MB07, flumequine, The therapeutic efficacy of Metformin can be increased when used in combination with Flumequine.]
[R03BA03, flunisolide, The risk or severity of hyperglycemia can be increased when Flunisolide is combined with Metformin.]
[S02BA08, fluocinolone acetonide, The risk or severity of hyperglycemia can be increased when Fluocinolone acetonide is combined with Metformin.]
[N02BG07, flupirtine, Metformin may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[A10AF01, insulin, regular, human, The risk or severity of adverse effects can be increased when Insulin human is combined with Metformin.]
[A02BA01, cimetidine, The serum concentration of Metformin can be increased when it is combined with Cimetidine.]
[V08CA04, gadoteridol, Metformin may decrease the excretion rate of Gadoteridol which could result in a higher serum level.]
[N07CA02, cinnarizine, The risk or severity of hypoglycemia can be increased when Cinnarizine is combined with Metformin.]
[J01MB06, cinoxacin, The therapeutic efficacy of Metformin can be increased when used in combination with Cinoxacin.]
[S03AA07, ciprofloxacin, The therapeutic efficacy of Metformin can be increased when used in combination with Ciprofloxacin.]
[N06AB04, citalopram, The risk or severity of hypoglycemia can be increased when Citalopram is combined with Metformin.]
[H01AC07, somapacitan, The therapeutic efficacy of Metformin can be decreased when used in combination with Somapacitan.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.]
[P01CA03, fexinidazole, The serum concentration of Metformin can be increased when it is combined with Fexinidazole.]
[H01AC09, lonapegsomatropin, The therapeutic efficacy of Metformin can be decreased when used in combination with Lonapegsomatropin.]
[V09AB03, ioflupane I-123, Metformin may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Metformin may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Metformin may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[M01AG01, mefenamic acid, Mefenamic acid may decrease the excretion rate of Metformin which could result in a higher serum level.]
[A10BB08, gliquidone, The risk or severity of hypoglycemia can be increased when Metformin is combined with Gliquidone.]
[N06AX25, St. John's wort extract, The therapeutic efficacy of Metformin can be decreased when used in combination with St. John's Wort.]
[D07AD01, clobetasol, The risk or severity of hyperglycemia can be increased when Clobetasol is combined with Metformin.]
[B06AX04, mitapivat, The therapeutic efficacy of Metformin can be increased when used in combination with Mitapivat.]
[N01BB10, levobupivacaine, Metformin may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[N06AA04, clomipramine, Clomipramine may decrease the hypoglycemic activities of Metformin.]
[N03AE01, clonazepam, Metformin may decrease the excretion rate of Clonazepam which could result in a higher serum level.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Metformin which could result in a higher serum level.]
[A10BX16, tirzepatide, The risk or severity of hypoglycemia can be increased when Metformin is combined with Tirzepatide.]
[C03BA03, clopamide, The therapeutic efficacy of Metformin can be increased when used in combination with Clopamide.]
[N05AH02, clozapine, The therapeutic efficacy of Metformin can be decreased when used in combination with Clozapine.]
[A10BX01, guar gum, The risk or severity of hypoglycemia can be increased when Metformin is combined with Guar gum.]
[A10BK06, sotagliflozin, The risk or severity of hypoglycemia can be increased when Metformin is combined with Sotagliflozin.]
[J01GB12, arbekacin, Metformin may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[D07AC12, halometasone, The risk or severity of hyperglycemia can be increased when Halometasone is combined with Metformin.]
[H01AC08, somatrogon, The therapeutic efficacy of Metformin can be decreased when used in combination with Somatrogon.]
[M01AX13, proquazone, Proquazone may decrease the excretion rate of Metformin which could result in a higher serum level.]
[M04AC01, colchicine, Metformin may decrease the excretion rate of Colchicine which could result in a higher serum level.]
[J01XB01, colistin, Metformin may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Metformin which could result in a higher serum level.]
[A04AA03, tropisetron, Metformin may decrease the excretion rate of Tropisetron which could result in a higher serum level.]
[N02BA16, imidazole-2-hydroxybenzoate, Imidazole salicylate may decrease the excretion rate of Metformin which could result in a higher serum level.]
[H01AC03, mecasermin, The risk or severity of hypoglycemia can be increased when Mecasermin is combined with Metformin.]
[A10AE04, insulin glargine, The risk or severity of adverse effects can be increased when Insulin glargine is combined with Metformin.]
[R03BA08, ciclesonide, The therapeutic efficacy of Metformin can be decreased when used in combination with Ciclesonide.]
[B01AC10, indobufen, Indobufen may decrease the excretion rate of Metformin which could result in a higher serum level.]
[J05AB14, valganciclovir, Metformin may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[J05AF09, emtricitabine, The excretion of Emtricitabine can be decreased when combined with Metformin.]
[C05BB03, invert sugar, Metformin may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, The risk or severity of adverse effects can be increased when Iodixanol is combined with Metformin.]
[V08AB05, iopromide, The risk or severity of adverse effects can be increased when Iopromide is combined with Metformin.]
[V08AB07, ioversol, The risk or severity of adverse effects can be increased when Ioversol is combined with Metformin.]
[V08AB12, ioxilan, The risk or severity of adverse effects can be increased when Ioxilan is combined with Metformin.]
[M01AH03, valdecoxib, Valdecoxib may decrease the excretion rate of Metformin which could result in a higher serum level.]
[H01AX01, pegvisomant, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Metformin.]
[N02CC05, almotriptan, Metformin may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[M01AH04, parecoxib, Parecoxib may decrease the excretion rate of Metformin which could result in a higher serum level.]
[S01AD03, acyclovir, The excretion of Acyclovir can be decreased when combined with Metformin.]
[N05BA10, ketazolam, Metformin may decrease the excretion rate of Ketazolam which could result in a higher serum level.]
[M01AA06, kebuzone, Kebuzone may decrease the excretion rate of Metformin which could result in a higher serum level.]
[L01EA01, imatinib, The serum concentration of Metformin can be increased when it is combined with Imatinib.]
[C08CA09, lacidipine, The risk or severity of hypoglycemia can be increased when Lacidipine is combined with Metformin.]
[N03AX09, lamotrigine, The serum concentration of Metformin can be increased when it is combined with Lamotrigine.]
[S01BA03, cortisone, The risk or severity of hyperglycemia can be increased when Cortisone is combined with Metformin.]
[N07BC04, lofexidine, Metformin may decrease the excretion rate of Lofexidine which could result in a higher serum level.]
[S01AE04, lomefloxacin, The therapeutic efficacy of Metformin can be increased when used in combination with Lomefloxacin.]
[M01AB09, lonazolac, Lonazolac may decrease the excretion rate of Metformin which could result in a higher serum level.]
[M02AA31, loxoprofen, Loxoprofen may decrease the excretion rate of Metformin which could result in a higher serum level.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Metformin which could result in a higher serum level.]
[C09AA03, lisinopril, The risk or severity of lactic acidosis can be increased when Lisinopril is combined with Metformin.]
[A06AD01, magnesium carbonate, Metformin may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[C08CA11, manidipine, The risk or severity of hypoglycemia can be increased when Manidipine is combined with Metformin.]
[S01BA08, medrysone, The risk or severity of hyperglycemia can be increased when Medrysone is combined with Metformin.]
[C07AA14, mepindolol, The therapeutic efficacy of Metformin can be increased when used in combination with Mepindolol.]
[H02AB15, meprednisone, The therapeutic efficacy of Metformin can be decreased when used in combination with Meprednisone.]
[J01DH02, meropenem, Metformin may decrease the excretion rate of Meropenem which could result in a higher serum level.]
[C04AX01, cyclandelate, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Metformin.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, Metformin may decrease the excretion rate of Melperone which could result in a higher serum level.]
[C03AA07, cyclopenthiazide, The therapeutic efficacy of Metformin can be decreased when used in combination with Cyclopenthiazide.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Metformin which could result in a higher serum level.]
[N06AX07, minaprine, Minaprine may increase the hypoglycemic activities of Metformin.]
[S01XA18, cyclosporine, Cyclosporine may decrease the excretion rate of Metformin which could result in a higher serum level.]
[N06AG02, moclobemide, Moclobemide may increase the hypoglycemic activities of Metformin.]
[C09AA13, moexipril, The risk or severity of lactic acidosis can be increased when Moexipril is combined with Metformin.]
[C10AA07, rosuvastatin, Metformin may increase the hypolipidaemic activities of Rosuvastatin.]
[M02AA02, mofebutazone, Mofebutazone may decrease the excretion rate of Metformin which could result in a higher serum level.]
[M01AX22, morniflumate, Morniflumate may decrease the excretion rate of Metformin which could result in a higher serum level.]
[C03XA02, conivaptan, Conivaptan may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH05, etoricoxib, Etoricoxib may decrease the excretion rate of Metformin which could result in a higher serum level.]
[L01AX04, dacarbazine, Metformin may decrease the excretion rate of Dacarbazine which could result in a higher serum level.]
[G03XA01, danazol, The therapeutic efficacy of Metformin can be decreased when used in combination with Danazol.]
[M01AX01, nabumetone, Nabumetone may decrease the excretion rate of Metformin which could result in a higher serum level.]
[N07BB05, nalmefene, Metformin may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[C07AB12, nebivolol, The therapeutic efficacy of Metformin can be increased when used in combination with Nebivolol.]
[S01GX04, nedocromil, Metformin may decrease the excretion rate of Nedocromil which could result in a higher serum level.]
[N06AX06, nefazodone, The risk or severity of hypoglycemia can be increased when Nefazodone is combined with Metformin.]
[C01DX16, nicorandil, Metformin may decrease the excretion rate of Nicorandil which could result in a higher serum level.]
[L02BB02, nilutamide, Metformin may decrease the excretion rate of Nilutamide which could result in a higher serum level.]
[B01AX05, fondaparinux, Metformin may decrease the excretion rate of Fondaparinux which could result in a higher serum level.]
[N06AB10, escitalopram, The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Metformin.]
[A07EC03, olsalazine, Olsalazine may increase the hypoglycemic activities of Metformin.]
[N06AA01, desipramine, Desipramine may decrease the hypoglycemic activities of Metformin.]
[H01BA02, desmopressin, Desmopressin may decrease the excretion rate of Metformin which could result in a higher serum level.]
[S01BA11, desonide, The risk or severity of hyperglycemia can be increased when Desonide is combined with Metformin.]
[D07XC02, desoximetasone, The risk or severity of hyperglycemia can be increased when Desoximetasone is combined with Metformin.]
[V04CH02, indigo carmine, Metformin may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[H02AA03, desoxycorticosterone, The risk or severity of hyperglycemia can be increased when Desoxycortone is combined with Metformin.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Metformin which could result in a higher serum level.]
[M01AE12, oxaprozin, Oxaprozin may decrease the excretion rate of Metformin which could result in a higher serum level.]
[S03BA01, dexamethasone, The therapeutic efficacy of Metformin can be decreased when used in combination with Dexamethasone.]
[N06BA02, dextroamphetamine, Amphetamine may decrease the excretion rate of Metformin which could result in a higher serum level.]
[N06AB05, paroxetine, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Metformin.]
[B01AC04, clopidogrel, The serum concentration of Metformin can be increased when it is combined with Clopidogrel.]
[P03AC04, permethrin, Metformin may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, Metformin may decrease the excretion rate of Diazepam which could result in a higher serum level.]
[V03AH01, diazoxide, The therapeutic efficacy of Metformin can be decreased when used in combination with Diazoxide.]
[N06AA08, dibenzepin, Dibenzepin may decrease the hypoglycemic activities of Metformin.]
[R05DA08, pholcodine, Metformin may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, The risk or severity of lactic acidosis can be increased when Diclofenamide is combined with Metformin.]
[S01BC03, diclofenac, Diclofenac may decrease the excretion rate of Metformin which could result in a higher serum level.]
[J05AD01, foscarnet, Foscarnet may decrease the excretion rate of Metformin which could result in a higher serum level.]
[A03AA07, dicyclomine, Metformin may decrease the excretion rate of Dicyclomine which could result in a higher serum level.]
[A07AB02, phthalylsulfathiazole, The therapeutic efficacy of Metformin can be increased when used in combination with Phthalylsulfathiazole.]
[J05AF02, didanosine, Metformin may decrease the excretion rate of Didanosine which could result in a higher serum level.]
[A03AX04, pinaverium, The risk or severity of hypoglycemia can be increased when Pinaverium is combined with Metformin.]
[C03CA03, piretanide, The therapeutic efficacy of Metformin can be increased when used in combination with Piretanide.]
[C08CA03, isradipine, The risk or severity of hypoglycemia can be increased when Isradipine is combined with Metformin.]
[D07XC04, diflucortolone, The therapeutic efficacy of Metformin can be decreased when used in combination with Difluocortolone.]
[N02BA11, diflunisal, Diflunisal may increase the hypoglycemic activities of Metformin.]
[C01AA05, digoxin, The serum concentration of Digoxin can be increased when it is combined with Metformin.]
[N02AA03, hydromorphone, Hydromorphone may decrease the excretion rate of Metformin which could result in a higher serum level.]
[L04AX04, lenalidomide, Metformin may decrease the excretion rate of Lenalidomide which could result in a higher serum level.]
[J05AE08, atazanavir, The therapeutic efficacy of Metformin can be decreased when used in combination with Atazanavir.]
[H03BC01, potassium perchlorate, Metformin may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.]
[V03AB04, pralidoxime, Metformin may decrease the excretion rate of Pralidoxime which could result in a higher serum level.]
[D07AC18, prednicarbate, The risk or severity of hyperglycemia can be increased when Prednicarbate is combined with Metformin.]
[C08DB01, diltiazem, The risk or severity of hypoglycemia can be increased when Diltiazem is combined with Metformin.]
[V03AB09, dimercaprol, Metformin may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[M02AX03, dimethyl sulfoxide, Metformin may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.]
[N02BB04, propyphenazone, Propyphenazone may decrease the excretion rate of Metformin which could result in a higher serum level.]
[M01AB14, proglumetacin, Proglumetacin may decrease the excretion rate of Metformin which could result in a higher serum level.]
[G02AD02, dinoprostone, The serum concentration of Metformin can be increased when it is combined with Dinoprostone.]
[R06AA02, diphenhydramine, The serum concentration of Metformin can be increased when it is combined with Diphenhydramine.]
[C09AA06, quinapril, The risk or severity of lactic acidosis can be increased when Quinapril is combined with Metformin.]
[N06AA23, quinupramine, Quinupramine may decrease the hypoglycemic activities of Metformin.]
[C09AA05, ramipril, The risk or severity of lactic acidosis can be increased when Ramipril is combined with Metformin.]
[S01XA23, sirolimus, The therapeutic efficacy of Metformin can be decreased when used in combination with Sirolimus.]
[S01AX06, resorcinol, Metformin may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Metformin.]
[S02AA12, rifamycin SV, The excretion of Metformin can be decreased when combined with Rifamycin.]
[N05AX08, risperidone, The therapeutic efficacy of Metformin can be decreased when used in combination with Risperidone.]
[R06AE09, levocetirizine, Metformin may decrease the excretion rate of Levocetirizine which could result in a higher serum level.]
[N01BB09, ropivacaine, Ropivacaine may decrease the excretion rate of Metformin which could result in a higher serum level.]
[J01MB01, rosoxacin, The therapeutic efficacy of Metformin can be increased when used in combination with Rosoxacin.]
[L01EX01, sunitinib, The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Metformin.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE07, fosamprenavir, The therapeutic efficacy of Metformin can be decreased when used in combination with Fosamprenavir.]
[G04BE08, tadalafil, Metformin may decrease the excretion rate of Tadalafil which could result in a higher serum level.]
[S01BC05, ketorolac, Ketorolac may decrease the excretion rate of Metformin which could result in a higher serum level.]
[C01EB18, ranolazine, The serum concentration of Metformin can be increased when it is combined with Ranolazine.]
[N02BA06, salsalate, Salsalate may decrease the excretion rate of Metformin which could result in a higher serum level.]
[R03AC12, salmeterol, The serum concentration of Metformin can be increased when it is combined with Salmeterol.]
[H05BA01, salmon calcitonin, Salmon calcitonin may decrease the excretion rate of Metformin which could result in a higher serum level.]
[C01CA07, dobutamine, Metformin may decrease the excretion rate of Dobutamine which could result in a higher serum level.]
[C01CA04, dopamine, The serum concentration of Dopamine can be increased when it is combined with Metformin.]
[N06AA16, dothiepin, Dosulepin may decrease the hypoglycemic activities of Metformin.]
[N06AA12, doxepin, Doxepin may decrease the hypoglycemic activities of Metformin.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Metformin which could result in a higher serum level.]
[N06AB06, sertraline, The risk or severity of hypoglycemia can be increased when Sertraline is combined with Metformin.]
[A08AA10, sibutramine, Metformin may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[C10AA01, simvastatin, Metformin may increase the hypolipidaemic activities of Simvastatin.]
[A12CA02, sodium sulfate, Metformin may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[C09AA11, spirapril, The risk or severity of lactic acidosis can be increased when Spirapril is combined with Metformin.]
[R03DA01, dyphylline, Metformin may decrease the excretion rate of Dyphylline which could result in a higher serum level.]
[A07AB04, succinylsulfathiazole, The therapeutic efficacy of Metformin can be increased when used in combination with Succinylsulfathiazole.]
[N02CC01, sumatriptan, The therapeutic efficacy of Metformin can be increased when used in combination with Sumatriptan.]
[V04CX07, edrophonium, Metformin may decrease the excretion rate of Edrophonium which could result in a higher serum level.]
[C07AB13, talinolol, The therapeutic efficacy of Metformin can be increased when used in combination with Talinolol.]
[H01AA01, corticotropin, The therapeutic efficacy of Metformin can be decreased when used in combination with Corticotropin.]
[J01MA05, temafloxacin, The therapeutic efficacy of Metformin can be increased when used in combination with Temafloxacin.]
[L01AX03, temozolomide, Metformin may decrease the excretion rate of Temozolomide which could result in a higher serum level.]
[M01AC02, tenoxicam, Tenoxicam may decrease the excretion rate of Metformin which could result in a higher serum level.]
[G04BD05, terodiline, The risk or severity of hypoglycemia can be increased when Terodiline is combined with Metformin.]
[C07AA16, tertatolol, The therapeutic efficacy of Metformin can be increased when used in combination with Tertatolol.]
[N06AX14, tianeptine, Tianeptine may decrease the hypoglycemic activities of Metformin.]
[C09AA02, enalapril, The risk or severity of lactic acidosis can be increased when Enalapril is combined with Metformin.]
[M01AG02, tolfenamic acid, Tolfenamic acid may decrease the excretion rate of Metformin which could result in a higher serum level.]
[N06AG03, toloxatone, Toloxatone may increase the hypoglycemic activities of Metformin.]
[N06BA09, atomoxetine, Atomoxetine may decrease the excretion rate of Metformin which could result in a higher serum level.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Metformin.]
[C03CA04, torsemide, The therapeutic efficacy of Metformin can be decreased when used in combination with Torasemide.]
[C09AA10, trandolapril, The risk or severity of lactic acidosis can be increased when Trandolapril is combined with Metformin.]
[N05CC01, chloral hydrate, Metformin may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.]
[H02CA01, trilostane, The risk or severity of hyperglycemia can be increased when Trilostane is combined with Metformin.]
[L02AE04, triptorelin, The therapeutic efficacy of Metformin can be decreased when used in combination with Triptorelin.]
[J01MA04, enoxacin, The therapeutic efficacy of Metformin can be increased when used in combination with Enoxacin.]
[N06AX16, venlafaxine, The risk or severity of hypoglycemia can be increased when Venlafaxine is combined with Metformin.]
[S01GA03, xylometazoline, The risk or severity of hypoglycemia can be increased when Xylometazoline is combined with Metformin.]
[C08CA12, mepirodipine, The risk or severity of hypoglycemia can be increased when Barnidipine is combined with Metformin.]
[S01EA01, epinephrine, The therapeutic efficacy of Metformin can be decreased when used in combination with Epinephrine.]
[C09AA15, zofenopril, The risk or severity of lactic acidosis can be increased when Zofenopril is combined with Metformin.]
[M01AB04, zomepirac, Zomepirac may decrease the excretion rate of Metformin which could result in a higher serum level.]
[N03AX15, zonisamide, The risk or severity of lactic acidosis can be increased when Zonisamide is combined with Metformin.]
[A10AB06, insulin glulisine, human, The risk or severity of adverse effects can be increased when Insulin glulisine is combined with Metformin.]
[L01XA02, carboplatin, Carboplatin may decrease the excretion rate of Metformin which could result in a higher serum level.]
[C02AC02, guanfacine, Metformin may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[L03AX05, pidotimod, Metformin may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[N05CD04, estazolam, Metformin may decrease the excretion rate of Estazolam which could result in a higher serum level.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Metformin which could result in a higher serum level.]
[G03CA03, estradiol, The therapeutic efficacy of Metformin can be decreased when used in combination with Estradiol.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may decrease the excretion rate of Metformin which could result in a higher serum level.]
[J04AK02, ethambutol, Ethambutol may decrease the excretion rate of Metformin which could result in a higher serum level.]
[R03BA05, fluticasone, The therapeutic efficacy of Metformin can be decreased when used in combination with Fluticasone.]
[C10AA04, fluvastatin, Metformin may increase the hypolipidaemic activities of Fluvastatin.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Metformin which could result in a higher serum level.]
[D07AC21, halobetasol, The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Metformin.]
[L02AA03, ethinyl estradiol, The therapeutic efficacy of Metformin can be decreased when used in combination with Ethinylestradiol.]
[C01BD05, ibutilide, Ibutilide may decrease the excretion rate of Metformin which could result in a higher serum level.]
[N03AD01, ethosuximide, The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Metformin.]
[M01AC06, meloxicam, Meloxicam may decrease the excretion rate of Metformin which could result in a higher serum level.]
[N01AX07, etomidate, Etomidate may decrease the excretion rate of Metformin which could result in a higher serum level.]
[L04AD02, tacrolimus, The therapeutic efficacy of Metformin can be decreased when used in combination with Tacrolimus.]
[J01MA08, fleroxacin, The therapeutic efficacy of Metformin can be increased when used in combination with Fleroxacin.]
[P01AX07, trimetrexate, Metformin may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, The excretion of Metformin can be decreased when combined with Bupropion.]
[N06AB08, fluvoxamine, The risk or severity of hypoglycemia can be increased when Fluvoxamine is combined with Metformin.]
[L02AE02, leuprolide, The therapeutic efficacy of Metformin can be decreased when used in combination with Leuprolide.]
[C10AA03, pravastatin, Metformin may increase the hypolipidaemic activities of Pravastatin.]
[M01CB01, gold sodium thiomalate, Metformin may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Metformin may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, Metformin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.]
[A02BA03, famotidine, The serum concentration of Metformin can be increased when it is combined with Famotidine.]
[A16AA01, levocarnitine, Metformin may decrease the excretion rate of Levocarnitine which could result in a higher serum level.]
[C08CA02, felodipine, The risk or severity of hypoglycemia can be increased when Felodipine is combined with Metformin.]
[C08EA01, fendiline, The risk or severity of hypoglycemia can be increased when Fendiline is combined with Metformin.]
[M01AE04, fenoprofen, Fenoprofen may decrease the excretion rate of Metformin which could result in a higher serum level.]
[N02AB03, fentanyl, Metformin may decrease the excretion rate of Fentanyl which could result in a higher serum level.]
[R03CC02, albuterol, Metformin may decrease the excretion rate of Salbutamol which could result in a higher serum level.]
[L01BB06, clofarabine, Metformin may decrease the excretion rate of Clofarabine which could result in a higher serum level.]
[N07AX03, cevimeline, Cevimeline may decrease the excretion rate of Metformin which could result in a higher serum level.]
[G04BD02, flavoxate, Metformin may decrease the excretion rate of Flavoxate which could result in a higher serum level.]
[C01BC04, flecainide, The excretion of Flecainide can be decreased when combined with Metformin.]
[N02BG04, floctafenine, Floctafenine may decrease the excretion rate of Metformin which could result in a higher serum level.]
[J02AC01, fluconazole, The risk or severity of hypoglycemia can be increased when Metformin is combined with Fluconazole.]
[J02AX01, flucytosine, Metformin may decrease the excretion rate of Flucytosine which could result in a higher serum level.]
[H02AA02, fludrocortisone, The therapeutic efficacy of Metformin can be decreased when used in combination with Fludrocortisone.]
[V03AB25, flumazenil, Metformin may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[D07XB01, flumethasone, The risk or severity of hyperglycemia can be increased when Flumethasone is combined with Metformin.]
[N07CA03, flunarizine, The risk or severity of hypoglycemia can be increased when Flunarizine is combined with Metformin.]
[D07AC08, fluocinonide, The risk or severity of hyperglycemia can be increased when Fluocinonide is combined with Metformin.]
[N06AA14, melitracen, Melitracen may decrease the hypoglycemic activities of Metformin.]
[H02AB03, fluocortolone, The therapeutic efficacy of Metformin can be decreased when used in combination with Fluocortolone.]
[L01BC09, floxuridine, Floxuridine may decrease the excretion rate of Metformin which could result in a higher serum level.]
[S01CB05, fluorometholone, The therapeutic efficacy of Metformin can be decreased when used in combination with Fluorometholone.]
[N06AB03, fluoxetine, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Metformin.]
[G03BA01, fluoxymesterone, Fluoxymesterone may increase the hypoglycemic activities of Metformin.]
[D07AC07, flurandrenolide, The risk or severity of hyperglycemia can be increased when Flurandrenolide is combined with Metformin.]
[N05CD01, flurazepam, The serum concentration of Metformin can be increased when it is combined with Flurazepam.]
[S01BC04, flurbiprofen, Flurbiprofen may decrease the excretion rate of Metformin which could result in a higher serum level.]
[N05AG01, fluspirilene, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Metformin.]
[L02BB01, flutamide, Metformin may decrease the excretion rate of Flutamide which could result in a higher serum level.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Metformin which could result in a higher serum level.]
[S02AA17, fosfomycin, Metformin may decrease the excretion rate of Fosfomycin which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Metformin which could result in a higher serum level.]
[L01BC03, tegafur, Metformin may decrease the excretion rate of Tegafur which could result in a higher serum level.]
[G01AX06, furazolidone, Furazolidone may increase the hypoglycemic activities of Metformin.]
[J05AE10, darunavir, The therapeutic efficacy of Metformin can be decreased when used in combination with Darunavir.]
[C03CA01, furosemide, The therapeutic efficacy of Metformin can be decreased when used in combination with Furosemide.]
[N05CF04, eszopiclone, Metformin may decrease the excretion rate of Eszopiclone which could result in a higher serum level.]
[C08DA02, gallopamil, The risk or severity of hypoglycemia can be increased when Gallopamil is combined with Metformin.]
[S01AD09, ganciclovir, The excretion of Ganciclovir can be decreased when combined with Metformin.]
[C10AB04, gemfibrozil, Metformin may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.]
[J01XA03, telavancin, Metformin may decrease the excretion rate of Telavancin which could result in a higher serum level.]
[A10BJ02, liraglutide, The risk or severity of hypoglycemia can be increased when Liraglutide is combined with Metformin.]
[N03AD03, methsuximide, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Metformin.]
[N05CM18, dexmedetomidine, Metformin may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.]
[C01BD04, dofetilide, The serum concentration of Dofetilide can be increased when it is combined with Metformin.]
[H01AB01, thyrotropin alfa, The therapeutic efficacy of Metformin can be decreased when used in combination with Thyrotropin alfa.]
[L01EX02, sorafenib, Metformin may decrease the excretion rate of Sorafenib which could result in a higher serum level.]
[M01CB04, aurothioglucose, Metformin may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Metformin may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[C09AA09, fosinopril, The risk or severity of lactic acidosis can be increased when Fosinopril is combined with Metformin.]
[S01EX01, guanethidine, Metformin may decrease the excretion rate of Guanethidine which could result in a higher serum level.]
[L02AE03, goserelin, The therapeutic efficacy of Metformin can be decreased when used in combination with Goserelin.]
[D07AD02, halcinonide, The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Metformin.]
[N05AD01, haloperidol, The therapeutic efficacy of Metformin can be decreased when used in combination with Haloperidol.]
[L02AE05, histrelin, The therapeutic efficacy of Metformin can be decreased when used in combination with Histrelin.]
[N05AH04, quetiapine, The therapeutic efficacy of Metformin can be decreased when used in combination with Quetiapine.]
[N06BX13, idebenone, Metformin may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[A10AD05, insulin aspart, human, The risk or severity of adverse effects can be increased when Insulin aspart is combined with Metformin.]
[M04AA01, allopurinol, Metformin may decrease the excretion rate of Allopurinol which could result in a higher serum level.]
[G03DC01, allylestrenol, Metformin may decrease the excretion rate of Allylestrenol which could result in a higher serum level.]
[A07EC02, mesalamine, Mesalazine may increase the hypoglycemic activities of Metformin.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Metformin which could result in a higher serum level.]
[C08CA10, nilvadipine, The risk or severity of hypoglycemia can be increased when Nilvadipine is combined with Metformin.]
[M02AA26, nimesulide, The risk or severity of hypoglycemia can be increased when Nimesulide is combined with Metformin.]
[C09AA04, perindopril, The risk or severity of lactic acidosis can be increased when Perindopril is combined with Metformin.]
[C02DB02, hydralazine, Metformin may decrease the excretion rate of Hydralazine which could result in a higher serum level.]
[C03AA03, hydrochlorothiazide, The therapeutic efficacy of Metformin can be decreased when used in combination with Hydrochlorothiazide.]
[S02BA01, hydrocortisone, The therapeutic efficacy of Metformin can be decreased when used in combination with Hydrocortisone.]
[D07AC16, hydrocortisone aceponate, The risk or severity of hyperglycemia can be increased when Hydrocortisone aceponate is combined with Metformin.]
[D07AB02, hydrocortisone butyrate, The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Metformin.]
[D07AB11, hydrocortisone probutate, The risk or severity of hyperglycemia can be increased when Hydrocortisone probutate is combined with Metformin.]
[C03AA02, hydroflumethiazide, The therapeutic efficacy of Metformin can be decreased when used in combination with Hydroflumethiazide.]
[B05XA17, potassium acetate, Metformin may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Metformin which could result in a higher serum level.]
[G04BD06, propiverine, Metformin may decrease the excretion rate of Propiverine which could result in a higher serum level.]
[P01BA02, hydroxychloroquine, The therapeutic efficacy of Metformin can be increased when used in combination with Hydroxychloroquine.]
[B05AA07, hetastarch, Metformin may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[S01BA13, rimexolone, The risk or severity of hyperglycemia can be increased when Rimexolone is combined with Metformin.]
[R02AX02, ibuprofen, Ibuprofen may decrease the excretion rate of Metformin which could result in a higher serum level.]
[B05XA08, sodium acetate, Metformin may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[L01AA06, ifosfamide, Metformin may decrease the excretion rate of Ifosfamide which could result in a higher serum level.]
[H01AC02, somatrem, Somatrem may decrease the hypoglycemic activities of Metformin.]
[N06AA02, imipramine, Imipramine may decrease the hypoglycemic activities of Metformin.]
[R01AD07, tixocortol, The risk or severity of hyperglycemia can be increased when Tixocortol is combined with Metformin.]
[L01CE01, topotecan, The excretion of Topotecan can be decreased when combined with Metformin.]
[C03BA11, indapamide, The therapeutic efficacy of Metformin can be decreased when used in combination with Indapamide.]
[S01BC01, indomethacin, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Metformin.]
[A11HA07, inositol, Metformin may decrease the excretion rate of Inositol which could result in a higher serum level.]
[N06AX17, milnacipran, The risk or severity of hypoglycemia can be increased when Milnacipran is combined with Metformin.]
[S01XA28, varenicline, The serum concentration of Metformin can be increased when it is combined with Varenicline.]
[N01BB08, articaine, The therapeutic efficacy of Metformin can be decreased when used in combination with Articaine.]
[V08AC04, iodipamide, The risk or severity of adverse effects can be increased when Iodipamide is combined with Metformin.]
[V08AB02, iohexol, The risk or severity of adverse effects can be increased when Iohexol is combined with Metformin.]
[N05BA12, alprazolam, Metformin may decrease the excretion rate of Alprazolam which could result in a higher serum level.]
[N05CH02, ramelteon, Metformin may decrease the excretion rate of Ramelteon which could result in a higher serum level.]
[V08AB04, iopamidol, The risk or severity of adverse effects can be increased when Iopamidol is combined with Metformin.]
[C10AA06, cerivastatin, Metformin may increase the hypolipidaemic activities of Cerivastatin.]
[C07AA01, alprenolol, The therapeutic efficacy of Metformin can be increased when used in combination with Alprenolol.]
[C03BA02, quinethazone, The therapeutic efficacy of Metformin can be decreased when used in combination with Quinethazone.]
[V03AB01, ipecac, Metformin may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[N06AA13, iprindole, Iprindole may decrease the hypoglycemic activities of Metformin.]
[N06AF05, iproniazid, Iproniazid may increase the hypoglycemic activities of Metformin.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the hypoglycemic activities of Metformin.]
[C09AA16, imidapril, The risk or severity of lactic acidosis can be increased when Imidapril is combined with Metformin.]
[J04AC01, isoniazid, The therapeutic efficacy of Metformin can be decreased when used in combination with Isoniazid.]
[J05AX05, inosine pranobex, Metformin may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[A10BJ01, exenatide, The risk or severity of hypoglycemia can be increased when Exenatide is combined with Metformin.]
[C01DA14, isosorbide mononitrate, Metformin may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.]
[D10BA01, isotretinoin, Metformin may decrease the excretion rate of Isotretinoin which could result in a higher serum level.]
[S01AA24, kanamycin, Metformin may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[H01AC01, somatropin, Somatotropin may decrease the hypoglycemic activities of Metformin.]
[N01AX03, ketamine, Metformin may decrease the excretion rate of Ketamine which could result in a higher serum level.]
[B01AC22, prasugrel, Metformin may decrease the excretion rate of Prasugrel which could result in a higher serum level.]
[H02CA04, levoketoconazole, The serum concentration of Metformin can be increased when it is combined with Levoketoconazole.]
[N05AH03, olanzapine, The therapeutic efficacy of Metformin can be decreased when used in combination with Olanzapine.]
[M02AA10, ketoprofen, Ketoprofen may decrease the excretion rate of Metformin which could result in a higher serum level.]
[S01GX08, ketotifen, The risk or severity of thrombocytopenia can be increased when Metformin is combined with Ketotifen.]
[D10AX03, azelaic acid, Metformin may decrease the excretion rate of Azelaic acid which could result in a higher serum level.]
[M01AE11, tiaprofenic acid, Tiaprofenic acid may decrease the excretion rate of Metformin which could result in a higher serum level.]
[C07AG01, labetalol, The therapeutic efficacy of Metformin can be increased when used in combination with Labetalol.]
[N04BB01, amantadine, The serum concentration of Amantadine can be increased when it is combined with Metformin.]
[A06AX03, lubiprostone, Metformin may decrease the excretion rate of Lubiprostone which could result in a higher serum level.]
[C03CC01, ethacrynic acid, The therapeutic efficacy of Metformin can be decreased when used in combination with Etacrynic acid.]
[G03AD01, levonorgestrel, The therapeutic efficacy of Metformin can be decreased when used in combination with Levonorgestrel.]
[C08EX01, lidoflazine, The risk or severity of hypoglycemia can be increased when Lidoflazine is combined with Metformin.]
[S01AA21, amikacin, Metformin may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[C03DB01, amiloride, The serum concentration of Metformin can be increased when it is combined with Amiloride.]
[N06AA07, lofepramine, Lofepramine may decrease the hypoglycemic activities of Metformin.]
[A07DA03, loperamide, The risk or severity of hypoglycemia can be increased when Loperamide is combined with Metformin.]
[N05BA06, lorazepam, Lorazepam may decrease the excretion rate of Metformin which could result in a higher serum level.]
[C10AA02, lovastatin, Metformin may increase the hypolipidaemic activities of Lovastatin.]
[L01EG01, temsirolimus, The therapeutic efficacy of Metformin can be decreased when used in combination with Temsirolimus.]
[B05XA11, magnesium chloride, Metformin may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Metformin may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.]
[V04CC02, magnesium sulfate, The risk or severity of hypoglycemia can be increased when Magnesium sulfate is combined with Metformin.]
[L01BA05, pralatrexate, Metformin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[L01EA03, nilotinib, The therapeutic efficacy of Metformin can be decreased when used in combination with Nilotinib.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, Metformin may decrease the excretion rate of Maprotiline which could result in a higher serum level.]
[C02BB01, mecamylamine, Metformin may decrease the excretion rate of Mecamylamine which could result in a higher serum level.]
[M02AA18, meclofenamic acid, Meclofenamic acid may decrease the excretion rate of Metformin which could result in a higher serum level.]
[C01AA08, medigoxin, The serum concentration of Metildigoxin can be increased when it is combined with Metformin.]
[C03BA05, mefruside, The therapeutic efficacy of Metformin can be increased when used in combination with Mefruside.]
[N06DX01, memantine, Metformin may decrease the excretion rate of Memantine which could result in a higher serum level.]
[N02AB02, meperidine, Metformin may decrease the excretion rate of Meperidine which could result in a higher serum level.]
[N01BB03, mepivacaine, Metformin may decrease the excretion rate of Mepivacaine which could result in a higher serum level.]
[G04BX16, tiopronin, Metformin may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.]
[G03BB01, mesterolone, Mesterolone may increase the hypoglycemic activities of Metformin.]
[N05AX13, paliperidone, The therapeutic efficacy of Metformin can be decreased when used in combination with Paliperidone.]
[J01MB04, pipemidic acid, The therapeutic efficacy of Metformin can be increased when used in combination with Pipemidic acid.]
[C01DA05, pentaerythritol tetranitrate, Metformin may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[R03BA09, fluticasone furoate, The therapeutic efficacy of Metformin can be decreased when used in combination with Fluticasone furoate.]
[J01MB02, nalidixic acid, The therapeutic efficacy of Metformin can be increased when used in combination with Nalidixic acid.]
[H01CB03, lanreotide, The therapeutic efficacy of Metformin can be decreased when used in combination with Lanreotide.]
[N07BC02, methadone, Metformin may decrease the excretion rate of Methadone which could result in a higher serum level.]
[N06BA03, methamphetamine, Metformin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.]
[J05AF05, lamivudine, Metformin may decrease the excretion rate of Lamivudine which could result in a higher serum level.]
[S01EC05, methazolamide, The risk or severity of lactic acidosis can be increased when Methazolamide is combined with Metformin.]
[H03BB02, methimazole, Metformin may decrease the excretion rate of Methimazole which could result in a higher serum level.]
[L01BA04, pemetrexed, Metformin may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Metformin which could result in a higher serum level.]
[N02BG08, ziconotide, The risk or severity of hypoglycemia can be increased when Ziconotide is combined with Metformin.]
[L04AX03, methotrexate, Methotrexate may decrease the excretion rate of Metformin which could result in a higher serum level.]
[N05AA02, methotrimeprazine, The therapeutic efficacy of Metformin can be decreased when used in combination with Methotrimeprazine.]
[D05BA02, methoxsalen, Metformin may decrease the excretion rate of Methoxsalen which could result in a higher serum level.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Metformin can be decreased when used in combination with Methyclothiazide.]
[C02AB01, methyldopa, Metformin may decrease the excretion rate of Methyldopa which could result in a higher serum level.]
[V04CG05, methylene blue, The serum concentration of Metformin can be increased when it is combined with Methylene blue.]
[H02AB04, methylprednisolone, The therapeutic efficacy of Metformin can be decreased when used in combination with Methylprednisolone.]
[G03EK01, methyltestosterone, Methyltestosterone may increase the hypoglycemic activities of Metformin.]
[A03FA01, metoclopramide, Metformin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[C03BA08, metolazone, The therapeutic efficacy of Metformin can be decreased when used in combination with Metolazone.]
[C07AB02, metoprolol, The therapeutic efficacy of Metformin can be increased when used in combination with Metoprolol.]
[V04CD01, metyrapone, Metformin may decrease the excretion rate of Metyrapone which could result in a higher serum level.]
[N02BB03, aminopyrine, Aminophenazone may decrease the excretion rate of Metformin which could result in a higher serum level.]
[N05CD08, midazolam, Metformin may decrease the excretion rate of Midazolam which could result in a higher serum level.]
[G03XB01, mifepristone, The risk or severity of hypoglycemia can be increased when Mifepristone is combined with Metformin.]
[J05AH01, zanamivir, Metformin may decrease the excretion rate of Zanamivir which could result in a higher serum level.]
[L03AC01, aldesleukin, Aldesleukin may decrease the excretion rate of Metformin which could result in a higher serum level.]
[C01BD01, amiodarone, The serum concentration of Metformin can be increased when it is combined with Amiodarone.]
[N06AA09, amitriptyline, Amitriptyline may decrease the hypoglycemic activities of Metformin.]
[A04AA05, palonosetron, Metformin may decrease the excretion rate of Palonosetron which could result in a higher serum level.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Metformin which could result in a higher serum level.]
[L04AB05, certolizumab pegol, Metformin may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.]
[G04BA01, ammonium chloride, Metformin may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.]
[L04AA06, mycophenolic acid, Metformin may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.]
[N06AA17, amoxapine, Amoxapine may decrease the hypoglycemic activities of Metformin.]
[C07AA12, nadolol, The therapeutic efficacy of Metformin can be increased when used in combination with Nadolol.]
[J01CA04, amoxicillin, Metformin may decrease the excretion rate of Amoxicillin which could result in a higher serum level.]
[V03AB15, naloxone, Metformin may decrease the excretion rate of Naloxone which could result in a higher serum level.]
[S01XA11, nandrolone, Nandrolone phenpropionate may increase the hypoglycemic activities of Metformin.]
[N06BA01, amphetamine, Amphetamine may decrease the excretion rate of Metformin which could result in a higher serum level.]
[M02AA12, naproxen, Naproxen may decrease the excretion rate of Metformin which could result in a higher serum level.]
[A10BG01, troglitazone, The risk or severity of hypoglycemia can be increased when Troglitazone is combined with Metformin.]
[N06AX21, duloxetine, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Metformin.]
[N04BX01, tolcapone, Tolcapone may decrease the excretion rate of Metformin which could result in a higher serum level.]
[S03AA01, neomycin, Metformin may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[B01AC17, tirofiban, Metformin may decrease the excretion rate of Tirofiban which could result in a higher serum level.]
[N05AX14, iloperidone, The therapeutic efficacy of Metformin can be decreased when used in combination with Iloperidone.]
[J02AA01, amphotericin B, Amphotericin B may decrease the excretion rate of Metformin which could result in a higher serum level.]
[S01AA19, ampicillin, Metformin may decrease the excretion rate of Ampicillin which could result in a higher serum level.]
[L03AX16, plerixafor, Metformin may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Metformin may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The risk or severity of hypoglycemia can be increased when Desvenlafaxine is combined with Metformin.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Metformin which could result in a higher serum level.]
[C01CE01, inamrinone, Metformin may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[C10AD02, niacin, The therapeutic efficacy of Metformin can be decreased when used in combination with Niacin.]
[N06AF02, nialamide, Nialamide may increase the hypoglycemic activities of Metformin.]
[C08CA04, nicardipine, The risk or severity of hypoglycemia can be increased when Nicardipine is combined with Metformin.]
[N07BA01, nicotine, The serum concentration of Metformin can be increased when it is combined with Nicotine.]
[C08CA05, nifedipine, The risk or severity of hypoglycemia can be increased when Nifedipine is combined with Metformin.]
[M02AA17, niflumic acid, Niflumic acid may decrease the excretion rate of Metformin which could result in a higher serum level.]
[C08CA06, nimodipine, The risk or severity of hypoglycemia can be increased when Nimodipine is combined with Metformin.]
[C08CA07, nisoldipine, The risk or severity of hypoglycemia can be increased when Nisoldipine is combined with Metformin.]
[C08CA08, nitrendipine, The risk or severity of hypoglycemia can be increased when Nitrendipine is combined with Metformin.]
[R07AX01, nitric oxide, Metformin may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Metformin may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[N05CF03, zaleplon, Metformin may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N04BC05, pramipexole, Metformin may decrease the excretion rate of Pramipexole which could result in a higher serum level.]
[C02DD01, nitroprusside, Nitroprusside may decrease the excretion rate of Metformin which could result in a higher serum level.]
[C01CA03, norepinephrine, The serum concentration of Norepinephrine can be increased when it is combined with Metformin.]
[G03DC02, norethindrone, The therapeutic efficacy of Metformin can be decreased when used in combination with Norethisterone.]
[S01AE02, norfloxacin, The therapeutic efficacy of Metformin can be increased when used in combination with Norfloxacin.]
[C02KX01, bosentan, The therapeutic efficacy of Metformin can be increased when used in combination with Bosentan.]
[N06AA10, nortriptyline, Nortriptyline may decrease the hypoglycemic activities of Metformin.]
[G02CA02, nylidrin, The risk or severity of hypoglycemia can be increased when Nylidrin is combined with Metformin.]
[H01CB02, octreotide, The therapeutic efficacy of Metformin can be decreased when used in combination with Octreotide.]
[S02AA16, ofloxacin, The therapeutic efficacy of Metformin can be increased when used in combination with Ofloxacin.]
[N06AA05, opipramol, Opipramol may decrease the hypoglycemic activities of Metformin.]
[N02AA02, opium, Metformin may decrease the excretion rate of Opium which could result in a higher serum level.]
[G04CA02, tamsulosin, The therapeutic efficacy of Metformin can be increased when used in combination with Tamsulosin.]
[J01CF04, oxacillin, Metformin may decrease the excretion rate of Oxacillin which could result in a higher serum level.]
[A14AA08, oxandrolone, Oxandrolone may increase the hypoglycemic activities of Metformin.]
[N05BA04, oxazepam, Metformin may decrease the excretion rate of Oxazepam which could result in a higher serum level.]
[J01MB05, oxolinic acid, The therapeutic efficacy of Metformin can be increased when used in combination with Oxolinic acid.]
[C07AA02, oxprenolol, The therapeutic efficacy of Metformin can be increased when used in combination with Oxprenolol.]
[A14AA05, oxymetholone, Oxymetholone may increase the hypoglycemic activities of Metformin.]
[S01BC02, oxyphenbutazone, Oxyphenbutazone may decrease the excretion rate of Metformin which could result in a higher serum level.]
[V04CH30, 4-aminohippuric acid, The serum concentration of Metformin can be increased when it is combined with Aminohippuric acid.]
[J04AA01, aminosalicylic acid, Aminosalicylic acid may increase the hypoglycemic activities of Metformin.]
[N05AH05, asenapine, The therapeutic efficacy of Metformin can be decreased when used in combination with Asenapine.]
[J04AB30, capreomycin, Metformin may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[H02AB05, paramethasone, The therapeutic efficacy of Metformin can be decreased when used in combination with Paramethasone.]
[C02KC01, pargyline, Pargyline may increase the hypoglycemic activities of Metformin.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Metformin which could result in a higher serum level.]
[J01MA03, pefloxacin, The therapeutic efficacy of Metformin can be increased when used in combination with Pefloxacin.]
[G04BD11, fesoterodine, Metformin may decrease the excretion rate of Fesoterodine which could result in a higher serum level.]
[C07AA23, penbutolol, The therapeutic efficacy of Metformin can be increased when used in combination with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of hypoglycemia can be increased when Penfluridol is combined with Metformin.]
[J01CE09, penicillin G procaine, Metformin may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N05CA01, pentobarbital, Pentobarbital may decrease the excretion rate of Metformin which could result in a higher serum level.]
[L01XX08, pentostatin, Metformin may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, Metformin may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.]
[C08EX02, perhexiline, The risk or severity of hypoglycemia can be increased when Perhexiline is combined with Metformin.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Metformin which could result in a higher serum level.]
[N06AF03, phenelzine, Phenelzine may increase the hypoglycemic activities of Metformin.]
[A10BA01, phenformin, The serum concentration of Metformin can be increased when it is combined with Phenformin.]
[C04AX02, phenoxybenzamine, The serum concentration of Metformin can be increased when it is combined with Phenoxybenzamine.]
[A08AA01, phentermine, The therapeutic efficacy of Metformin can be increased when used in combination with Phentermine.]
[V03AB36, phentolamine, Metformin may decrease the excretion rate of Phentolamine which could result in a higher serum level.]
[M02AA01, phenylbutazone, Phenylbutazone may decrease the excretion rate of Metformin which could result in a higher serum level.]
[N03AB02, phenytoin, The therapeutic efficacy of Metformin can be decreased when used in combination with Phenytoin.]
[S01AE05, levofloxacin, The therapeutic efficacy of Metformin can be increased when used in combination with Levofloxacin.]
[B02BA01, vitamin K1, Metformin may decrease the excretion rate of Phylloquinone which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Metformin which could result in a higher serum level.]
[C08CX01, mibefradil, The risk or severity of hypoglycemia can be increased when Mibefradil is combined with Metformin.]
[C07AA03, pindolol, The therapeutic efficacy of Metformin can be increased when used in combination with Pindolol.]
[C10AA05, atorvastatin, Metformin may increase the hypolipidaemic activities of Atorvastatin.]
[J01CA12, piperacillin, Piperacillin may decrease the excretion rate of Metformin which could result in a higher serum level.]
[J05AE01, saquinavir, The therapeutic efficacy of Metformin can be decreased when used in combination with Saquinavir.]
[P02CB01, piperazine, The therapeutic efficacy of Metformin can be decreased when used in combination with Piperazine.]
[N05AC04, pipothiazine, The therapeutic efficacy of Metformin can be decreased when used in combination with Pipotiazine.]
[N06BX03, piracetam, Metformin may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[S01BC06, piroxicam, Piroxicam may decrease the excretion rate of Metformin which could result in a higher serum level.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Metformin which could result in a higher serum level.]
[J01MA11, grepafloxacin, The therapeutic efficacy of Metformin can be increased when used in combination with Grepafloxacin.]
[C03AA05, polythiazide, The therapeutic efficacy of Metformin can be decreased when used in combination with Polythiazide.]
[J05AE03, ritonavir, The therapeutic efficacy of Metformin can be decreased when used in combination with Ritonavir.]
[B05XA01, potassium chloride, Metformin may decrease the excretion rate of Potassium chloride which could result in a higher serum level.]
[A10AD04, insulin lispro, The risk or severity of adverse effects can be increased when Insulin lispro is combined with Metformin.]
[C10AA08, pitavastatin, Metformin may increase the hypolipidaemic activities of Pitavastatin.]
[C07AB01, practolol, The therapeutic efficacy of Metformin can be increased when used in combination with Practolol.]
[S03BA02, prednisolone, The therapeutic efficacy of Metformin can be decreased when used in combination with Prednisolone.]
[H02AB07, prednisone, The therapeutic efficacy of Metformin can be decreased when used in combination with Prednisone.]
[C01DX02, prenylamine, The risk or severity of hypoglycemia can be increased when Prenylamine is combined with Metformin.]
[M04AB01, probenecid, The therapeutic efficacy of Metformin can be increased when used in combination with Probenecid.]
[C01BA02, procainamide, The excretion of Procainamide can be decreased when combined with Metformin.]
[S01HA05, procaine, Procaine may increase the hypoglycemic activities of Metformin.]
[L01XB01, procarbazine, Procarbazine may increase the hypoglycemic activities of Metformin.]
[C10AB05, fenofibrate, Metformin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.]
[G03DA04, progesterone, The therapeutic efficacy of Metformin can be decreased when used in combination with Progesterone.]
[R06AD02, promethazine, Metformin may decrease the excretion rate of Promethazine which could result in a higher serum level.]
[C01BC03, propafenone, The therapeutic efficacy of Metformin can be increased when used in combination with Propafenone.]
[A03AB05, propantheline, Metformin may decrease the excretion rate of Propantheline which could result in a higher serum level.]
[C07AA05, propranolol, The therapeutic efficacy of Metformin can be increased when used in combination with Propranolol.]
[N02CC04, rizatriptan, Metformin may decrease the excretion rate of Rizatriptan which could result in a higher serum level.]
[B01AC09, epoprostenol, Metformin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N06AA11, protriptyline, Protriptyline may decrease the hypoglycemic activities of Metformin.]
[R01BA02, pseudoephedrine, The therapeutic efficacy of Metformin can be decreased when used in combination with Pseudoephedrine.]
[N05AX12, aripiprazole, The therapeutic efficacy of Metformin can be decreased when used in combination with Aripiprazole.]
[N07XX07, dalfampridine, The serum concentration of Dalfampridine can be increased when it is combined with Metformin.]
[P02CC01, pyrantel, Metformin may decrease the excretion rate of Pyrantel which could result in a higher serum level.]
[J04AK01, pyrazinamide, Metformin may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.]
[P01BD01, pyrimethamine, The excretion of Metformin can be decreased when combined with Pyrimethamine.]
[P01AX05, quinacrine, The serum concentration of Metformin can be increased when it is combined with Quinacrine.]
[C01BA01, quinidine, Metformin may decrease the excretion rate of Quinidine which could result in a higher serum level.]
[P01BC01, quinine, The risk or severity of hypoglycemia can be increased when Quinine is combined with Metformin.]
[D07AC10, diflorasone, The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Metformin.]
[A02BA02, ranitidine, The serum concentration of Ranitidine can be increased when it is combined with Metformin.]
[C02AA01, rescinnamine, The risk or severity of lactic acidosis can be increased when Rescinnamine is combined with Metformin.]
[C02AA02, reserpine, Reserpine may decrease the excretion rate of Metformin which could result in a higher serum level.]
[J05AP01, ribavirin, Metformin may decrease the excretion rate of Ribavirin which could result in a higher serum level.]
[N02BA05, salicylamide, Salicylamide may decrease the excretion rate of Metformin which could result in a higher serum level.]
[A07EC01, sulfasalazine, Sulfasalazine may increase the hypoglycemic activities of Metformin.]
[S01BC08, salicylic acid, Salicylic acid may increase the hypoglycemic activities of Metformin.]
[N05CA06, secobarbital, Metformin may decrease the excretion rate of Secobarbital which could result in a higher serum level.]
[N04BD01, selegiline, Selegiline may increase the hypoglycemic activities of Metformin.]
[J01GB08, sisomicin, Metformin may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Metformin may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, Metformin may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[C07AA07, sotalol, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Metformin.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.]
[D07AC14, methylprednisolone aceponate, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Metformin.]
